

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

ΚΑΤΕΡΙΝΑ Μ. ΑΝΤΩΝΙΟΥ

Καθηγήτρια Πνευμονολογίας

Πανεπιστημίου Κρήτης

ΗΡΑΚΛΕΙΟ ΚΡΗΤΗΣ
ΣΕΠΤΕΜΒΡΙΟΣ 2025

ΠΕΡΙΕΧΟΜΕΝΑ

Περίληψη επιστημονικού έργου

Απεικόνιση δημοσιεύσεων και αναφορών στην βάση δεδομένων Scopus

1. ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ

2. ΕΚΠΑΙΔΕΥΣΗ

1. Βασική εκπαίδευση

2. Πανεπιστημιακή εκπαίδευση

3. Μετεκπαίδευση

Εργαστηριακή

Κλινική

3. ΔΙΠΛΩΜΑΤΑ

4. ΑΔΕΙΕΣ ΑΣΚΗΣΗΣ ΕΠΑΓΓΕΛΜΑΤΟΣ

5. ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΣΤΑΔΙΟΔΡΟΜΙΑ - ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΘΕΣΕΙΣ

6. ΔΙΟΙΚΗΤΙΚΗ ΕΜΠΕΙΡΙΑ

6.1 ΜΕΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΠΙΤΡΟΠΩΝ – ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ ΣΤΟ ΕΣΩΤΕΡΙΚΟ

6.2 ΜΕΛΟΣ ΔΙΕΘΝΩΝ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΠΙΤΡΟΠΩΝ – ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ

7. ΕΠΙΣΤΗΜΟΝΙΚΟ ΕΡΓΟ

7.1 ΧΡΗΜΑΤΟΔΟΤΗΣΕΙΣ ΕΡΕΥΝΗΤΙΚΩΝ ΠΡΟΓΡΑΜΜΑΤΩΝ

7.2 ΕΡΕΥΝΗΤΙΚΗ ΣΥΜΜΕΤΟΧΗ ΣΕ ΕΚΠΟΝΗΣΗ ΚΛΙΝΙΚΩΝ ΜΕΛΕΤΩΝ

7.3 ΥΠΟΤΡΟΦΙΕΣ - ΒΡΑΒΕΥΣΕΙΣ

7.4 ΟΡΓΑΝΩΣΗ ΣΥΝΕΔΡΙΩΝ

7.5 ΠΡΟΕΔΡΕΙΑ ΣΕ ΔΙΕΘΝΗ ΣΥΝΕΔΡΙΑ

7.6 ΠΡΟΣΚΕΚΛΗΜΕΝΗ ΟΜΙΛΗΤΡΙΑ ΣΕ ΔΙΕΘΝΗ ΣΥΝΕΔΡΙΑ

7.7 ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΔΙΕΘΝΗ ΠΕΡΙΟΔΙΚΑ ΜΕ ΚΡΙΤΕΣ (PUBMED, SCOPUS, ISI)

7.8 ΚΕΦΑΛΑΙΑ ΣΕ ΔΙΕΘΝΕΙΣ ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΕΚΔΟΣΕΙΣ

7.9 ΕΡΓΑΣΙΕΣ ΣΕ ΔΙΕΘΝΗ ΕΠΙΣΤΗΜΟΝΙΚΑ ΣΥΝΕΔΡΙΑ

7.10 ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΕΛΛΗΝΙΚΑ ΠΕΡΙΟΔΙΚΑ ΚΑΙ ΚΕΦΑΛΑΙΑ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΕΚΔΟΣΕΙΣ

7.11 ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΕΔΡΙΑ-ΣΥΜΠΟΣΙΑ ΜΕ ΕΙΣΗΓΗΣΕΙΣ-ΔΙΑΛΕΞΕΙΣ ΣΤΟ ΕΣΩΤΕΡΙΚΟ

7.12 ΠΡΟΕΔΡΕΙΑ ΣΤΟ ΕΣΩΤΕΡΙΚΟ

8. ΕΚΠΑΙΔΕΥΤΙΚΟ – ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ

8.1 ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΕΠΙΠΕΔΟ ΠΡΟΠΤΥΧΙΑΚΗΣ ΕΚΠΑΙΔΕΥΣΗΣ

8.2 ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΕΠΙΠΕΔΟ ΜΕΤΑΠΤΥΧΙΑΚΗΣ ΕΚΠΑΙΔΕΥΣΗΣ

8.3 ΟΜΙΛΙΕΣ ΣΕ ΜΕΤΕΚΠΑΙΔΕΥΤΙΚΑ ΣΕΜΙΝΑΡΙΑ

8.4 ΕΠΙΒΛΕΨΗ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΦΟΙΤΗΤΩΝ

8.5 ΕΠΙΒΛΕΨΗ ΔΙΔΑΚΤΟΡΙΚΩΝ ΔΙΑΤΡΙΒΩΝ

Ως επιβλέπουσα

Ως μέλος τριμελούς

Ως μέλος επταμελούς

8.6 ΥΠΟΤΡΟΦΙΕΣ-ΒΡΑΒΕΙΑ ΜΕΛΩΝ ΤΗΣ ΕΡΕΥΝΗΤΙΚΗΣ ΟΜΑΔΑΣ ΔΙΑΜΕΣΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ

ΠΝΕΥΜΟΝΑ

9. ΣΥΣΤΑΤΙΚΕΣ ΕΠΙΣΤΟΛΕΣ

KATERINA M. ANTONIOU, MD, PhD

ERS Assembly 12 Head (2021-2024)

Professor of Respiratory Medicine, School of Medicine, University of Crete
Molecular & Cellular Pulmonology Laboratory, Dept. of Respiratory MedicineEmail: kantoniou@uoc.gr**Date of birth:** 25.07.1972**Place of birth:** Heraklion Crete**Medical specialties:** Respiratory Medicine 2000-2005 (Boards 2005)**Academic Degrees:**

- MD, Naples University 1998
- PhD, Faculty of Medicine, University of Crete, 2004

Research interests: Interstitial Lung Diseases, Connective tissue Diseases, Pleural Diseases, Epigenetics & Genetics in Chronic Lung Diseases, Lung Cancer Pathogenesis, Severe Asthma**Supervisor in 18 PhD theses and 2 MSc thesis** in the Faculty of Medicine, University of Crete**Editor:** Guest editor, Frontiers in Immunology, Research Topic "Mechanisms of Lung Fibrosis: is Immunity Back in the Game?"**Associate Editor:** ERR, Breath, Pulmonology.**Reviewer of Journals:** Lancet, Lancet Respir Med, AJRCCM, BMJ, Eur. Respir Journal, Chest, Respir Res, Respir Med, Respirology, Respiration, Pulmonary Pharmacology & Therapeutics, etc**Publications:** 258 (Pub Med, ISI, Scopus)**Citations:** 14,393 by Scopus, 17,379 by Researchgate (26/03/2025)**H- index:** 60 by Scopus, 54 by Researchgate (26/03/2025)**Invited speaker in international congresses:** >150**Chair in international meetings-congresses:** >150**Principal and Sub/ Investigator in IPF clinical trials:** 31**Co-chair in CTD-ILD Guidelines (ERS-EULAR)** "Clinical practice guideline on connective tissue diseases with interstitial lung (ILD) involvement" (TF-2020-03)**Co-chair of ERS Statement on Covid-19 Follow-Up** (TF-2020-14, Eur Respir J under revision)**Member of ERS/ATS research statement:** Interstitial pneumonia with autoimmune features (Eur Respir J 2015; 46:976-87)**Member of ERS Guidelines for management of Covid-19** (Eur Respir J 2021)**Member of the Statement on Combined pulmonary fibrosis and emphysema (CPFE)** (TF-2018-15)**Member of Idiopathic Pulmonary Fibrosis (IPF)-An update of diagnosis and treatment recommendations:** Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines (TF-2019-18); *under revision***Member in ERS clinical practice guidelines on treatment of sarcoidosis** (Eur Respir J. 2021)**Member of PVRI Working group about PH-ILDs (2021-today)**

Member of Idiopathic Pulmonary Fibrosis (IPF)-An update of diagnosis and treatment recommendations: Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines (TF-2019-18, Eur Respir J 2022)

Member in "Update of the International Multidisciplinary Classification of the Interstitial Pneumonias: An ERS/ATS Statement", Eur Respir J. (under submission)

Member of ERS Research Statement: diagnosis and management of post-COVID interstitial lung disease (ongoing, ERS TF-2022-09)

Posts:

- Honorary Research Fellow (ERS long term fellowship, Prof Wells, Royal Brompton Hospital, 2005-2006)
- Pre- Lecturer in the Department of Respiratory Medicine Faculty of Medicine, University of Crete (2006- 2009)
- Lecturer of Respiratory Medicine, Faculty of Medicine, University of Crete (2009- 2014)
- Assistant Professor of Respiratory Medicine, Faculty of Medicine, University of Crete (2014- 2018)
- Associate Professor of Respiratory Medicine, Faculty of Medicine, University of Crete (2018-today)
- Vice Dean, Faculty of Medicine (2015-2017)
- Coordinator of Public Relationship Committee (Rectorship, University of Crete) (2016-2017)
- Chair of the Committee of Protocol-Extroversion and Public Relations, Faculty of Medicine, University of Crete (2020-2022)
- Coordinator of ILD Working Group of the Hellenic Thoracic Society (2011-2017)
- ERS Interstitial Lung Diseases Group Secretary (2011-2014)
- ERS Interstitial Lung Diseases Group Chair (2014-2017)
- ERS Assembly 12 Secretary (2018-2021)
- ERS Assembly 12 Chair (2021- 2024)
- WASOG executive committee: (2021- today)
- Head of Laboratory of Molecular and Cellular Pulmonology, University of Crete (2014-today)
- Member of the Ethics Committee of the University General Hospital of Heraklion, Crete (2014-today)
- Alternate Member of the Board of the University General Hospital of Heraklion, Crete (2020-2021)
- Member of the Postgraduate Studies Committee, Faculty of Medicine, University of Crete (2014-2016)
- Faculty Member of the General Assembly, Faculty of Medicine, University of Crete (2009-2012), (2014-2016), (2019-2020), (2021-2022)
- Member of the ERS Evaluation Committee for Fellowships and Visiting Professorships, 2011-2017
- ERS Abstract Reviewer 2010- 2021
- Member of the ERS Evaluation Committee for Fellowships and Visiting Professorships, 2011-2017
- Member of the General Medical Council
- Member of ERS, ATS, HTS, WASOG

Organization of international conferences:

- Member of Organizing Committee of 9th WASOG Meeting & 11th BAL International Conference
- Pulmonary Review and Refreshing Course of Pulmonary Medicine in Interstitial Lung Diseases, 2009
- ERS Research Seminar on “Novel insights in pulmonary fibrogenesis” from bench to bedside 2010
- Scientific Committee of the Hellenic Thoracic Society Congress (21th) 2012
- National Congresses of the Hellenic Thoracic Society, Coordinator of the ILD Group 2012-2017
- IPF and Sleep: Common pathways and implications in therapy; Endorsed by the ERS 2013
- ERS Research Seminar on “IPF and Cancer: Wounds that do not heal” 2015
- Cretan Summer School of Respiratory Department (SHARE), Interstitial Lung diseases (ILDs) course: from bench to bedside 2017, University of Crete
- International WASOG conference (endorsed by ERS), Heraklion 2018
- 2nd Cretan Summer School of Respiratory Department SHARE, Heraklion 2022
- 3rd SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Heraklion 2023
- 4th SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Heraklion 2024
- 5th SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Heraklion 2025
- 1st ILD Turkish Greek Workshop, Izmir, 2024
- 2nd ILD Turkish Greek Workshop, Heraklion, 2025

Achievements of the ILD Team, University of Crete:

1. Short term research fellowship, European Respiratory Society (2008) to George Margaritopoulos Interstitial Lung Disease Unit, Royal Brompton Hospital
2. Short term research fellowship, European Respiratory Society to Katerina Samara 2010
3. Long term research fellowship (12 months), European Respiratory Society (2010) to George Margaritopoulos, Interstitial Lung Disease Unit, Royal Brompton Hospital,
4. ERS Lung Science Congress Bursary 2010 to Konstantinos Karagiannis
5. ERS Travel Award, 2009 to Ismini Lasithiotaki, ERS Annual Congress, Vienna
6. ERS Travel Award, 2009 to A. Proklou, ERS Annual Congress, Vienna
7. ERS Lung Science Congress Bursary 2009 to F. Economidou
8. Long term research fellowship (12 months), European Respiratory Society (2012) to Konstantinos Karagiannis, Interstitial Lung Disease Unit, Royal Brompton Hospital, London
9. Short term research fellowship, European Respiratory Society (2015) to Athanasia Proklou, Interstitial Lung Disease Unit, Royal Brompton Hospital
10. ERS Lung Science Congress Bursary 2018 to Eliza Tsitoura

11. ERS Lung Science Congress Bursary 2019 to Athina Trachalaki
12. Short Term ERS fellowship 2020 to Athina Trachalaki, Interstitial Lung Disease Unit, Royal Brompton Hospital
13. Long Term ERS fellowship 2020 to Eirini Vasarmidi, University of Paris, Professor Crestani

Author in Statements-Guidelines-Position papers- Working Groups papers

1. **Antonίου KM**, Vasarmidi E, Russell AM, Andrejak C, Crestani B, Delcroix M, et al. ERS Statement on COVID-19 follow-up. Eur Respir J. 2021. *under revision*
2. Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, **Antonίου K**, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021:2004079.
3. Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, **Antonίου KM**, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021;57(4):2100048.
4. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, **Antonίου KM**, et al. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019;200(9):1146-53.
5. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group: Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name? Eur Respir J. 2019;53(2).
6. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, **Antonίου KM**, Athol Wells, IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. Eur Respir J. 2017;50(2).
7. Johansson KA, Strambu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, et al. Erice ILD Working Group. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? Lancet Respir Med. 2017;5(7):591-8.
8. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, **Antonίου KM** et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265-75.
9. Fischer A, **Antonίου KM**, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976-87.
10. Wuyts WA, **Antonίου KM**, Borensztajn K, Costabel U, Cottin V, Crestani B, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. 2014;2(11):933-42.
11. Walsh SL, Wells AU, Sverzellati N, Keir GJ, Calandriello L, **Antonίου KM**, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med. 2014;2(2):123-30.
12. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP,

Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, **Antoniou K**, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*. 2014;69(5):428-36.

13. Bouros D, **Antoniou KM**, Light RW. Intrapleural streptokinase for pleural infection. *BMJ*. 2006;332(7534):133-4.

Περίληψη επιστημονικού έργου:

	2022	2017	Μεταβολή
Δημοσιεύσεις σε διεθνή περιοδικά με κριτές (PUBMED, SCOPUS, ISI)	218	134	84
Αναφορές (Scopus)	5.220	2.174	3.046
H-Index (Scopus)	38	27	11
Total impact Factor	1.413	628	785
Mean Impact Factor	7.4	4.9	2,5
Χρηματοδοτήσεις Ερευνητικών Προγραμμάτων	18	13	5
Προσκεκλημένη ομιλήτρια σε διεθνή συνέδρια	104	59	45
Εργασίες σε διεθνή επιστημονικά συνέδρια	202	154	48

Δημοσιεύσεις σε διεθνή περιοδικά με κριτές (PUBMED, SCOPUS, ISI)	218	%
Original research papers	91	45,8
Position papers/Guidelines	6	3,0
Reviews	53	26,6
Case reports	13	6,5
Editorial/ letter to the editor/ comment	36	18,1
1 ^η συγγραφέας:	57	28,1
2 ^η συγγραφέας:	35	13,6
3 ^η συγγραφέας:	19	9,6
1 ^η , 2 ^η , 3 ^η συγγραφέας:	111	51,3
Τελευταία συγγραφέας:	39	22,6

Απεικόνιση δημοσιεύσεων και αναφορών στην βάση δεδομένων Scopus:

Antoniou, Katerina M.

University of Crete, Rethymnon, Greece

Author ID:34568077600


Metrics overview

177 Documents by author


5220 Citations by 4180 documents

38 *h*-index: [View *h*-graph](#)

Document & citation trends



Documents by source



1. ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ

Όνοματεπώνυμο:	Κατερίνα Αντωνίου
Όνομα πατρός:	Μιχαήλ
Όνομα μητρός:	Αναστασία
Ημερομηνία γέννησης:	25.07.1972
Τόπος γέννησης	Ηράκλειο, Κρήτη
Οικογενειακή κατάσταση:	Συζευγμένη, δύο παιδιά
Υπηκοότητα:	Ελληνική
Διεύθυνση κατοικίας:	Λιλής Ζωγράφου 21, Πόρος, 71307, Ηράκλειο, Κρήτη
Ηλεκτρονική διεύθυνση (e-mail):	kantoniou@uoc.gr
Γλώσσες:	• Ελληνική (Μητρική) • Αγγλική (First Certificate University of Cambridge) • Γαλλική (Certificat de Langue Française) • Ιταλική (άπταιστη γνώση)

2. ΕΚΠΑΙΔΕΥΣΗ

1.Βασική εκπαίδευση

- 1978-1987** Πρωτοβάθμια, Ηράκλειο Κρήτης
1987-1990 Δευτεροβάθμια, Ηράκλειο Κρήτης

2. Πανεπιστημιακή εκπαίδευση

- 1991-1998** Ιατρική Σχολή Πανεπιστημίου Napoli Federico II, Italy
1995-1997 Συμμετοχή στις δραστηριότητες και τις εφημερίες της Γενικής Χειρουργικής, Θωρακοχειρουργικής, Παθολογικής, Ορθοπαιδικής, Καρδιολογικής, Γαστρεντερολογικής, Νευρολογικής, ΩΡΛ, Ψυχιατρικής, Εντατικής, Ουρολογικής κλινικής του Πανεπιστημιακού νοσοκομείου Napoli Federico II, Italy
1997-1998 Συμμετοχή στις δραστηριότητες και τις εφημερίες (Senior Thesis) της Πνευμονολογικής κλινικής του Πανεπιστημιακού νοσοκομείου Napoli Federico II, Italy

3. Μετεκπαίδευση

Εργαστηριακή

- Απρίλιος 2000 - Ιούλιος 2000** Short Term Research Fellowship, European Respiratory Society, Imperial College Royal Brompton Hospital
2000 – 2004 Εκπόνηση διδακτορικής διατριβής στο Πανεπιστήμιο Κρήτης, Τμήμα Ιατρικής Σχολής
 Τίτλος Διδακτορικής Διατριβής: «Μελέτη μοριακών και φλεγμονωδών δεικτών μετά από μακροχρόνια χορήγηση ιντερφερόνης γάμμα-1β ή κολχικίνης σε ασθενείς με ιδιοπαθή πνευμονική ίνωση»
Σεπτέμβριος 2002 -Νοέμβριος 2002 Εργαστήριο Νοσημάτων Θώρακος, Ιατρική σχολή, Πανεπιστημιακό νοσοκομείο Napoli Federico II, Italy
2005 – 2006 Long Term Research Fellow, European Respiratory Society, Imperial College Royal Brompton Hospital Τίτλος εργασίας: Diffuse parenchymal lung disease: is smoking-related damage increased in prevalence, and does smoking status influence outcome?
2007 - σήμερα Collaboration with the ILDU Royal Brompton Hospital, Imperial College
2016 - σήμερα Collaboration with Professor Crestani, Hopital, University of Paris, France

Κλινική

- Αύγουστος 1999 -Νοέμβριος 1999** Εκπλήρωση τρίμηνης υποχρεωτικής εκπαίδευσης (Παθολογική , Καρδιολογική και Χειρουργική Κλινική) στο «Βενιζέλειο-Πανάνειο» Νοσοκομείο Ηρακλείου Κρήτης

- Νοέμβριος 2000 - Φεβρουάριος 2000** Μερική εκπλήρωση υποχρεωτικής υπηρεσίας υπαίθρου, ως αγροτική ιατρός στο Σταθμό Αιμοδοσίας Βενιζελίου, Ηρακλείου Κρήτης.
- 2000 - 2003** Ειδικευόμενη Ιατρός, Πνευμονολογικής Κλινικής Γενικού Περιφερειακού Νοσοκομείου Ηρακλείου «Βενιζέλιο-Πανάνειο»
- 2003 - 2005** Ειδικευόμενη Ιατρός, Πνευμονολογικής Κλινικής Πανεπιστημιακού Γενικού Νοσοκομείου Ηρακλείου (ΠΑΓΝΗ)
- 2005 -2006** Συμμετοχή ως Honorary Clinical Research Fellow (Επιστημονικός Συνεργάτης) στις δραστηριότητες της Πνευμονολογικής κλινικής του Πανεπιστημιακού Νοσοκομείου Royal Brompton Hospital, Imperial College, Faculty of Medicine, London, UK

3. ΔΙΠΛΩΜΑΤΑ

- 1998** Πτυχίο Ιατρικής (άριστα), Ιατρική Σχολή Πανεπιστημίου Napoli Federico II, Italy
- 2004** Διδακτορική διατριβή, Πανεπιστήμιο Κρήτης, Τμήμα Ιατρικής Σχολής

4. ΑΔΕΙΕΣ ΑΣΚΗΣΗΣ ΕΠΑΓΓΕΛΜΑΤΟΣ

- 1999** Άδεια άσκησης ιατρικού επαγγέλματος
- 2005** Τίτλος ειδικότητας Πνευμονολογίας, Πανεπιστημιακό Νοσοκομείο Ηρακλείου, Κρήτη

5. ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΣΤΑΔΙΟΔΡΟΜΙΑ - ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΘΕΣΕΙΣ

- 2006 - 2009** Λέκτορας Πνευμονολογίας (Συμβασιούχος Π.Δ. 407/80) Ιατρικής Σχολής Πανεπιστημίου Κρήτης
- 2009 -2014** Λέκτορας Πνευμονολογίας Ιατρικής Σχολής Πανεπιστημίου Κρήτης
- 2014 -2018** Επίκουρη Καθηγήτρια Πνευμονολογίας Ιατρικής Σχολής Πανεπιστημίου Κρήτης
- 2018 - 2022** Αναπληρώτρια Καθηγήτρια Πνευμονολογίας Ιατρικής Σχολής Πανεπιστημίου Κρήτης
- 2006 - σήμερα** Εξωτερικό Πνευμονολογικό Ιατρείο Πνευμονολογικής Κλινικής, ΠΑΓΝΗ
- 2007 - σήμερα** Υπεύθυνη Ιατρείου Διαμέσων Νοσημάτων Πνευμονολογικής Κλινικής, ΠΑΓΝΗ
- 2018 - σήμερα** Υπεύθυνη Ιατρείου Σοβαρού Άσθματος Πνευμονολογικής Κλινικής, ΠΑΓΝΗ
- 2014 - σήμερα** Υπεύθυνη Εργαστηρίου Μοριακής και Κυτταρικής Πνευμονολογίας Πανεπιστημίου Κρήτης
- 2022 – σήμερα** Καθηγήτρια Πνευμονολογίας Ιατρικής Σχολής Πανεπιστημίου Κρήτης

6. ΔΙΟΙΚΗΤΙΚΗ ΕΜΠΕΙΡΙΑ

6.1 ΜΕΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΠΙΤΡΟΠΩΝ - ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ ΣΤΟ ΕΣΩΤΕΡΙΚΟ

1. Μέλος της Κοσμητείας της Ιατρικής Σχολής Πανεπιστημίου Κρήτης (2015-2017)
2. Συντονίστρια Επιτροπής Εξωστρέφειας και Επικοινωνίας Πρυτανείας Πανεπιστημίου Κρήτης (2016-2017)
3. Συντονίστρια Επιτροπής Εξωστρέφειας-Εθιμοτυπίας-Δημοσίων Σχέσεων της Ιατρικής Σχολής (2020-2022)
4. Μέλος της Γενικής Συνέλευσης του Τμήματος Ιατρικής, Πανεπιστήμιο Κρήτης για τα ακαδημαϊκά έτη (2009-2012), (2014-2017) (2021-2022)
5. Συντονίστρια Επιτροπής Διασύνδεσης Ιατρικής – Γραφείο Αποφοίτων Ιατρικής Σχολής Πανεπιστημίου Κρήτης (2016-2017)
6. Μέλος της Ομάδας Εργασίας της Επιτροπής Προπτυχιακών Σπουδών του Τμήματος Ιατρικής για την Κλινική Άσκηση στην Παθολογία, υπό την Καθηγήτρια Κα Ελένη Παπαδάκη (2012)
7. Μέλος της Επιτροπής Μεταπτυχιακών Σπουδών Ιατρικής Σχολής Πανεπιστημίου Κρήτης (2014-2015) (2017-2018)
8. Μέλος Επιτροπής Ηθικής & Δεοντολογίας του Πανεπιστημιακού Γενικού Νοσοκομείου Ηρακλείου (2014-σήμερα)
9. Αναπλ. Μέλος του Διοικητικού Συμβουλίου του Πανεπιστημιακού Γενικού Νοσοκομείου Ηρακλείου (2020-2021)
10. Μέλος της Επιστημονικής Ομάδας Εργασίας για την επικαιροποίηση των Διαγνωστικών και Θεραπευτικών Πρωτοκόλλων Συνταγογράφησης για τα Αναπνευστικά Νοσήματα, Συντονιστής Κος Λουκίδης Στυλιανός (Σεπτέμβριος 2021-σήμερα)
11. Μέλος της Επιτροπής Στρατηγικού Σχεδιασμού της Ιατρικής Σχολής (2020-2021) (2021-2022)
12. Μέλος της Επιτροπής Πολιτισμού του Πανεπιστημίου Κρήτης (Οκτώβριος 2023-σήμερα)

6.2 ΜΕΛΟΣ ΔΙΕΘΝΩΝ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΠΙΤΡΟΠΩΝ – ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ

1. ERS Interstitial Lung Diseases Group, Secretary (2011-2014)
2. ERS Interstitial Lung Diseases Group, Chair (2014-2017)
3. Coordinator of ILD Working Group of the Hellenic Thoracic Society (2011-2017)
4. ERS Abstract Reviewer (2010-2021)
5. ERS Evaluation Committee for Fellowships and Visiting Professorships (2011-2017)
6. Reviewer of Journals: Lancet, Lancet Respir Med, BMJ, Eur. Respir Journal, Chest, Respir Res, Respir Med, Respiriology, Respiration, Pulmonary Pharmacology & Therapeutics, etc

7. Guest editor, Frontiers in Immunology, Research Topic "Mechanisms of Lung Fibrosis: is Immunity Back in the Game?"
8. Associate Editor: ERR, Breath, Pulmonology
9. General Medical Council, reference number : 6127849
10. ERS/ATS research statement: Interstitial pneumonia with autoimmune features (Eur Respir J 2015 Oct;46(4):976-87)
11. "International Working Group on Undifferentiated forms of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)", ATS/ERS Task Force
12. Statement on Combined Pulmonary Fibrosis and Emphysema (CPFE), ERS Task Force (TF-2018-15)
13. Idiopathic Pulmonary Fibrosis (IPF)-An update of diagnosis and treatment recommendations, ERS Task Force (TF-2019-18); under revision
14. CTD-ILD Guidelines (ERS-EULAR) "Clinical practice guideline on connective tissue diseases with interstitial lung (ILD) involvement", Co-chair (TF-2020-03)
15. ERS clinical practice guidelines on treatment of sarcoidosis (Eur Respir J. 2021)
16. ERS Statement on Covid-19 Follow-Up, Co-chair (TF-2020-14, Eur Respir J under revision)
17. ERS Guidelines for management of Covid-19 (Eur Respir J 2021)
18. ERS Assembly 12 Secretary (2018-2021)
19. ERS Assembly 12 Head (2021-2024)
20. WASOG executive committee (elected) (2021- today)
21. Member of PVRI Working group about PH-ILDs (2021-today)

7. ΕΠΙΣΤΗΜΟΝΙΚΟ ΕΡΓΟ

7.1 ΧΡΗΜΑΤΟΔΟΤΗΣΕΙΣ ΕΡΕΥΝΗΤΙΚΩΝ ΠΡΟΓΡΑΜΜΑΤΩΝ

1. (Ε.Π.Ε.Α.Ε.Κ. ΙΙ) PYTHAGORAS ΙΙ: Support grant at the universities (50.000 euros): Somatic Mutations at the level of microsatellite DNA; discovering the responsible cell in chronic obstructive diseases of the lung, Heraklion 2005-2007
2. 1st Award GlaxoSmithKline annual research grant, Hellenic Thoracic Society Congress 2007, Title of the biological axis SDF-1a-CXCR4 expression in BM-MSCs and pulmonary tissue in patients with IPF (15.000 euros)
3. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2008 for the project entitled, Bone marrow derived stem cells in COPD: role in vascular remodelling (15.000 euros)
4. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2009 for the project entitled, Phenotypical and molecular characteristics of Bone Marrow Mesenchymal Stem Cells in Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) (15.000 euros)
5. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2010 for the project entitled, Investigation of the role of inflammasomes in the pathogenesis of lung fibrosis (15.000 euros).
6. 7th Framework Programme for Research, EU. Title: "Enhancing University of Crete Medical School Scientific Excellence and Translational Research Potential in Human Diseases". 3,410,160 euros). January 2012-December 2014. (Co-Applicant).
7. Idiopathic Pulmonary Fibrosis Research Award, ERS Vienna 2012, Supported by Intermune, (7.500Euros)
8. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2012 for the project entitled, "Regulation of microRNAs in response to Herpes Simplex Virus type-1 (HSV-1) infection in IPF: Implications in pathogenesis and disease progression" (15.000 euros)
9. Successful application for European Respiratory Society (ERS) Respire2 Respiratory Host Center (for post-doc fellowship position, 20000 euros/fellow –year)
10. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2013 for the project entitled, "Regulation of autophagy in IPF bronchoalveolar lavage fluid (BALF)" (15.000 euros)
11. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2015 for the project entitled, 'Investigation of Mitochondria homeostasis in Idiopathic Pulmonary Fibrosis (IPF) macrophages - a mitophagy study in bronchoalveolar lavage fluid (BALF) (15.000 euros)
12. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2016 for the project entitled, "Development of 'anti-fibrotic/fibrolytic' HSV-1 recombinant vectors targeting IL-13 responsive cells to combat pulmonary fibrosis". (15000 euros)

13. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2017 for the project entitled, "Lung microbiome and innate immune responses in Idiopathic Pulmonary Fibrosis". (15000 euros)
14. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2018 for the project entitled, "Identification of putative common and distinct phenotypic and metabolic states of Alveolar macrophage sub-populations in Idiopathic Pulmonary Fibrosis(IPF) and non-IPF fibrotic ILDs" (15000 euros)
15. 3 Unrestricted research grants by Hoffman La-Roche 2015, 2016, 2017, 2018.
16. 4 Unrestricted grants by Boehringer Ingelheim 2016, 2017, 2018, 2020.
17. Recipient of Hellenic Foundation for Research and Innovation HFRI grant for Faculty members (2020), "Metabolic FibroClock" (180,000 euros)
18. 1st Unrestricted grant by Hellenic Thoracic Society, Clinical Research Award for 2022 for the project entitled, "The role of the anti-aging protein, a-Klotho, on metabolism and mitochondrial homeostasis of monocytes/macrophages in IPF patients and patients with progressive pulmonary fibrosis (PPF)." (15000 euros)

7.2 ΕΡΕΥΝΗΤΙΚΗ ΣΥΜΜΕΤΟΧΗ ΣΕ ΕΚΠΟΝΗΣΗ ΚΛΙΝΙΚΩΝ ΜΕΛΕΤΩΝ

1. 1199.33 B.I An open label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis.
2. 1199.252 INDULGE IPF B.I Investigating idiopathic pulmonary fibrosis in Greece (INDULGE IPF).
3. MA29957 ROCHE A Phase IIb Multicenter, Randomised, Double-Blind, Placebo controlled Study to evaluate the efficacy, safety, and tolerability of Sildenafil added to Pirfenidone in patients with advanced idiopathic Pulmonary Fibrosis and intermediate or high probability of group 3 Pulmonary Hypertension.
4. ML39259 ROCHE A Multicenter, Post Marketing, Non Interventional Observational Study to evaluate quality of life in patients in Greece with Idiopathic Fibrosis under treatment with pirfenidone– The Pneumon Study.
5. DRI11772 SANOFI Phase II Efficacy and safety of SAR156597 in the treatment of Idiopathic Pulmonary Fibrosis: A Randomised, double-blind, placebo controlled, 52-week dose-ranging study.
6. CC-90001-IPF-001. CELGENE A Phase II, 24-week, randomised, double-blind, placebo - controlled, multicenter study, followed by 28-week treatment extension, to evaluate the efficacy and safety of CC-90001 in subjects with Idiopathic Pulmonary Fibrosis.
7. MA39189 ROCHE Phase III multicenter, international, double-blind, two-arm, randomized, placebo-controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD.
8. MA39293-DIET CIBER. An open label phase IV, multicenter, international, interventional study to evaluate the effect of diet on gastrointestinal adverse events in patients with IPF treated with

Pirfenidone.

9. 203PF203 BIOGEN. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis.
10. 1199-0355 BOEHRINGER INGELHEIM. Investigating Trends in Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Treatment with Nintedanib.
11. GLPG1690-CL-303 GALAPAGOS. A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local started of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.
12. 0352-2144 BOEHRINGER INGELHEIM. An interventional study without an investigational medicinal product to differentially diagnose patients with interstitial lung diseases (ILDs), to monitor disease progression, and to identify molecular markers.
13. RPL554-CO-301 VERONA PHARMA. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks (With a 48-Week Safety Subset) in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.
14. WA42294 :A phase III open-label extension study to evaluate long-term safety and efficacy of prm-151 in patients with idiopathic pulmonary fibrosis (IPF)
15. WA 42293 : A phase III Randomised , Double –blind, Placebo –controlled ,trial to evaluate the efficacyand safety of PRM -151 with patients with idiopathic pulmonary fibrosis (IPF)
16. A Randomized ,Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy Safety, and Tolerability of Dupilumab in Patients with Moderate – to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation EFC15808(NOTUS).
17. 0352-2144 B.I. An interventional study without an investigational medicinal product to differentially diagnose patients with interstitial lung diseases (ILDs), to monitor disease progression, and to identify molecular markers.
18. HZNP-HZN-825-303. A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis.
19. LYT-100-2022-204. A randomized double-blind, four arm active and placebo-controlled dose-finding trial to evaluate the efficacy, tolerability, and safety dose response of LYT-100 in patients with Idiopathic Pulmonary Fibrosis (IPF).
20. 1305-0014. A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF).

21. 1305-0023. A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
22. GB44496. A two-cohort, phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of vixarelimab compared with placebo in patients with Idiopathic pulmonary fibrosis and in patients with systemic sclerosis associated interstitial lung disease.
23. GB44332 ARNASA: A Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of astegolimab in patients with chronic obstructive pulmonary disease.
24. 1305-0031: An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
25. 218224: APhase 2/3, randomized, double-blind , placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)
26. PLN-74809-IPF-206: A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
27. OATD-01-C-03: A randomized, double-blind, dose-ranging, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase-1 (CHIT1), for the treatment of active pulmonary sarcoidosis.
28. IM0271015: A Multicenter, Randomized, double-blind, dose-ranging, placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
29. 1462-0004: A randomized, double-blind, dose-ranging, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF)
30. 1490-0004: A Phase IIa/IIb, randomized, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
31. VP-C21-011: A randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multicenter trial evaluating the fefficacy and safety of 2 doses of buloxibutid over 52 weeks in people with idiopathic pulmonary fibrosis.
32. 10961: Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

7.3 ΥΠΟΤΡΟΦΙΕΣ – ΒΡΑΒΕΥΣΕΙΣ

Μάιος 2000-Ιούλιος 2000	Short Term Research Fellowship, European Respiratory Society, Imperial College Royal Brompton Hospital. 10.000 Euros Short Term
Οκτώβριος 2003	Alfred Soffer Research Award ACCP Annual Meeting, Orlando, Florida, 1000 US Dollars
Μάρτιος 2005- Απρίλιος 2006	Long Term Research Fellowship, European Respiratory Society, Imperial College Royal Brompton Hospital. 36.000 Euros
Δεκέμβριος 2005	A' Best Presentation Award, Hellenic Thoracic Society Annual Congress 2005. Title: "Study of IFN-gamma 1b in Idiopathic Pulmonary Fibrosis.", 1.000 Euros
Νοέμβριος 2006	A' Best Presentation Award, Pankrition Congress 2006. Title: "Study of angiogenetic balance CXC Chemokines in Bronchoalveolar lavage fluid in patients Idiopathic Pulmonary Fibrosis.", 1.500 Euros
Δεκέμβριος 2007	A' Best Presentation Award, Hellenic Thoracic Society Annual Congress 2007. Title: "Investigation of the expression of the biological axis SDF-1A-CXCL12 and receptor CXCR4 in BM-MSCs and pulmonary tissue of patients with IPF", 1.500 Euros
Δεκέμβριος 2009	B' Best project Hellenic Thoracic Society Annual Congress. Title of project "Title: "Investigation of the expression of the biological axis CXCR4-SDF-1a in BM-MSCs in patients with Rheumatoid Arthritis interstitial lung disease", 700 Euros
Δεκέμβριος 2009	A' Best Thematic Poster Award, Hellenic Thoracic Society Annual Congress 2009. Title: "Toll-like receptors expression in Fibrotic interstitial pneumonias; preliminary results." 1.000 Euros
Δεκέμβριος 2010	A' Best Presentation Award, Hellenic Thoracic Society Annual Congress 2007. Title: "Investigation of telomerase expression and telomere length in autoimmune and idiopathic pulmonary fibrosis", 1.500 Euros

Δεκέμβριος 2010	Best Thematic Poster Award, Hellenic Thoracic Society Annual Congress 2010. Title: "Expression of TACI and BAFF-R proteins in patients with Sarcoidosis"
Νοέμβριος 2011	Oral presentation Award, Hellenic Thoracic Society Annual Congress 2011, Title: "Investigation of Telomerase expression-telomere length in BM-MSCs of patients with Rheumatoid Lung,
Νοέμβριος 2011	Best project Award Hellenic Thoracic Society Annual Congress 2011, Title of project "Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases."
Οκτώβριος 2012	Best Poster Award in ILDs Thematic Session, Hellenic Thoracic Society Annual Congress 2012, Title: "Investigation of Citrullination Enzymes in bronchoalveolar lavage fluid in patients with IPF"
Οκτώβριος 2012	Best Poster Award in ILDs Thematic Session, Hellenic Thoracic Society Annual Congress 2012, Title: "Investigation of TACI and BAFF-R proteins with pulmonary sarcoidosis"
Δεκέμβριος 2013	Best publication 22nd Hellenic Thoracic Society Congress 2013 Title: "The presence of Merkel cell polyomavirus is associated with deregulated expression of BRAF and Bcl-2 genes in non-small cell lung cancer."
Νοέμβριος 2015	1st award – oral presentation, 24th Hellenic Thoracic Society Congress, 2015 Title: "Investigation of Mitochondria homeostasis in Idiopathic Pulmonary Fibrosis (IPF) macrophages- a mitophagy study in bronchoalveolar lavage fluid." 1st award - e-poster: 24th Hellenic Thoracic Society Congress, 2015. Title: "Expression of miR-185 targets, DNA methyltransferase 1 and Cyclin D2 in IPF and lung cancer in BALF cells: Preliminary results."
Ιούνιος 2016	3rd award - oral presentation, 25th Hellenic Thoracic Society Congress, 2016. Title: "MiR-185/AKT and MiR-29a/Collagen1a pathways are activated in IPF alveolar macrophages." Best Publication, Hellenic Thoracic Society Congress 2016; Title; "NLRP3 inflammasome expression in Idiopathic Pulmonary Fibrosis & Rheumatoid lung"
Δεκέμβριος 2021	Research Scholarship Award, Hellenic Thoracic Society. "Title: The effect

of SGLT2 inhibitors on metabolism, mitochondrial homeostasis of monocytes/macrophages and progression of fibrosis in IPF and CTD-ILD patients.”

7.4 ΟΡΓΑΝΩΣΗ ΣΥΝΕΔΡΙΩΝ

1. 9th WASOG Meeting & 11th BAL International Conference
2. Pulmonary Review and Refreshing Course of Pulmonary Medicine in Interstitial Lung Diseases, December 2009
3. ERS Research Seminar on “Novel insights in pulmonary fibrogenesis” from bench to bedside, in November 12-13th , 2010, Athens
4. Organizing Member of the Scientific Committee of the Hellenic Thoracic Society Congress (21th) , 18-21 October 2012
5. Scientific Committee of the National Congresses of the Hellenic Thoracic Society as Coordinator of the ILD Group of the Hellenic Thoracic Society (HTS), 2012-2017
6. IPF and Sleep: Common pathways and implications in therapy; Endorsed by the ER, 5 December 2013, Megaron Athens International Conference Center
7. ERS Research Seminar on “IPF and Cancer: Wounds that do not heal” Athens, Greece, 13-14 February 2015
8. Cretan Summer School of Respiratory Department (SHARE), Interstitial Lung diseases (ILDs) course: from bench to bedside Heraklion, Crete, 20-22 July 2017
9. International WASOG conference (endorsed by ERS), Heraklion, June 7-9, 2018.
10. 2nd Cretan Summer School of Respiratory Department Share, June 30-July 03, Heraklion 2022
11. 3rd SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Heraklion 2023
12. 4th SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Heraklion 2024
13. 5th SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Heraklion 2025
14. 1st ILD Turkish Greek Workshop, Izmir, 2024
15. 2nd ILD Turkish Greek Workshop, Heraklion, 2025

7.5 ΠΡΟΕΔΡΕΙΑ ΣΕ ΔΙΕΘΝΗ ΣΥΝΕΔΡΙΑ

1. “Novel insights in pulmonary fibrogenesis from bench to bedside”; ERS Research Seminar, November 12-13, 2010
2. Thematic Poster Session; ERS Vienna Congress, 2009
3. Thematic Poster Session: “Clinical aspects in pulmonary in pulmonary fibrosis”, and “Biomarkers in diffuse parenchymal lung disease”; ERS Barcelona Congress, 2010
4. Postgraduate Course on Idiopathic Pulmonary Fibrosis (PG11); ERS Vienna, 2012
5. Oral Presentation: “Interstitial lung disease from bench to bedside” (session 472); ERS Vienna 2012
6. Imaging Group, CTD-ILD Working Group; Washington Dulles Meeting, July 12, 2012
7. Session: “Infectious Diseases”; 17th World Congress on Advances on Oncology and 15th International Symposium on Molecular Medicine, 2012
8. Session: “Drug induced pulmonary toxicity and around”; 5th International Meeting on Pulmonary Rare Diseases and Orphan Drugs, Milan, Italy, February 8-9, 2013
9. Oral Presentation Session: “Idiopathic pulmonary fibrosis: Pathogenesis”, Session 361; ERS Barcelona, Spain, September 7-11, 2013
10. Session: “Exogenous ILDs I”; Fibrosing Interstitial Lung Diseases of Idiopathic and exogenous origin. Phenotype approach; ERS, AIPO, Prague, Czech Republic, June 19-21, 2014
11. Session: “Exogenous ILDs II and Pulmonary manifestations of Connective Tissue diseases (CTDs)”; Fibrosing Interstitial Lung Diseases of Idiopathic and exogenous origin. Phenotype approach; ERS, AIPO, Prague, Czech Republic, June 19-21, 2014
12. Session: “Poster Session and discussion”, Fibrosing Interstitial Lung Diseases of Idiopathic and exogenous origin. Phenotype approach; ERS, AIPO, Prague, Czech Republic, June 19-21, 2014
13. Oral Presentation session: “IPF & Surroundings”; ERS International Congress, Munich, Germany, September 6-10, 2014
14. Grand Round: “Diffuse parenchymal lung disease and interventional pulmonology procedures” an interactive session; ERS International Congress, Munich, Germany, September 6-10, 2014
15. Evening Mini Symposium: “New aspects of the clinical value of biomarkers in diffuse lung diseases”; ERS International Congress, Munich, Germany, September 6-10, 2014
16. Oral Presentation Session: “IPF Pathogenesis”; ERS International Congress, Munich, Germany, September 6-10, 2014
17. Session: “Are IPF and cancer twin diseases? A biological point of view”; IPF and Cancer: wounds that do not heal, ERS Research Seminar, Athens, Greece, February 13-14, 2015
18. Session: “IPF pathogenesis session”; ERS Annual Congress, 2015

19. Research (AIR) 2015; Hilton Hotel, Prague, Czech Republic, November 27-28, 2015
20. Chairs: Alexander G. Chuchalin (Moscow, Russian Federation), Katerina Antoniou (Heraklion, Crete, Greece), ERS 2016, PG17
21. Session: "Aetiology, pathology, and diagnosis of Interstitial Lung Disorders (ILDs)", 8th International WASOG (Conferenec on Diffuse Parenchymal Lung Diseases), Gdansk, Poland, June 2-4, 2016
22. Session 6: Advancing IPF research: Future directions; Panel discussion: Challenges in IPF diagnosis: What's missing from the guidelines; Advancing in IPF
23. "Transbronchial Cryobiospy in diffuse parenchymal lung disease"; Ravenna, October 27-28, 2016 Endorsed by ERS
24. "Integrating sysyems biology approach in IPF research"; ERS Research Seminar, Barcelona, Spain, December 15-16, 2016
25. Session: "Idiopathic Pulmonary Fibrosis: where we are"; 7th International meeting on Pulmonary Rare diseases and orphan dtugs, (endorsed by ERS), Milan, Italy, February, 2017
26. Session: "Molecular Oncology"; 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine, Crete-Greece, October 10-12, 2013
27. Session: "Closing Remarks", Areas of research need in IPF and Sleep, IPF & Sleep: Common pathways and implications in therapy (endorded by the ERS), 22nd Panhelelnic Congress, Athens, December, 2013
28. Session; "Diagnosis and monitoring of pulmonary and extrapulmonary sarcoidosis 2"; 3RD WASOG- BAL Congress, , Kusadasi, Turkey October 8-11, 2014
29. Session: "Infectious diseases/ molecular medicine"; 19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, , Athens- Greece, October 9-11, 2014
30. "Interstitial Lung Disease"; 3rd HTS-ERS Hermes Summer School, Athens, Greece, August 28-31, 2014
31. Session: "Hot topics in Rare Pulmonary diseases and orphan drugs"; 6th International meeting on Pulmonary rare diseases and orphan drugs; February 27-28, 2015
32. Corso ERS STUDY GROUP, "Update on Diffuse Parenechymal Lung Diseases"; Pneumotrieste, Trieste, April 13-15, 2015
33. "Interstitial Lung Disease"; 4TH HTS-ERS Hermes Summer School, Athens, Greece, September 3-6, 2015
34. Sessions: "An overview and the clinical corner I", in Transbronchial Cryobiospy in diffuse parenchymal lung disease, (Endorsed by the ERS), Ravenna, September 8-9, 2015
35. International School for Interstitial Lung diseases; Ettore Majorana Foundation Erice, December 9-11, 2015
36. Oral Presentation session: "Idiopathic pulmonary fibrosis (IPF): treatment highlights."; ERS Annual Congress, 2017
37. SymposiumState of the art session: "Interstitial lung disease and pulmonary vascular diseases" Clinical ERS Annual Congress, 2017

38. Session 2: “Idiopathic Pulmonary Fibrosis”, Interstitial Lung diseases (ILDs) course: from bench to bedside; Cretan Summer School of Respiratory Department (SHARE), Heraklion, Crete, July 20-22, 2017
39. Session 3: “Sarcoidosis”, Interstitial Lung diseases (ILDs) course: from bench to bedside; Cretan Summer School of Respiratory Department (SHARE), Heraklion, Crete, July 20-22, 2017
40. “Keynote Lecture: Should I treat Pulmonary Hypertension in Chronic Lung Diseases?”; WASOG-Sarcoidosis & Interstitial Lung Diseases, Heraklion, Crete, June 07-09, 2018
41. “Debate: Autoimmunity/ Inflammation is important in IPF”; WASOG-Sarcoidosis & Interstitial Lung Diseases, Heraklion, Crete, June 07-09, 2018
42. “Diagnosis in ILDs”; WASOG-Sarcoidosis & Interstitial Lung Diseases, Heraklion, Crete, June 07-09, 2018.
43. Special Lecture: “The value of cooperation, the magic of synergies!”; WASOG-Sarcoidosis & Interstitial Lung Diseases, Heraklion, Crete, June 07-09, 2018
44. “State of the art Lecture: ANCA-Associated Vasculitis and the Lung-Novel Insights”; WASOG-Sarcoidosis & Interstitial Lung Diseases, Heraklion, Crete, June 07-09, 2018
45. “Mechanistic overlap between IPF and cancer: focus on the TGF β signaling axis”; WASOG-Sarcoidosis & Interstitial Lung Diseases, Heraklion, Crete, June 07-09, 2018
46. “Assembly members’ meeting: Assembly 12 Interstitial lung diseases-Session 144”; ERS International Congress 2018, Paris, France, September 15-19, 2018
47. “Grand round: Clinical Grand Round Diffuse parenchymal lung diseases-Session 489”; ERS International Congress 2018, Paris, France, September 15-19, 2018
48. “Genetics: diagnosing, counseling, and optimising therapy in fibrotic lung diseases”; ERS Satellites, Athens, Greece, February 21, 2019
49. “Assembly members meeting: Assembly 12: Interstitial lung diseases”; ERS International Congress, Madrid, Spain, Sept 28 –Oct 02, 2019
50. “Symposium: State of the art session: International lung diseases”; ERS International Congress, Madrid, Spain, Sept 28 –Oct 02, 2019
51. “Poster Session 11 “Diffuse lung diseases/Others 1”; WASOG/JSSOG, Tokyo, October 09-11, 2019
52. “Meilleurs articles”; 24^e CPLF Congres De Pneumologie De Langue Francaise, Paris, January 24-26, 2020
53. “Impact in children and in adults with premorbid respiratory disease (acute and long-term)”; ERS International Congress, Munich, Germany, September 06-09, 2020 (webinar)
54. “Symposium: Severe thoracic sarcoidosis: where do we stand?”; ERS International Congress, Munich, Germany, September 06-09, 2020 (webinar)
55. “Lungs on fire: Interstitial lung diseases?”; ERS International Congress, Munich, Germany, September 06-09, 2020 (webinar)

56. "Expert view: Smoking, nicotine and COVID-19 myths and facts. What is the evidence?"; ERS International Congress, Munich, Germany, September 06-09, 2020 (webinar)
57. "Pro/Con debate: Is the global warming potential of inhaler propellants significant?"; ERS International Congress, Munich, Germany, 06-09 September 2020 (webinar)
58. "Lungs on fire: Pulmonary vascular diseases?"; ERS International Congress, Munich, Germany, September 06-09, 2020 (webinar)
59. "Respiratory medicine meets rheumatology: What is new in connective tissue diseases-ILD"; ERS webinar (<https://ersnet.org>) , June 14, 2021
60. "Assembly members' meeting: Assembly 12: Interstitial lung diseases"; ERS International Congress, September 01, 2021 (webinar)
61. "Symposium: Holistic care in interstitial lung disease: monitoring the patient's pathway Monitoring patients with interstitial lung disease via telemedicine"; ERS International Congress, Studio Munich, September 05, 2021 (webinar)
62. "Pro-Con debate: Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease?"; ERS International Congress, Studio Munich, September 05, 2021 (webinar)
63. "Guidelines session: ERS clinical practice guidelines on treatment of sarcoidosis"; ERS International Congress, Studio Munich, September 05, 2021 (webinar)
64. "State of the art session: Interstitial lung diseases Novel insights into interstitial lung diseases in 2021"; ERS International Congress, Studio Barcelona, September 06, 2021 (webinar)
65. "Lungs on fire: LoF Interstitial lung diseases?"; ERS International Congress, Studio Barcelona, September 06, 2021 (webinar)
66. "Symposium: Emerging imaging biomarkers in lung disease" ; ERS International Congress, Studio Barcelona, September 06, 2021 (webinar)
67. "Journal session: Interstitial lung diseases: from disease mechanisms to novel treatment options A joint ERS/Lancet session" ; ERS International Congress, Studio Barcelona, September 06, 2021 (webinar)
68. "Symposium: Holistic care in interstitial lung disease: monitoring the patient's pathway"; ERS International Congress, Zurich, Switzerland, September 05-08, 2021 (webinar)
69. "Pro-Con debate: Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease?"; ERS International Congress, Zurich, Switzerland, September 05-08, 2021 (webinar)
70. "Guidelines session: ERS clinical practice guidelines on treatment of sarcoidosis" ; ERS International Congress, Zurich, Switzerland, September 05-08, 2021 (webinar)
71. "State of the art session: Interstitial lung diseases" ; ERS International Congress, Zurich, Switzerland, September 05-08, 2021 (webinar)

72. “Lungs on fire: LoF Interstitial lung diseases?” ; ERS International Congress, Zurich, Switzerland, September 05-08, 2021 (webinar)
73. “Symposium: Emerging imaging biomarkers in lung disease” ; ERS International Congress, Zurich, Switzerland, September 05-08, 2021 (webinar)
74. “Journal session: Interstitial lung diseases: from disease mechanisms to novel treatment options” ; ERS International Congress, Zurich, Switzerland, September 05-08, 2021 (webinar)
75. “Session: Basic Science Corner/Connections”; Transbronchial Cryobiopsy in Diffuse Parenchymal Lung Disease 8th edition, September 16-17, 2021 (webinar)
76. “Debate - Controversies in interstitial lung disease”; ERS webinar (<https://ersnet.org>), November 09, 2021
77. Session 14: “Challenging issues in acute exacerbations of interstitial lung disease-Part 1”; ERS Virtual academy on interstitial lung diseases, December 03, 2021 (webinar) Round table discussions: COVID-ILD; Virtual masterclass on interstitial lung diseases, 5–6 April 2022
78. “Holistic approach in IPF”; Virtual masterclass on interstitial lung diseases, 5–6 April 2022
79. “The new challenge of CTD-ILD: from basic science to clinical setting”; ERS webinar (<https://ersnet.org>), June 15, 2022
80. “Oral presentation: Hot topics in connective tissue disease-associated interstitial lung disease”; ERS International Congress, Barcelona, Spain, September 04-06, 2022
81. “State of the art session: Interstitial lung diseases”; ERS International Congress, Barcelona, Spain, September 04-06, 2022
82. “Clinical cases: Lungs on fire: Interstitial lung diseases?”; ERS International Congress, Barcelona, Spain, September 04-06, 2022
83. “Backstage discussion: Backstage discussion for ALERT 3: COVID and interstitial lung diseases”; ERS International Congress, Barcelona, Spain, September 04-06, 2022
84. “Symposium: Asthma: confusion in diagnosis, recognising comorbidities and understanding pathophysiological connections”; ERS International Congress, Barcelona, Spain, September 04-06, 2022
85. “Hot topics: Towards elimination of COPD”; ERS International Congress, Barcelona, Spain, September 04-06, 2022
86. “Lung involvement in rheumatic disease”; 10th International Meeting on Pulmonary Rare Diseases and Orphan Drugs, Milan, Italy, March 03-04, 2023
87. “How to use your diagnostic tools in sarcoidosis”; ERS Virtual School of Sarcoidosis, Online, 06-07 June 2023
88. “Symposium: Difficult treatment decisions in pulmonary Hypertension”; ERS International Congress, Milan, Italy, September 09-13 2023

89. "Mini Symposium: Symptom burden in interstitial lung disease"; ERS International Congress, Milan, Italy, September 09-13 2023
90. "Symposium: Pulmonary hypertension and interstitial lung diseases: dilemmas in diagnosis and the conundrum of treatment"; ERS International Congress, Milan, Italy, September 09-13 2023
91. "Mini Symposium: Complex pleural disease: management in the critically ill patient"; ERS International Congress, Milan, Italy, September 09-13 2023
92. "Assembly members' meeting: Assembly 12: Interstitial lung diseases"; ERS International Congress, Milan, Italy, September 09-13 2023
93. "Basic science in IPF: update", Transbronchial Cryobiopsy in Diffuse Parenchymal Lung Disease 10th edition, Ravenna, October 05-06 2023

7.6 ΠΡΟΣΚΕΚΛΗΜΕΝΗ ΟΜΙΛΗΤΡΙΑ ΣΕ ΔΙΕΘΝΗ ΣΥΝΕΔΡΙΑ

1. "Collagen Vascular Diseases with interstitial lung involvement: outcome in relation to smoking status"; 12th State of the Art, Interdisciplinary Review Course on Pulmonary Diseases Critical Care Emergency Medicine & Nursing Care, Athens, Greece, April 11-13, 2008
2. "Smoking and ILDs"; 9th WASOG Meeting & 11th BAL International Conference, Athens, Greece, June 19-22, 2008
3. "Acute respiratory symptoms in a patient with idiopathic thrombocytopenic purpura", Clinical Grand Round Session; ERS, 2009
4. "Sarcoidosis: diagnostic procedures and treatment approaches"; Pulmonary Review and Refreshing Course of Pulmonary Medicine, December 2009
5. "Idiopathic Pulmonary Fibrosis"; 'Pulmonary Review and Refreshing Course of Pulmonary Medicine, December 2009
6. "Early diagnosis in DPLD: the quest for new invasive and non-invasive biomarkers" – "Interstitial Lung Disease: A clinical state of the art"; 11th International Symposium of K.U. Leuven, March 18-20, 2010 – "Interstitial Lung Disease: A clinical state of the art"
7. "Pathogenetic events in NSIP"; ERS School, Update on Diffuse Parenchymal Lung Diseases, Italian Congress, PneumoTrieste, Trieste, Italy, May 10-12, 2010
8. "Connective Tissue Lung Diseases, Mesenchymal Stem cells in fibrotic lung disorders"; 14th State of the Art, Interdisciplinary Review Course on Pulmonary Diseases Critical Care Emergency Medicine & Nursing Care, Athens, Greece, June 18-19, 2010

9. "Novel insights in pulmonary fibrogenesis: from bench to bedside"; Smoking and Interstitial lung diseases, ERS Research Seminar, Athens, Greece, November 12-13, 2010
10. "Sarcoidosis: diagnostic procedures and treatment approaches"; Pulmonary Review and Refreshing Course of Pulmonary Medicine, Cyprus July 2-4, 2010
11. "Smoking related ILDs"; ERS School, Update on Diffuse Parenchymal Lung Diseases, Trieste, Italian Congress, PneumoTrieste, Trieste, Italy, April 4-6, 2011
12. "A 65-year-old woman with lung mass and pleural effusion", Clinical Grand Round Session; ERS 2011
13. "Novel insights in the pathogenesis of Rheumatoid Lung"; 15th State of the Art, Interdisciplinary Review Course on Pulmonary Diseases Critical Care Emergency Medicine & Nursing Care, Athens, Greece, April 7-9, 2011
14. "Novel Therapeutic Approaches for IPF"; 2nd ACCP-HTS Pulmonary Board Review Course, Athens Greece, June 6-10, 2012
15. "Sarcoidosis"; 1st Hellenic Thoracic Society HERMES Summer School, Fodele, Heraklion, Crete, July 5-8, 2012
16. "ILDs in Collagen Vascular Diseases", ERS School, Update on Diffuse Parenchymal Lung Diseases; Italian Congress, PneumoTrieste, Trieste, Italy, March 26-28, 2012
17. "Novel therapeutic approaches in IPF"; ERS CME online, ERS Headquarters, Lausanne, May 2012
18. "Imaging in CTD-ILDs"; CTD-ILD Working Group, Washington Dulles Meeting, July 12, 2012
19. "The role of Citrullination in the pathogenesis of Fibrotic Lung Diseases"; 7th International Colloquium on Lung and Airways Fibrosis, Modena, Italy, September 29 – October 3, 2012
20. "Regulation of microRNAs in response to Herpes Simplex Simplex Virus type-1 (HSV-1) infection in Idiopathic Pulmonary Fibrosis (IPF): Preliminary results"; TransPOT biannual meeting, Heraklion, Crete, January 28, 2012
21. "Therapeutic Strategies in IPF"; 5th International Meeting on Pulmonary Rare Diseases and Orphan Drugs, Milan, Italy, February 8-9, 2013
22. "Smoking and ILDS"; ERS School, PneumoTrieste Meeting, Trieste, Italy, April 8-10, 2013
23. "ILD"; 6th international conference, WASOG Paris, Sorbonne, France, June, 2013
24. "Sarcoidosis"; 2nd Hellenic Thoracic Society HERMES Summer School, Fodele, Heraklion, Crete, July, 2013
25. "Clinical Year in Review: Interstitial lung diseases" Session 138; ERS Annual Congress, Barcelona, Spain, September 7-11, 2013
26. The IPF Research Award on IPF Ceremony–Ceremony for ERS Research Award on Idiopathic Pulmonary Fibrosis (financially supported by InterMune)

27. IPF comorbidities and their potential relevance to OSA , IPF & Sleep: Common pathways and implications in therapy; Annual Congress 2013 22nd Panhelelnic Congress, Athens, December, 2013 (endorded by the ERS)
28. “Pathogenesis of hypersensitivity pneumonitis”; Fibrosing Interstitial Lung Diseases of Idiopathic and exogenous origin. Phenotype approach, Prague, Chech Republic, June 19-21, 2014
29. “Hypersensitivity pneumonitis; Causes, clinical course, diagnosis and differential diagnosis, treatment”; Fibrosing Interstitial Lung Diseases of Idiopathic and exogenous origin. Phenotype approach, Prague, Chech Republic, June 19-21, 2014
30. “Pulmonary manifestations of CTDs. Diagnosis, differential diagnosis and treatment”, Fibrosing Interstitial Lung Diseases of Idiopathic and exogenous origin. Phenotype approach, Prague, Chech Republic, June 19-21, 2014
31. “Sarcoidosis in Interstitial Lung Disease”; 3rd HTS-ERS Hermes Summer School, Athens, Greece, August 28-31, 2014
32. “The challenge of acute exacerbation of pulmonary fibrosis.– PG01 Challenges faced when diagnosing idiopathic interstitial lung disease”; ERS Annual International Congress, Munich, 2014
33. “ERS Statement: Idiopathic pulmonary fibrosis”; ERS Annual International Congress, Munich, 2014
34. “Should Azathioprine be used in treating Interstitial Lung diseases? (PRO) vs G. Raghu (CON), Session: Thearpy of Interstitial Lung Disease 2; 3RD WASOG- BAL Congress, Kusadasi, Turkey, October 8 -11, 2014
35. “Risk/benefit considerations with surgical biopsy”; 4th Annual meeting, Advancing in IPF Research (AIR), Copenhagen, Denmark, November 14-15, 2014
36. Epigenetics in IPF and Lung Cancer; IPF and Cancer: wounds that do not heal, Athens, Greece, February 13-14, 2015
37. “What’s new on smoking related lung diseases”, Session: IPF and around: where we are; 6th International meeting on Pulmonary rare diseases and orphan drugs, February 27-28, 2015
38. “Genetic investigations”, Corso ERS Study group; Update on Diffuse Parenechymal Lung Diseases; PneumoTrieste, Trieste, Italy, April 13-15, 2015
39. “Comorbidities in IPF”; 7th International WASOG (Conference on Diffuse Parenchymal Lung Diseases), Sao Paolo, Brazil, June 4-6, 2015
40. “IPF- Exacerbations”; 7th International WASOG (Conference on Diffuse Parenchymal Lung Diseases), Sao Paolo, Brazil, June 4-6, 2015
41. Update of Classification of IIPs; 8TH International WASOG (Conferenec on Diffuse Parenchymal Lung Diseases), 7th International WASOG Conferenece on Diffuse Paerenechymal Lung Diseases , Sao Paolo, Brazil, June 4-6, 2015

42. "Diffuse parenchymal lung diseases: the clinical point of view"; Transbronchial Cryobiospy in diffuse parenchymal lung disease, Ravenna, September 8-9, 2015
43. Session: Sarcoidosis in Interstitial Lung Disease; 4th HTS-ERS Hermes Summer School, Athens, Greece, September 3-6, 2015
44. ERS Task Forces and Guidelines: procedures, methodology and publication; ERS Annual International Congress Amsterdam, 2015
45. PG17 Lung fibrosis and sarcoidosis: The diagnostic and therapeutic standard; International Congress, Amsterdam, 2015
46. Panel discussion: Challenges in IPF diagnosis: What's missing from the guidelines; Advancing in IPF Research (AIR), Prague, Czech Republic, November 27-28, 2015
47. "Diagnosis testing and imaging"; Advancing in IPF Research (AIR), Prague, Czech Republic, 27-28 November 2015
48. International School for Interstitial Lung diseases; Ettore Majorana Foundation Erice, December 9-11, 2015
49. "Moving Stem Cell therapies to patients with IPF", Symposium: What, when, where :clearing the air on stem cell therapies in pulmonary diseases; ATS , San Francisco California, May 13-18, 2016
50. "Pulmonary Hypertension in ILD"; 8th International WASOG (Conferenec on Diffuse Parenchymal Lung Diseases) , Gdansk, Poland, June 2-4, 2016
51. "Comorbidities in IPF in Idiopathic pulmonary Fibrosis and Sleep Symposium"; 6th Panhellenic Interdisciplinary Congress on Sleep Research, June 30-July 3, 2016
52. Session: Idiopathic pulmonary fibrosis: classification, epidemiology, course and prognosis; ERS Annual International Congress, Russia, 2016
53. Diagnostic and therapeutic standards in lung fibrosis and sarcoidosis PG6 Lung fibrosis and sarcoidosis: ERS Annual International Congress, Russia, 2016
54. BAL: still a valid diagnostic tool in ILDs; Transbronchial Cryobiospy in diffuse parenchymal lung disease, (endorsed by ERS), Ravenna, October 27 -28, 2016
55. "IPF with autoimmune features (IPAF): do we need new approaches?"; 7th International meeting on Pulmonary Rare diseases and orphan dtugs, (endorsed by ERS), Milan, Italy, February, 2017
56. "Management of IPF", Interstitial Lung diseases (ILDs) course: from bench to bedside; Cretan Summer School of Respiratory Department (SHARE) Heraklion, Crete, July 20-22, 2017
57. "Pathogenesis of Sarcoidosis; what's new" Interstitial Lung diseases (ILDs) course: from bench to bedside; Cretan Summer School of Respiratory Department (SHARE) Heraklion, Crete, July 20-22, 2017
58. "CTDs and the Lung", An overview Interstitial Lung diseases (ILDs) course: from bench to bedside; Cretan Summer School of Respiratory Department (SHARE) Heraklion, Crete, July 20-22, 2017

59. "IPAF" Interstitial Lung diseases (ILDs) course: from bench to bedside; Cretan Summer School of Respiratory Department (SHARE) Heraklion, Crete, July 20-22, 2017
60. Discussion: "Granuloma Biology Symposium: Etiology & pathogenesis of sarcoidosis/ part B"; WASOG, Heraklion, Crete, June 07-09, 2018
61. "Usefulness of bronchoscopy in acute interstitial lung diseases"; ERS International Congress, Paris, France, September 15-19, 2018
62. "Undifferentiated systemic rheumatic diseases and overlap syndromes: when can we diagnose interstitial pneumonia with autoimmune features (IPAF)?"; ERS International Congress, Paris, France, September 15-19, 2018
63. Debate: Is it time to change the name of IPF?; AIR, Munich, Germany, November 16-17, 2018
64. "OP08-Let7c is reduced in IPF BAL cells relative to other f-ILDs and is associated with disease progression and survival in fibrotic lung diseases."; 17th ERS Lung Science Conference, Estoril, Portugal, March 7-10, 2019
65. "Sarcoidosis", Guideline Meeting; ATS Meeting, Dallas TX, May 17-22, 2019
66. "CPFE", Guideline Meeting; ATS Meeting, Dallas TX, May 17-22, 2019
67. "Descifrando la FPI: experiencia clinica y RWE (Roche)"; Congreso Separ, Santiago de Compostela, Spain, June 13-16, 2019
68. Pulmonary hypertension in ILDs: novel therapeutic data, ERS International Congress, Madrid, Spain, 28 Sept-02 Oct 2019
69. Pathogenetic mechanisms common to disease progression in fibrotic ILDs: the yang of pathogenetic thinking, ERS International Congress, Madrid, Spain, 28 Sept-02 Oct 2019
70. Common Pathogenetic Mechanisms Management: A World Survey, WASOG/JSSOG, Tokyo, 09-11 October 2019
71. "Como tratar a Pneumonia Intersticial"; 35^o Congresso de Pneumologia, Algarve, Portugal, November 7-10, 2019
72. "New pathogenetic ideas on fibrosing ILDs"; XX Congresso Nazionale Della Pneumologia Italiana, AIPO, Italy, November 13-16, 2019
73. Attendance a Scientific Advisory Hoc Expert meeting for OFEV (nintedanib), European Medicines Agency, Amsterdam, 22 January 2020
74. "COVID-19 and the management of Interstitial Lung Diseases patients: challenges and recommendations"; e-learning resources (<https://www.ers-education.org>), June 04, 2020 (webinar)
75. "Mitochondrial dysfunction and ILDs"; Transbronchial Cryobiopsy in Diffuse Parenchymal Lung Disease 7th edition, AIPO, September 18, 2020 (webinar)

76. "Residual fibrotic lung disease in post-COVID-19 patients: pure imagination or solid reality?"; ECCVID ESCMID Conference on Coronavirus, September 23-25, 2020 (webinar)
77. "Biologic disease modifying treatments for IPF: ready for prime time?"; PneumoTrieste, October 5-7, 2020 (webinar)
78. "Interactive ILD Board I 2 cases from participants"; ERS Online Course Virtual school on Interstitial Lung Diseases, November 3-4, 2020 (webinar)
79. "Introduction to roundtable discussions and switch to breakouts"; AIR, November 20, 2020 (webinar)
80. "Living with rare respiratory diseases through the COVID-19 pandemic"; ERS Vision-Live Panel Discussion (<https://www.ersnet.org>), March 23, 2021 (webinar)
81. "ERS and SRP-contributions to ILD care development"; 4th National Conference of Interstitial Lung Diseases, The Romanian ILD Conference, May 27-29, 2021 (webinar)
82. "Patient centered approach of ILD"; 4th National Conference of Interstitial Lung Diseases, The Romanian ILD Conference, May 27-29, 2021 (webinar)
83. "ERS initiatives in COVID-19"; 4th National Conference of Interstitial Lung Diseases, The Romanian ILD Conference, May 27-29, 2021 (webinar)
84. "Novel therapies in IPF"; 4th National Conference of Interstitial Lung Diseases, The Romanian ILD Conference, May 27-29, 2021 (webinar)
85. "Diagnostic approaches based on molecular biology"; Idiopathic Pulmonary Fibrosis IPF & FRIENDS, June 11, 2021 (webinar)
86. "PF-ILD Therapeutic approach" 10th Oporto Interstitial Lung Diseases Meeting, July 16-17, 2021 (webinar)
87. "How monitoring an interstitial lung disease?"; Seminar New Challenges in Interstitial Lung Diseases and Pulmonary Hypertension, Buenos Aires, Argentina, August 20, 2021 (webinar)
88. "Pulmonary Hypertension and IPF"; ERS Virtual International Congress, August 23, 2021 (webinar)
89. "Interstitial lung diseases and COVID-19: myths and reality"; ERS Virtual International Congress, September 07, 2021 (webinar)
90. "Experts view: Pulmonary hypertension and interstitial pulmonary fibrosis"; ERS International Congress, Zurich, Switzerland, September 05-08, 2021 (webinar)
91. Language session: Chinese programme 2021; ERS International Congress, Zurich, Switzerland, September 05-08, 2021 (webinar)
92. "Treatments for non-IPF pulmonary fibrosis"; PnemoTrieste, September 20-22, 2021 (webinar)
93. Round table discussions: COVID-ILD; ERS Virtual academy on interstitial lung diseases, November 16-17, 2021 (webinar)
94. "Holistic approach in IPF"; ERS Virtual academy on interstitial lung diseases, November 16-17, 2021 (webinar)

95. "2020: what did we learn?"; AIR, November 18-19, 2021 (webinar)
96. "Facilitated panel discussion and audience Q&A"; AIR, November 18-19, 2021 (webinar)
97. "Most Patients with Progressive Fibrotic Sarcoidosis Should Receive Antifibrotics"; WASOG/AASOG 2021: Multidisciplinary Meeting for Sarcoidosis & ILD, November 29 - December 02, 2021 (webinar)
98. "The fibrotic progression after COVID-19"; Impact of COVID-19 on ILD ERS, December 7, 2021 (webinar)
99. "ERS Statement on COVID-19 Follow-Up"; ERS CTS Joint Session during CTS annual meeting, Beijing, December 11, 2021
100. "MASTERCLASS. New advances in interstitial lung diseases"; 24 TEN TOPICS. Josep Font in autoimmune diseases & rheumatology February 9-11, 2022 (Virtual)
101. ILD. "State of the art in ILD: a clinical talk on treatable traits of people with pulmonary fibrosis: the management of the side effects, the approach to palliative care and the treatment of refractory breathlessness" ERS Satellites February 24, 2022 (Virtual)
102. "Industry Evening Symposium: IPF and COPD: close siblings or distant cousins?"; ERS International Congress, Barcelona, Spain, September 04-06, 2022
103. "Macrophages: their role in pathogenesis of pulmonary fibrosis"; Transbronchial cryobiopsy in diffuse parenchymal lung disease 9th edition, Ravenna, Italy, September 22-23, 2022
104. "IPF and Progressive pulmonary fibrosis guidelines"; Transbronchial cryobiopsy in diffuse parenchymal lung disease 9th edition, Ravenna, Italy, September 22-23, 2022
105. "Novel insights into pathogenesis"; WASOG Congress 2022, Sibiu, November 14-17, 2022
106. "Pulmonologist/ rheumatologist perspective on CTD-ILDs"; WASOG Congress 2022, Sibiu, November 14-17, 2022
107. "Sarcoidosis treatment practice guidelines"; 10th International Meeting on Pulmonary Rare Diseases and Orphan Drugs, Milan, Italy, March 03-04, 2023
108. "Progressive Pulmonary Fibrosis in Adults-An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline"; 12th Oporto Interstitial Lung Diseases Meeting, Porto, Portugal, April 19-24, 2023
109. "Is SARS-CoV-2 a cause of Fibrotic Interstitial Lung Diseases?"; 12th Oporto Interstitial Lung Diseases Meeting, Porto, Portugal, April 19-24, 2023
110. "ALERT 1: pharmacological treatments"; ERS International Congress, Milan, Italy, September 09-13 2023
111. "Reumatoid arthritis and the lungs: new concepts and treatments"; ERS International Congress, Milan, Italy, September 09-13 2023

7.7 ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΔΙΕΘΝΗ ΠΕΡΙΟΔΙΚΑ ΜΕ ΚΡΙΤΕΣ (PUBMED, SCOPUS, ISI)

1. Bouros D, **Antoniou KM**, Siafakas NM. Deep venous thrombosis as a possible complication of interferon-gamma treatment. *Sarcoidosis Vasc Diffuse Lung Dis.* 2001;18(2):201.
2. Bouros D, Plataki M, **Antoniou KM**. Parapneumonic effusion and empyema: best therapeutic approach. *Monaldi Arch Chest Dis.* 2001;56(2):144-8.
3. Bouros D, **Antoniou KM**, Chalkiadakis G, Drositis J, Petrakis I, Siafakas N. The role of video-assisted thoracoscopic surgery in the treatment of parapneumonic empyema after the failure of fibrinolytics. *Surg Endosc.* 2002;16(1):151-4.
4. **Antoniou KM**, Ferdoutsis E, Bouros D. Interferons and their application in the diseases of the lung. *Chest.* 2003;123(1):209-16.
5. **Antoniou KM**, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Perisinakis K, Tzortzaki EG, et al. Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). *Sarcoidosis Vasc Diffuse Lung Dis.* 2004;21(2):105-10.
6. **Antoniou KM**, Bouros D, Siafakas NM. Top Ten List in Idiopathic Pulmonary Fibrosis. *Chest.* 2004;125(5):1885-7.
7. Bouros D, Alexandrakis MG, **Antoniou KM**, Agouridakis P, Pneumatikos I, Anevlavis S, et al. The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome. *BMC Pulm Med.* 2004;4:6.
8. **Antoniou KM**, Alexandrakis M, Tzanakis N, Tsiligianni I, Tzortzaki EG, Siafakas NM, et al. Induced sputum versus bronchoalveolar lavage fluid in the evaluation of patients with idiopathic pulmonary fibrosis. *Respiration.* 2005;72(1):32-8.
9. **Antoniou KM**, Alexandrakis MG, Siafakas NM, Bouros D. Cytokine network in the pathogenesis of idiopathic pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis.* 2005;22(2):91-104.
10. **Antoniou KM**, Tzortzaki EG, Alexandrakis MG, Zervou M, Tzanakis N, Sfiridaki K, et al. Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. *Sarcoidosis Vasc Diffuse Lung Dis.* 2005;22(3):204-9.
11. Bouros D, **Antoniou KM**. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. *Eur Respir J.* 2005;26(4):693-702.
12. Bouros D, **Antoniou KM**. IL-18: a role in nonspecific interstitial pneumonitis pathogenesis and discrimination? *Respiration.* 2005;72(1):28-9.
13. Schiza SE, **Antoniou KM**, Economidou FN, Siafakas NM. Pharmacotherapy in complicated parapneumonic pleural effusions and thoracic empyema. *Pulm Pharmacol Ther.* 2005;18(6):381-9.

14. Tsiligianni I, **Antoniou KM**, Kyriakou D, Tzanakis N, Chrysosfakis G, Siafakas NM, et al. Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis. *BMC Pulm Med*. 2005;5:8.
15. Tzanakis N, Samiou M, Lambiri I, **Antoniou K**, Siafakas N, Bouros D. Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. *Eur J Intern Med*. 2005;16(2):105-12.
16. **Antoniou KM**, Siafakas NM, Bouros D. Does interferon-gamma-1b therapy improve survival in IPF via angiogenic pathway? *Chest*. 2006; electronic letter to the editor.
17. **Antoniou KM**, Malagari K, Tzanakis N, Perisinakis K, Symvoulakis EK, Karkavitsas N, et al. Clearance of technetium-99m-DTPA and HRCT findings in the evaluation of patients with Idiopathic Pulmonary Fibrosis. *BMC Pulm Med*. 2006;6:4.
18. **Antoniou KM**, Nicholson AG, Dimadi M, Malagari K, Latsi P, Rapti A, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. *Eur Respir J*. 2006;28(3):496-504.
19. **Antoniou KM**, Tsiligianni I, Kyriakou D, Tzanakis N, Tzouvelekis A, Siafakas NM, et al. Perforin down-regulation and adhesion molecules activation in pulmonary sarcoidosis: an induced sputum and BAL study. *Chest*. 2006;129(6):1592-8.
20. **Antoniou KM**, Tzanakis N, Malagari K, Symvoulakis KE, Perisinakis K, Karkavitsas N, et al. Clearance of technetium-99m-DTPA in pulmonary sarcoidosis. *Monaldi Arch Chest Dis*. 2006;65(3):141-4.
21. **Antoniou KM**, Tzanakis N, Tzouvelekis A, Samiou M, Symvoulakis EK, Siafakas NM, et al. Quality of life in patients with active sarcoidosis in Greece. *Eur J Intern Med*. 2006;17(6):421-6.
22. **Antoniou KM**, Tzouvelekis A, Alexandrakis MG, Sfridaki K, Tsiligianni I, Rachiotis G, et al. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. *Chest*. 2006;130(4):982-8.
23. **Antoniou KM**, Tzouvelekis A, Alexandrakis MG, Tsiligianni I, Tzanakis N, Sfridaki K, et al. Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. *J Interferon Cytokine Res*. 2006;26(6):400-5.
24. Bouros D, **Antoniou KM**, Light RW. Intrapleural streptokinase for pleural infection. *BMJ*. 2006;332(7534):133-4.
25. Bouros D, **Antoniou KM**, Tzouvelekis A, Siafakas NM. Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis. *Expert Opin Biol Ther*. 2006;6(10):1051-60.
26. Bouros D, Tzouvelekis A, **Antoniou KM**. Current medical management of pleural infection. *Therapy*. 2006;3(1):163-74.
27. **Antoniou KM**, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. *Clin Exp Rheumatol*. 2007;25(1):23-8.

28. **Antoniou KM**, Pataka A, Bouros D, Siafakas NM. Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. *Pulm Pharmacol Ther.* 2007;20(5):453-61.
29. Bouros D, Tzouvelekis A, **Antoniou KM**, Heffner JE. Intrapleural fibrinolytic therapy for pleural infection. *Pulm Pharmacol Ther.* 2007;20(6):616-26.
30. Economidou F, Tzortzaki EG, Schiza S, **Antoniou KM**, Neofytou E, Zervou M, et al. Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions. *Oncol Rep.* 2007;18(6):1507-12.
31. Siafakas NM, **Antoniou KM**, Tzortzaki EG. Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2007;2(4):453-62.
32. Spagnolo P, Sato H, Marshall SE, **Antoniou KM**, Ahmad T, Wells AU, et al. Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. *Invest Ophthalmol Vis Sci.* 2007;48(7):3019-25.
33. Tzortzaki EG, **Antoniou KM**, Zervou MI, Lambiri I, Koutsopoulos A, Tzanakis N, et al. Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. *Respir Med.* 2007;101(8):1821-9.
34. **Antoniou KM**, Economidou F, Voloudaki A, Protopapadakis C, Mitrouska I, Siafakas NM. Pulmonary consolidation with fever is not always pneumonia: A case of microscopic polyangiitis and review of the literature. *Respiratory Medicine CME.* 2008;1(2):169-75.
35. **Antoniou KM**, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. *Am J Respir Crit Care Med.* 2008;177(2):190-4.
36. **Antoniou KM**, Tzanakis N, Tzortzaki EG, Malagari K, Koutsopoulos AV, Alexandrakis M, et al. Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. *Pulm Pharmacol Ther.* 2008;21(6):840-4.
37. **Antoniou KM**, Wells AU. Scleroderma lung disease: evolving understanding in light of newer studies. *Curr Opin Rheumatol.* 2008;20(6):686-91.
38. Economidou F, **Antoniou KM**, Tzanakis N, Sfiridaki K, Siafakas NM, Schiza SE. Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions. *Respir Med.* 2008;102(5):774-9.
39. **Antoniou KM**, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. *Eur Respir J.* 2009;33(4):882-96.
40. **Antoniou KM**, Papadaki HA, Soufla G, Siafakas NM. Short telomeres and treatment of pulmonary fibrosis: implications for early intervention. *Am J Respir Crit Care Med.* 2009;179(10):970.
41. **Antoniou KM**, Soufla G, Proklou A, Margaritopoulos G, Choulaki C, Lymbouridou R, et al. Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study. *Clin Dev Immunol.* 2009;2009:537929.

42. Economidou F, Samara KD, **Antoniou KM**, Siafakas NM. Induced sputum in interstitial lung diseases: novel insights in the diagnosis, evaluation and research. *Respiration*. 2009;77(3):351-8.
43. Karakatsani A, Papakosta D, Rapti A, **Antoniou KM**, Dimadi M, Markopoulou A, et al. Epidemiology of interstitial lung diseases in Greece. *Respir Med*. 2009;103(8):1122-9.
44. Marten K, Milne D, **Antoniou KM**, Nicholson AG, Tennant RC, Hansel TT, et al. Non-specific interstitial pneumonia in cigarette smokers: a CT study. *Eur Radiol*. 2009;19(7):1679-85.
45. Proklou A, Economidou F, **Antoniou KM**, Tzortzaki EG, Voloudaki A, Malagari K, et al. Clinical, radiological and molecular effects in three patients with idiopathic pulmonary fibrosis after long-term treatment with interferon gamma-1b. *Pneumon*. 2009;22(2):162-8.
46. Protopapadakis C, **Antoniou KM**, Nicholson AG, Voloudaki A, Tzanakis N, Karantanas A, et al. Erdheim-Chester disease: pulmonary presentation in a case with advanced systemic involvement. *Respiration*. 2009;77(3):337-40.
47. Protopapadakis C, **Antoniou KM**, Voloudaki A, Samara K, Proklou A, Margaritopoulos G, et al. Rituximab-induced nonspecific interstitial pneumonia like reaction in a patient with idiopathic thrombocytopenic purpura. *Respiratory Medicine CME*. 2009;2(4):176-8.
48. **Antoniou KM**, Margaritopoulos GA, Soufla G, Symvoulakis E, Vassalou E, Lymbouridou R, et al. Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). *J Recept Signal Transduct Res*. 2010;30(4):262-9.
49. **Antoniou KM**, Papadaki HA, Soufla G, Kastrinaki MC, Damianaki A, Koutala H, et al. Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in Idiopathic Pulmonary Fibrosis (IPF). *Respir Med*. 2010;104(10):1535-42.
50. **Antoniou KM**, Soufla G, Lymbouridou R, Economidou F, Lasithiotaki I, Manousakis M, et al. Expression analysis of angiogenic growth factors and biological axis CXCL12/CXCR4 axis in idiopathic pulmonary fibrosis. *Connect Tissue Res*. 2010;51(1):71-80.
51. Economidou F, **Antoniou KM**, Soufla G, Lasithiotaki I, Karagiannis K, Lymbouridou R, et al. Role of VEGF-stromal cell-derived factor-1alpha/CXCL12 axis in pleural effusion of lung cancer. *J Recept Signal Transduct Res*. 2010;30(3):154-60.
52. Economidou F, Margaritopoulos G, **Antoniou KM**, Siafakas NM. The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications. *Exp Ther Med*. 2010;1(1):3-7.
53. Margaritopoulos GA, **Antoniou KM**, Karagiannis K, Samara KD, Lasithiotaki I, Vassalou E, et al. Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study. *Fibrogenesis Tissue Repair*. 2010;3:20.

54. Margaritopoulos GA, **Antoniou KM**, Karagiannis K, Vassalou E, Lasithiotaki I, Lambiri I, et al. Investigation of angiogenetic axis Angiopoietin-1 and -2/Tie-2 in fibrotic lung diseases: a bronchoalveolar lavage study. *Int J Mol Med*. 2010;26(6):919-23.
55. Margaritopoulos GA, **Antoniou KM**, Soufla G, Karagiannis K, Proklou A, Lasithiotaki I, et al. Upregulation of stromal cell derived factor-1alpha in collagen vascular diseases-associated interstitial pneumonias (CVDs-IPs). *Pulm Pharmacol Ther*. 2010;23(2):115-20.
56. Margaritopoulos GA, Nicholson AG, Giannarakis G, Lambiri I, Siafakas NM, **Antoniou KM**. A 35 year old smoker with shortness of breath. *BMJ*. 2010;341:c4793.
57. Symvoulakis EK, Vardavas CI, Fountouli P, Stavroulaki A, **Antoniou KM**, Duijker G, et al. Time interval from cigarette smoke exposure to blood donation and markers of inflammation: should a smoking cut-off be designated? *Xenobiotica*. 2010;40(9):613-20.
58. **Antoniou KM**, Bouros D. Pirfenidone for idiopathic pulmonary fibrosis: could it be a panacea? *Pneumon*. 2011;24(4).
59. Lasithiotaki I, **Antoniou KM**, Vlahava VM, Karagiannis K, Spandidos DA, Siafakas NM, et al. Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases. *PLoS One*. 2011;6(12):e27800.
60. Margaritopoulos GA, **Antoniou KM**, Soufla G, Vassalou E, Spandidos DA, Siafakas NM. Yin Yang-1(YY-1) expression in idiopathic pulmonary fibrosis. *J Recept Signal Transduct Res*. 2011;31(2):188-91.
61. Papakosta D, Pitsiou G, Daniil Z, Dimadi M, Stagaki E, Rapti A, **Antoniou K**, et al. Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters. *Lung*. 2011;189(5):391-9.
62. Samara KD, Margaritopoulos G, Wells AU, Siafakas NM, **Antoniou KM**. Smoking and pulmonary fibrosis: novel insights. *Pulm Med*. 2011;2011:461439.
63. Samara KD, Tsetis D, **Antoniou KM**, Protopapadakis C, Maltezas G, Siafakas NM. Bronchial artery embolization for management of massive cryptogenic hemoptysis: a case series. *J Med Case Rep*. 2011;5:58.
64. **Antoniou KM**, Cottin V. The challenge of acute exacerbation of pulmonary fibrosis. *Respiration*. 2012;83(1):13-6.
65. **Antoniou KM**, Daniil Z, Polychronopoulos V, Papiris S, Bouros D. Current guidelines for the management of idiopathic pulmonary fibrosis. *Pneumon*. 2012;25(sup1):110-2.
66. **Antoniou KM**, Margaritopoulos GA, Proklou A, Karagiannis K, Lasithiotaki I, Soufla G, et al. Investigation of Telomerase/Telomeres system in Bone Marrow Mesenchymal Stem Cells derived from IPF and RA-UIP. *J Inflamm (Lond)*. 2012;9(1):27.

67. Kakoliris NI, Symvoulakis EK, **Antoniou KM**, Grammatikopoulos I, Tzanakis N, Siafakas NM, et al. A snapshot of primary care physicians educational needs regarding COPD in crete, greece: An exploratory case study. *HealthMED*. 2012;6(3):781-6.
68. Karatzanis AD, Samara KD, **Antoniou KM**, Lymbouridou R, Chatzakis N, Spandidos DA, et al. Investigation of angiogenetic pathways in nasal polyposis. *Mol Med Rep*. 2012;5(5):1158-62.
69. Margaritopoulos GA, Proklou A, Lagoudaki E, Voloudaki A, Siafakas NM, **Antoniou KM**. Sarcoidosis in a 65-year-old woman presenting with a lung mass and pericardial effusion: a case report. *J Med Case Rep*. 2012;6:259.
70. Margaritopoulos GA, Romagnoli M, Poletti V, Siafakas NM, Wells AU, **Antoniou KM**. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. *Eur Respir Rev*. 2012;21(123):48-56.
71. Samara KD, **Antoniou KM**, Karagiannis K, Margaritopoulos G, Lasithiotaki I, Koutala E, et al. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. *Int J Oncol*. 2012;40(5):1397-404.
72. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L, European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. *Thorax*. 2012;67(11):938-40.
73. **Antoniou KM**, Lasithiotaki I, Symvoulakis E, Derdas SP, Psaraki A, Spandidos DA, et al. Molecular pathological findings of Merkel cell polyomavirus in lung cancer: a possible etiopathogenetic link? *Int J Cancer*. 2013;133(12):3016-7.
74. **Antoniou KM**, Margaritopoulos GA, Giannarakis I, Choulaki C, Fountoulakis N, Siafakas NM, et al. Adult Onset Still's Disease: A Case Report with a Rare Clinical Manifestation and Pathophysiological Correlations. *Case Rep Med*. 2013;2013:981232.
75. **Antoniou KM**, Margaritopoulos GA, Siafakas NM. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. *Eur Respir Rev*. 2013;22(129):281-91.
76. **Antoniou KM**, Samara KD, Lasithiotaki I, Margaritopoulos GA, Soufla G, Lambiri I, et al. Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer. *Oncol Rep*. 2013;30(6):2617-24.
77. **Antoniou KM**, Walsh SL, Hansell DM, Rubens MR, Marten K, Tennant R, et al. Smoking-related emphysema is associated with idiopathic pulmonary fibrosis and rheumatoid lung. *Respirology*. 2013;18(8):1191-6.
78. **Antoniou KM**, Wells AU. Acute exacerbations of idiopathic pulmonary fibrosis. *Respiration*. 2013;86(4):265-74.

79. Daniil Z, Mollaki V, Malli F, Koutsokera A, **Antoniou KM**, Rodopoulou P, et al. Polymorphisms and haplotypes in MyD88 are associated with the development of sarcoidosis: a candidate-gene association study. *Mol Biol Rep*. 2013;40(7):4281-6.
80. Lasithiotaki I, **Antoniou KM**, Derdas SP, Sarchianaki E, Symvoulakis EK, Psaraki A, et al. The presence of Merkel cell polyomavirus is associated with deregulated expression of BRAF and Bcl-2 genes in non-small cell lung cancer. *Int J Cancer*. 2013;133(3):604-11.
81. Margaritopoulos GA, **Antoniou KM**, Lasithiotaki I, Proklou A, Soufla G, Siafakas NM. Expression of SDF-1/CXCR4 axis in bone marrow mesenchymal stem cells derived from rheumatoid arthritis-usual interstitial pneumonia. *Clin Exp Rheumatol*. 2013;31(4):610-1.
82. Margaritopoulos GA, Giannarakis I, Siafakas NM, **Antoniou KM**. An update on idiopathic pulmonary fibrosis. *Panminerva Med*. 2013;55(2):109-20.
83. Margaritopoulos GA, Tsitoura E, Tzanakis N, Spandidos DA, Siafakas NM, Sourvinos G, **Antoniou KM**. Self-eating: friend or foe? The emerging role of autophagy in idiopathic pulmonary fibrosis. *Biomed Res Int*. 2013;2013:420497.
84. Mermigkis C, Bouloukaki I, **Antoniou KM**, Mermigkis D, Psathakis K, Giannarakis I, et al. CPAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: does it offer a better quality of life and sleep? *Sleep Breath*. 2013;17(4):1137-43.
85. Samara KD, Papadogiannis G, Nicholson AG, Magkanas E, Stylianos K, Siafakas N, **Antoniou KM**. A patient presenting with bilateral lung lesions, pleural effusion, and proteinuria. *Case Rep Med*. 2013;2013:489362.
86. Wuyts WA, Agostini C, **Antoniou KM**, Bouros D, Chambers RC, Cottin V, et al. The pathogenesis of pulmonary fibrosis: a moving target. *Eur Respir J*. 2013;41(5):1207-18.
87. **Antoniou KM**, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. *Eur Respir Rev*. 2014;23(131):40-54.
88. **Antoniou KM**, Symvoulakis EK, Margaritopoulos GA, Lionis C, Wells AU. Early diagnosis of IPF: time for a primary-care case-finding initiative? *Lancet Respir Med*. 2014;2(1):e1.
89. Bouros D, Manai DE, Papiris AS, **Antoniou KM**. Therapeutic protocol for idiopathic pulmonary fibrosis. *Pneumon*. 2014;29(4):287-288.
90. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014;370(22):2071-82.
91. Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group; OMERACT Connective Tissue

- Disease-Interstitial Lung Diseases Working Group. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. *J Rheumatol*. 2014;41(4):792-8.
92. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, **Antoniou K**, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*. 2014;69(5):428-36.
 93. Sarchianaki E, Derdas SP, Ntaoukakis M, Vakonaki E, Lagoudaki ED, Lasithiotaki I, Sarchianaki A, Koutsopoulos A, Symvoulakis EK, Spandidos DA, **Antoniou KM**, Sourvinos G. Detection and genotype analysis of human papillomavirus in non-small cell lung cancer patients. *Tumour Biol*. 2014;35(4):3203-9.
 94. Walsh SL, Wells AU, Sverzellati N, Keir GJ, Calandriello L, **Antoniou KM**, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. *Lancet Respir Med*. 2014;2(2):123-30.
 95. Wells AU, **Antoniou KM**. The prognostic value of the GAP model in chronic interstitial lung disease: the quest for a staging system. *Chest*. 2014;145(4):672-4.
 96. Wells AU, Margaritopoulos GA, **Antoniou KM**, Denton C. Interstitial lung disease in systemic sclerosis. *Semin Respir Crit Care Med*. 2014;35(2):213-21.
 97. Wuyts WA, **Antoniou KM**, Borensztajn K, Costabel U, Cottin V, Crestani B, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? *Lancet Respir Med*. 2014;2(11):933-42.
 98. **Antoniou KM**, Symvoulakis EK, Anyfantakis D, Wells AU. New Treatments for Idiopathic Pulmonary Fibrosis: 'Die Another Day' if Diagnosed Early? *Respiration*. 2015;90(4):352.
 99. **Antoniou KM**, Tomassetti S, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. *Curr Opin Pulm Med*. 2015;21(6):626-33.
 100. Fischer A, **Antoniou KM**, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *Eur Respir J*. 2015;46(4):976-87.
 101. Lammi MR, Baughman RP, Birring SS, Russell AM, Ryu JH, Scholand M, Distler O, LeSage D, Sarver C, **Antoniou K**, et al. Outcome Measures for Clinical Trials in Interstitial Lung Diseases. *Curr Respir Med Rev*. 2015;11(2):163-74.
 102. Margaritopoulos GA, Vasarmidi E, Jacob J, Wells AU, **Antoniou KM**. Smoking and interstitial lung diseases. *Eur Respir Rev*. 2015;24(137):428-35.
 103. Mermigkis C, Bouloukaki I, **Antoniou K**, Papadogiannis G, Giannarakis I, Varouchakis G, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. *Sleep Breath*. 2015;19(1):385-91.

104. Schiza S, Mermigkis C, Margaritopoulos GA, Daniil Z, Harari S, Poletti V, Renzoni EA, Torre O, Visca D, Bouloukaki I, Sourvinos G, **Antoniou KM**. Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night. *Eur Respir Rev*. 2015;24(136):327-39.
105. Tsitoura E, Lasithiotaki I, Vasarmidi E, Sourvinos G, **Antoniou KM**. Lung cancer and idiopathic pulmonary fibrosis: From Epigenetics to drug therapy. *Pneumon*. 2015;28(1):23-5.
106. Vogiatzis I, Marvisi M, Coolen J, Gasparini S, **Antoniou KM**, Stallberg B, et al. Clinical highlights: messages from Munich. *ERJ Open Res*. 2015;1(1):00002-2015.
107. Wells AU, Costabel U, Poletti V, Crestani B, Egan J, Margaritopoulos G, **Antoniou K**. Challenges in IPF diagnosis, current management and future perspectives. *Sarcoidosis Vasc Diffuse Lung Dis*. 2015;32 Suppl 1:28-35.
108. Annema JT, Vogiatzis I, Grgic A, **Antoniou K**, Stallberg B, Herth FF. Clinical highlights from Amsterdam. *ERJ Open Res*. 2016;2(3):00031-2016.
109. **Antoniou KM**, Margaritopoulos GA, Goh NS, Karagiannis K, Desai SR, Nicholson AG, et al. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension. *Arthritis Rheumatol*. 2016;68(4):1004-12.
110. **Antoniou KM**, Wuyts W, Wijsenbeek M, Wells AU. Medical Therapy in Idiopathic Pulmonary Fibrosis. *Semin Respir Crit Care Med*. 2016;37(3):368-77.
111. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, **Antoniou KM** et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *Am J Respir Crit Care Med*. 2016;194(3):265-75.
112. Lasithiotaki I, Giannarakis I, Tsitoura E, Samara KD, Margaritopoulos GA, Choulaki C, Vasarmidi E, Tzanakis N, Voloudaki A, Sidiropoulos P, Siafakas NM, **Antoniou KM**. NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung. *Eur Respir J*. 2016;47(3):910-8.
113. Margaritopoulos GA, **Antoniou KM**. Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis? *Am J Respir Crit Care Med*. 2016;193(7):810-1.
114. Margaritopoulos GA, Harari S, Caminati A, **Antoniou KM**. Smoking-related idiopathic interstitial pneumonia: A review. *Respirology*. 2016;21(1):57-64.
115. Margaritopoulos GA, Vasarmidi E, **Antoniou KM**. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. *Core Evid*. 2016;11:11-22.
116. Tsitoura E, Bibaki E, Vasarmidi E, **Antoniou KM**. Hot topics in IPF Pathogenesis: ERS and ATS highlights. *Pneumon*. 2016;29(2).
117. Tsitoura E, Wells AU, Karagiannis K, Lasithiotaki I, Vasarmidi E, Bibaki E, Koutoulaki C, Sato H, Spandidos DA, Siafakas NM, Sourvinos G, **Antoniou KM**. MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF BAL cells. *Oncotarget*. 2016;7(46):74569-81.

118. Lasithiotaki I, Tsitoura E, Koutsopoulos A, Lagoudaki E, Koutoulaki C, Pitsidianakis G, Spandidos DA, Siafakas NM, Sourvinos G, **Antoniou KM**. Aberrant expression of miR-21, miR-376c miR-145 and their target host genes in Merkel cell polyomavirus-positive non-small cell lung cancer. *Oncotarget*. 2016;8(68):112371-83.
119. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, **Antoniou KM**, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *Am J Respir Crit Care Med*. 2016 Aug 1;194(3):265-75.
120. **Antoniou KM**, Bibaki E, Margaritopoulos GA. Controversies in Fibrosis and Emphysema. *Arch Bronconeumol*. 2017;53(5):231-2.
121. **Antoniou KM**, Karagiannis K, Tsitoura E, Tzanakis N. Mesenchymal stem cell treatment for IPF-time for phase 2 trials? *Lancet Respir Med*. 2017;5(6):472-3.
122. Cottin V, Hansell DM, Sverzellati N, Weycker D, **Antoniou KM**, Atwood M, et al. Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2017;196(9):1162-1171.
123. Detorakis EE, Magkanas E, Lasithiotaki I, Sidiropoulos P, Boumpas DT, Gourtsoyiannis N, **Antoniou K** et al. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF- α agents. *Clin Exp Rheumatol*. 2017;35(1):43-52.
124. Johansson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? *Lancet Respir Med*. 2017;5(7):591-598.
125. Kahn N, Fregonese L, Barrecheguren M, Franssen FME, Grgic A, Gompelmann D, Bibaki E, **Antoniou KM**, et al. Clinical highlights from the 2016 European Respiratory Society International Congress. *ERJ Open Res*. 2017;3(2):00147-2016.
126. Karagiannis K, Proklou A, Tsitoura E, Lasithiotaki I, Kalpadaki C, Moraitaki D, Sperelakis I, Kontakis G, **Antoniou KM**, Tzanakis N. Impaired mRNA Expression of the Migration Related Chemokine Receptor CXCR4 in Mesenchymal Stem Cells of COPD Patients. *Int J Inflam*. 2017;2017:6089425.
127. Margaritopoulos GA, **Antoniou KM**. Reply: Heparin versus Warfarin in Interstitial Pulmonary Fibrosis: The Quest for the Right Anticoagulant Continues. *Am J Respir Crit Care Med*. 2017;195(1):142-3.
128. Margaritopoulos GA, **Antoniou KM**. Reply: Is a Trial of Vitamin K Antagonists and Bisphosphonates Possible in IPF? *Am J Respir Crit Care Med*. 2017;195(2):271-2.
129. Margaritopoulos GA, **Antoniou KM**, Denton CP, Wells AU. Reply. *Arthritis Rheumatol*. 2017;69(1):240-1.

130. Margaritopoulos GA, **Antoniou KM**, Wells AU. Comorbidities in interstitial lung diseases. *European Respiratory Review*. 2017;26(143).
131. Margaritopoulos GA, Lasithiotaki I, **Antoniou KM**. Toll-like receptors and autophagy in interstitial lung diseases. *Eur J Pharmacol*. 2017;808:28-34.
132. Molina-Molina M, Agusti A, Crestani B, Schwartz DA, Königshoff M, Chambers RC, Maher TM, Faner R, Mora AL, Rojas M, **Antoniou KM**, Sellares J. Towards a global initiative for fibrosis treatment (GIFT). *ERJ Open Res*. 2017;3(4):00106-2017.
133. Samara KD, Trachalaki A, Tsitoura E, Koutsopoulos AV, Lagoudaki ED, Lasithiotaki I, Margaritopoulos G, Pantelidis P, Bibaki E, Siafakas NM, Tzanakis N, Wells AU, **Antoniou KM**. Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis. *Respir Res*. 2017;18(1):218.
134. Touman A, Bolaki M, Vitsas V, Bibaki E, Aggelakis L, Tringidou R, Mandilara A, Tzanakis N, **Antoniou KM**, Koulouris N, Stratakis GK. Large endotracheal tumor obstructing the central airway: The role of interventional pulmonology. *Pneumon*. 2017;30(2):102-4.
135. Bibaki E, Trachalaki A, Vasarmidi E, **Antoniou A**. IPAF: Interstitial pneumonia with autoimmune features. A new entity?. *Pneumon*. 2017;30(1):14–16 .
136. Vassalou EE, Raissaki M, Magkanas E, **Antoniou KM**, Karantanis AH. Lung Ultrasonography in Patients With Idiopathic Pulmonary Fibrosis: Evaluation of a Simplified Protocol With High-Resolution Computed Tomographic Correlation. *J Ultrasound Med*. 2018;37(3):689-96.
137. Vassalou EE, Raissaki M, Magkanas E, **Antoniou KM**, Karantanis AH. Modified Lung Ultrasonographic Technique for Evaluation of Idiopathic Pulmonary Fibrosis: Lateral Decubitus Position. *J Ultrasound Med*. 2017;36(12):2525-32.
138. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, **Antoniou KM** et al. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *Eur Respir J*. 2017;50(2):1700936.
139. Wells AU, **Antoniou KM**. The Genomic Detection of Usual Interstitial Pneumonia from Transbronchial Biopsy Tissue: A Dress Rehearsal for the Future? *Ann Am Thorac Soc*. 2017;14(11):1632-3.
140. **Antoniou K**, Trachalaki A, Bibaki E, Poletti V. Assembly 12: interstitial lung diseases. *Breathe (Sheff)*. 2018;14(4):345-6.
141. **Antoniou KM**, Karagiannis K, Tsitoura E, Bibaki E, Lasithiotaki I, Proklou A, et al. Clinical applications of mesenchymal stem cells in chronic lung diseases. *Biomed Rep*. 2018;8(4):314-8.
142. Bibaki E, Tsitoura E, Vasarmidi E, Margaritopoulos G, Trachalaki A, Koutoulaki C, Georgopoulou T, Spandidos DA, Tzanakis N, **Antoniou KM**. miR-185 and miR-29a are similarly expressed in the bronchoalveolar lavage cells in IPF and lung cancer but common targets DNMT1 and COL1A1 show disease specific patterns. *Mol Med Rep*. 2018;17(5):7105-12.

143. Bolaki M, Karagiannis K, Bertias G, Mitrouska I, Tzanakis N, **Antoniou KM**. New respiratory symptoms and lung imaging findings in a woman with polymyositis. *Breathe (Sheff)*. 2018;14(2):e34-e39.
144. Bouros D, Daniil Z, Papakosta D, **Antoniou KM**, Markopoulou K, Kolilekas L, et al. Design, Rationale, Methodology, and Aims of a Greek Prospective Idiopathic Pulmonary Fibrosis Registry: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF). *Respiration*. 2018;96(1):41-7.
145. Daniil Z, Kotsiou OS, Grammatikopoulos A, Peletidou S, Gkika H, Malli F, **Antoniou K**, et al. Detection of mitochondrial transfer RNA (mt-tRNA) gene mutations in patients with idiopathic pulmonary fibrosis and sarcoidosis. *Mitochondrion*. 2018;43:43-52.
146. Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, **Antoniou K**, et al. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. *N Engl J Med*. 2018;379(23):2209-19.
147. Lasithiotaki I, Tsitoura E, Samara KD, Trachalaki A, Charalambous I, Tzanakis N, **Antoniou KM**. NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer. *PLoS One*. 2018;13(10):e0205242.
148. Margaritopoulos GA, Trachalaki A, Wells AU, Vasarmidi E, Bibaki E, Papastratigakis G, Detorakis S, Tzanakis N, **Antoniou KM**. Pirfenidone improves survival in IPF: results from a real-life study. *BMC Pulm Med*. 2018;18(1):177.
149. Morisset J, Johansson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; HP Delphi Collaborators. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. *Am J Respir Crit Care Med*. 2018;197(8):1036-44.
150. Proklou A, Bolaki M, Vassalou EE, Bibaki E, Vasarmidi E, Margaritopoulos GA, Karantanis AH, Tzanakis N, **Antoniou KM**. Paroxysmal cough and left sacroiliac joint pain in a 50-year-old Caucasian man. *Breathe (Sheff)*. 2018;14(2):e59-e67.
151. Vasarmidi E, Sarantoulaki S, Trachalaki A, Margaritopoulos G, Bibaki E, Spandidos DA, Tzanakis N, **Antoniou K**. Investigation of key autophagy-and mitophagy-related proteins and gene expression in BALF cells from patients with IPF and RA-ILD. *Mol Med Rep*. 2018;18(4):3891-7.
152. Wells AU, **Antoniou KM**. Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail. *Respirology*. 2018;23(3):244-5.
153. Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, **Antoniou K**, Poletti V. Research highlights from the 2018 ERS International Congress: interstitial lung diseases. *ERJ Open Res*. 2019;5(1).

154. **Antoniou KM**, Tzilas V, Vasarmidi E, Symvoulakis EK, Tzouvelekis A, Bouros D. Interstitial lung abnormalities: ignotum per ignotius. *Lancet Respir Med*. 2019;7(5):376-8.
155. Lim RK, Humphreys C, Morisset J, Holland AE, Johansson KA; O2 Delphi Collaborators. Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. *Eur Respir J*. 2019;54(2).
156. Malli F, Papakosta D, **Antoniou K**, Dimadi M, Polychronopoulos V, Malagari K, et al. Combined pulmonary fibrosis and emphysema characteristics in a Greek cohort. *ERJ Open Res*. 2019;5(1).
157. Tsitoura E, Vasarmidi E, Bibaki E, Trachalaki A, Koutoulaki C, Papastratigakis G, Chalepakis G, Tzanakis N, **Antoniou KM**. Accumulation of damaged mitochondria in alveolar macrophages with reduced OXPHOS related gene expression in IPF. *Respir Res*. 2019;20(1):264.
158. Tzouvelekis A, Tzilas V, **Antoniou KM**, Bouros D. Human pentraxin 2 protein treatment for IPF. *Lancet Respir Med*. 2019;7(8):640-1.
159. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, **Antoniou KM**, et al. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2019;200(9):1146-53.
160. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. ; IPF Consensus Working Group; IPF Consensus Working Group: Pulmonary fibrosis: "idiopathic" is not "cryptogenic". *Eur Respir J*. 2019;53(3).
161. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group: Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name? *Eur Respir J*. 2019;53(2).
162. **Antoniou K**, Kamekis A., Symvoulakis EK, Kokosi M, Swigris JJ. Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review. *Current opinion in pulmonary medicine*. 2020(26(5)):457-63.
163. **Antoniou K**, Bolaki M, Bibaki E, Vasarmidi E, Trachalaki A, Tsitoura E, Bouros D. COVID19 alert: Do we know our enemy? *Pneumon*. 2020(33(1)):25-7.
164. **Antoniou K**, Markopoulou K, Tzouvelekis A, Trachalaki A, Vasarmidi E, Organtzis J, et al. Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. *ERJ Open Res*. 2020;6(1):00172-2019.
165. **Antoniou KM**, Raghu G, Tzilas V, Bouros D. Management of Patients with Interstitial Lung Disease in the Midst of the COVID-19 Pandemic. *Respiration*. 2020;99(8):625-7.
166. **Antoniou KM**, Trachalaki A, Tzouvelekis A, Poletti V, Vasarmidi E, Sfrikakis P, et al. A role of antifibrotics in the treatment of Scleroderma-ILD? *Pulmonology*. 2020;26(1):1-2.
167. Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR; CHP Exposure Assessment Collaborators. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. *Chest*. 2020;157(6):1506-12.

168. Bolaki M, **Antoniou KM**. Combined Pulmonary Fibrosis and Emphysema. *Semin Respir Crit Care Med*. 2020;41(2):177-83.
169. Bolaki M, Tsitoura E, Spandidos DA, Symvoulakis EK, **Antoniou KM**. [COMMENT] Respiratory diseases in the era of COVID-19: Pearls and pitfalls. *Exp Ther Med*. 2020;20(2):691-3.
170. Kallieri M, Zervas E, Katsoulis K, Fouka E, Porpodis K, Samitas K, Papaioannou AI, Kipourou M, Gaki E, Vittorakis S, Markatos M, Dimakou K, Ampelioti S, Koukidou S, Makris M, Ntakoula M, Mitrova MH, Glynos K, **Antoniou KM**. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis. *Int Arch Allergy Immunol*. 2020;181(8):613-7.
171. Schiza SE, Bouloukaki I, Bolaki M, **Antoniou KM**. Obstructive sleep apnea in pulmonary fibrosis. *Curr Opin Pulm Med*. 2020;26(5):443-8.
172. Sperelakis I, Tsitoura E, Koutoulaki C, Mastrodimitrou S, Tosounidis TH, Spandidos DA, **Antoniou KM**, Kontakis G. Influence of reaming intramedullary nailing on MSC population after surgical treatment of patients with long bone fracture. *Mol Med Rep*. 2020;22(3):2521-7.
173. Tsitoura E, Bibaki E, Bolaki M, Vasarmidi E, Trachalaki A, Symvoulakis EK, Spandidos DA, **Antoniou KM**. [Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. *Exp Ther Med*. 2020;20(1):147-50.
174. Tzilas V, Tzouvelekis A, Bouros E, Karampitsakos T, Ntassiou M, Avdoula E, Trachalaki A, **Antoniou K**, et al. Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. *ERJ Open Res*. 2020;6(4):00152-2020.
175. Tzouvelekis A, Karampitsakos T, Gomatou G, Bouros E, Tzilas V, Manali E, Tomos I, Trachalaki A, Kolilekas L, Korbila I, Tomos P, Chrysikos S, Gaga M, Daniil Z, Bardaka F, Papanikolaou IC, Euthymiou C, Papakosta D, Steiropoulos P, Ntoliou P, Tringidou R, Papiris S, **Antoniou K**, Bouros D. Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece. *Pulm Pharmacol Ther*. 2020;60:101880.
176. Vasarmidi E, Tsitoura E, Spandidos DA, Tzanakis N, **Antoniou KM**. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review). *Exp Ther Med*. 2020;20(3):2557-60.
177. Vassalou EE, Karantanas AH, **Antoniou KM**. Proposed Lung Ultrasound Protocol During the COVID-19 Outbreak. *J Ultrasound Med*. 2021;40(2):397-399.
178. Behr J, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, **Antoniou K**, et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. *Lancet Respir Med*. 2021;9(1):85-95.
179. **Antoniou KM**, Raghu G, Tzilas V, Bouros D. Management of Patients with Interstitial Lung Disease in the Midst of the COVID-19 Pandemic. *Respiration*. 2020;99(8):625-627.

180. Dupin C, Fernandes V, Hernandez-Gonzalez F, Torrisi SE, Alfaro TM, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, **Antoniou K**, Poletti V. ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly. *ERJ Open Res.* 2020;6(4):00143-2020.
181. Papadogiannis G, Bouloukaki I, Mermigkis C, Michelakis S, Ermidou C, Mauroudi E, Moniaki V, Tzanakis N, **Antoniou KM**, Schiza SE. Patients with idiopathic pulmonary fibrosis with and without obstructive sleep apnea: differences in clinical characteristics, clinical outcomes, and the effect of PAP treatment. *J Clin Sleep Med.* 2021;17(3):533-544.
182. Papiris SA, Bouros D, Markopoulou K, Kolilekas L, Papaioannou AI, Tzilas V, Tzouvelekis A, Fouka E, Papakosta D, Daniil Z, Steiropoulos P, Gogali A, Papanikolaou IC, Xyfteri A, Haritou A, Korbila I, Tomos IP, Loukides S, Bellelli R, Kounti G, Rampiadou C, Karampitsakos T, Dimeas I, Kirgou P, Bompoki A, Vasarmidi E, Loverdos K, Antonogiannaki EM, Blizou M, Bouros E, Kagouridis K, Maniati M, Karakatsani A, **Antoniou KM**, Manali ED. Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial "impact" beyond any expectation. *Eur Respir J.* 2021;57(3):2003111.
183. Tzouvelekis A, **Antoniou K**, Kreuter M, Evison M, Blum TG, Poletti V, et al. The DIAMORFOSIS (DIAGnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. *ERJ Open Res.* 2021;7(1):00529-2020.
184. **Antoniou KM**, Tsitoura E, Vasarmidi E, Symvoulakis EK, Aidinis V, Tzilas V, et al. Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care. *Curr Opin Pharmacol.* 2021;57:71-80.
185. Bouloukaki I, Mermigkis C, **Antoniou KM**, Schiza SE. PAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: multum non multa. *J Clin Sleep Med.* 2021;17(6):1327-1328.
186. Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, **Antoniou KM**, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. *Eur Respir J.* 2021;57(4):2100048.
187. Kyriakopoulos C, Gogali A, Exarchos K, Potonos D, Tatsis K, Apollonatos V, Loukides S, Papiris S, Sigala I, Katsaounou P, Aggelidis M, Fouka E, Porpodis K, Kontakiotis T, Sampsonas F, Karampitsakos T, Tzouvelekis A, Bibaki E, Karagiannis K, **Antoniou K**, et al. Reduction in Hospitalizations for Respiratory Diseases during the First COVID-19 Wave in Greece. *Respiration.* 2021;100(7):588-93.
188. Karampitsakos T, Torrisi S, **Antoniou K**, Manali E, Korbila I, Papaioannou O, et al. Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis. *Respir Res.* 2021;22(1):140.

189. Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, **Antonίου K**, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;2004079. *Online ahead of print*
190. Trachalaki A, Tsitoura E, Mastrodimou S, Invernizzi R, Vasarmidi E, Bibaki E, Tzanakis N, Molyneaux PL, Maher TM, **Antonίου K**. Enhanced IL-1 β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis. *Front Immunol*. 2021;12:661811.
191. Juge PA, Solomon JJ, van Moorsel CHM, Garofoli R, Lee JS, Louis-Sydney F, Rojas-Serrano J, González-Pérez MI, Mejia M, Buendia-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, **Antonίου KM**, et al. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. *Semin Arthritis Rheum*. 2021;51(5):996-1004.
192. Bizymi N, Pitsidianakis G, Ierodiakonou D, Stathakis G, Vasarmidi E, Hiraki S, Bolaki M, Karagiannis K, Fanaridis M, Liopyrakis K, Marinos L, Xilouri I, **Antonίου KM**, Tzanakis N. Case Report: Diagnosis of Myelodysplastic Syndrome in a 72-Year-Old Female With Interstitial Lung Disease. *Front Med (Lausanne)*. 2021;8:673573.
193. **Antonίου KM**, Bolaki M, Karagiannis K, Trachalaki A, Ierodiakonou D, Stamatopoulou V, et al. Real-life Cretan asthma registry focused on severe asthma: On behalf of 'The Cretan registry of the use of Biologics in Severe Asthma'. *Exp Ther Med*. 2021;22(5):1239.
194. Symvoulakis EK, Kamekis A, Drakonaki E, Mastrodemou S, Ryerson J, **Antonίου K**. Frailty and Chronic Respiratory Disease: The Need for a Multidisciplinary Care Model. *Sarcoidosis Vasc Diffuse Lung Dis*. 38(3): e2021031.
195. Ntatsoulis K, Karampitsakos T, Tsitoura E, Stylianaki EA, Matralis AN, Tzouvelekis A, **Antonίου K**, Aidinis V. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. *Front Immunol*. 2021;12: 687397
196. Tsitoura E, Trachalaki A, Vasarmidi E, Mastrodemou S, Margaritopoulos GA, Kokosi M, Fanidis D, Galaris A, Aidinis V, Renzoni E, Tzanakis N, Wells AU, **Antonίου KM**. Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality. *Front Immunol*. 2021;12:645548.
197. Hilberg O, Hoffmann-Vold AM, Smith V, Bouros D, Kilpeläinen M, Guiot J, Morais A, Clemente S, Daniil Z, Papakosta D, Fretheim H, Neves S, Alfaro TM, **Antonίου KM**, Valveny N, Asijee G, Soulard S, Wuyts W. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. *ERJ Open Res*. 2022;8(1):00597-2021.

198. Pitsidianakis G, Vassalou EE, Vasarmidi E, Bolaki M, Klontzas ME, Xirouchaki N, Georgopoulos D, Karantanas AH, Tzanakis N, **Antoniou KM**. Performance of Lung Ultrasound for Monitoring Interstitial Lung Disease. *J Ultrasound Med*. 2022;41(5):1077-1084.
199. Hunninghake GM, Goldin JG, Kadoch MA, Kropski JA, Rosas IO, Wells AU, Yadav R, Lazarus HM, Abtin FG, Corte TJ, de Andrade JA, Johansson KA, Kolb MR, Lynch DA, Oldham JM, Spagnolo P, Strek ME, Tomassetti S, Washko GR, White ES; ILA Study Group. Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative. *Chest*. 2022;161(2):470-482.
200. Teoh AKY, Holland AE, Morisset J, Flaherty KR, Wells AU, Walsh SLF, Glaspole I, Wuyts WA, Corte TJ; ILD MDM Delphi Collaborators. Essential Features of an Interstitial Lung Disease Multidisciplinary Meeting: An International Delphi Survey. *Ann Am Thorac Soc*. 2022 ;19(1):66-73.
201. Gatselis NK, Lygoura V, Lyberopoulou A, Giannoulis G, Samakidou A, Vaiou A, Vavidis G, **Antoniou K**, Stefanos A, Georgiadou S, Sagris D, Sveroni D, Stergioula D, Gabeta S, Ntaios G, Dalekos GN. Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients. *Viruses*. 2022;14(4):787.
202. **Antoniou KM**, Vasarmidi E, Russell AM, Andrejak C, Crestani B, Delcroix M, Dinh-Xuan AT, Poletti V, Sverzellati N, Vitacca M, Witzernath M, Tonia T, Spanevello A. European Respiratory Society Statement on Long COVID-19 Follow-Up. *Eur Respir J*. 2022 Aug 4;60(2):2102174.
203. Cottin V, Tomassetti S, Valenzuela C, Walsh S, **Antoniou K**, Bonella F, Brown KK, Collard HR, Corte TJ, Flaherty K, Johansson KA, Kolb M, Kreuter M, Inoue Y, Jenkins G, Lee JS, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers J, Nathan SD, Poletti V, Quadrelli S, Raghu G, Rajan SK, Ravaglia C, Remy-Jardin M, Renzoni E, Richeldi L, Spagnolo P, Troy L, Wijsenbeek M, Wilson KC, Wuyts W, Wells AU, Ryerson C. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. *Am J Respir Crit Care Med*. 2022 Aug 1;206(3):247-259
204. Froidure A, **Antoniou K**, Bocchino M, Conte E. Editorial: Mechanisms of Lung Fibrosis: Is Immunity Back in the Game? *Front Immunol*. 2022 Mar 17;13:882979.
205. **Antoniou KM**, Vasarmidi E, Russell AM, Andrejak C, Crestani B, Delcroix M, Dinh-Xuan AT, Poletti V, Sverzellati N, Vitacca M, Witzernath M, Tonia T, Spanevello A. European Respiratory Society Statement on Long COVID-19 Follow-Up. *Eur Respir J*. 2022 Aug 4;60(2):2102174
206. Manali ED, Kannengiesser C, Borie R, Ba I, Bouros D, Markopoulou A, **Antoniou K**, Kolilekas L, Papaioannou AI, Tzilas V, Tzouveleakis A, Daniil Z, Fouka E, Papakosta D, Xyfteri A, Karakatsani A, Loukides S, Korbila I, Tomos IP, Konstantinidis AK, Gogali A, Steiropoulos P, Papanikolaou IC, Bazaka C, Haritou A, Vassilakopoulos T, Maniati M, Kagouridis K, Markozannes E, Bouros E, Rampiadou C, Kounti G, Trachalaki A, Dimeas I, Karampitsakos T, Lyberopoulos P, Malamadakis N, Spyropoulou S, Revy P, Lainey E, Dieudé P, Rebah K, Ménard C, Oudin C, Masson C, Plessier A, Legendre M, Nathan N, Coulomb-L'Hermine A,

- Clement A, Amselem S, Boileau C, Crestani B, Papiris S; Greek Group of ILD Investigators. Genotype-Phenotype Relationships in Inheritable Idiopathic Pulmonary Fibrosis: A Greek National Cohort Study. *Respiration*. 2022;101(6):531-543.
207. Karampitsakos T, Spagnolo P, Mogulkoc N, Wuyts WA, Tomassetti S, Bendstrup E, Molina-Molina M, Manali ED, Unat OS, Kahn N, Kolilekas L, Rosi E, Gori L, Ravaglia C, Daniil Z, Skovhus Prior T, Papanikolaou IC, Samantha Aso S, Tryfon S, Papakosta D, Balestro E, Papiris S, **Antoniou K**, Bouros D, Michael Kreuter M, Tzouvelekis A. Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe. *Respirology*. 2022 Sep 18.
208. Kallieri M, Zervas E, Fouka E, Porpodis K, Mitrova MH, Tzortzaki E, Makris M, Ntakoula M, Papaioannou AI, Lyberopoulos P, Dimakou K, Koukidou S, Ampelioti S, Papaporfyriou A, Katsoulis K, Kipourou M, Rovina N, Antoniou K, Vittorakis S, Bakakos P, Steiropoulos P, Markopoulou K, Avarlis P, Papanikolaou IC, Markatos M, Gaki E, Samitas K, Glynos K, Papiris SA, Papakosta D, Tzanakis N, Gaga M, Kostikas K, Loukides S. RELight: A two-year REal-Life study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response. *Allergy*. 2022 Sep;77(9):2848-2852.
209. Wells AU, Sverzellati N, Jacob J, Cross G, Barnett J, De Lauretis A, **Antoniou K**, Weycker D, Atwood M, Kirchgaessler K-U, Cottin V. Development and testing of a formula for predicting emphysema extent in patients with idiopathic pulmonary fibrosis with emphysema. *In preparation*
210. Guler SA, Cuevas Ocana S, Nasser M, Wuyts WA, Wijsenbeek MS, Froidure A, Bargagli E, Renzoni E, Veltkamp M, Spagnolo P, Nunes H, McCarthy C, Bonella F, Poletti V, Kreuter M, **Antoniou KM**, Moor CC. ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly. *ERJ Open Res*. 2022 May 23;8(2):00640-2021.
211. Wijsenbeek M, Molina-Molina M, Chassany O, Fox J, Galvin L, Geissler K, Hammitt KM, Kreuter M, Moua T, O'Brien EC, Slagle AF, Krasnow A, Reaney M, Baldwin M, Male N, Rohr KB, Swigris J, **Antoniou K**. Development of a conceptual model of progressive fibrosing interstitial lung disease and evaluation of existing patient-reported outcome measures. *ERJ Open Res*. 2022 May 3;8(2):00681-2021.
212. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, **Antoniou KM**, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2022 May 1;205(9):e18-e47.
213. Roche N, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, **Antoniou KM**, Ulrik CS, Parks H, Wang C, Vandendriessche T, Qu J, Stolz D, Brightling C, Welte T, Aliberti S, Simonds AK, Tonia T,

- Chalmers JD. Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. *Eur Respir J*. 2022 Aug 10;60(2):2200803.
214. Hoffmann-Vold AM, Distler O, Crestani B, **Antonίου KM**. Recent advances in the management of systemic sclerosis-associated interstitial lung disease. *Curr Opin Pulm Med*. 2022 Sep 1;28(5):441-447.
215. Cottin V, Selman M, Inoue Y, Wong AW, Corte TJ, Flaherty KR, Han MK, Jacob J, Johansson KA, Kitaichi M, Lee JS, Agusti A, **Antonίου KM**, Bianchi P, Caro F, Florenzano M, Galvin L, Iwasawa T, Martinez FJ, Morgan RL, Myers JL, Nicholson AG, Occhipinti M, Poletti V, Salisbury ML, Sin DD, Sverzellati N, Tonia T, Valenzuela C, Ryerson CJ, Wells AU. Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. *Am J Respir Crit Care Med*. 2022.
216. Terwiel M, Borie R, Crestani B, Galvin L, Bonella F, Fabre A, Froidure A, Griesse M, Grutters JC, Johansson K, Kannengiesser C, Kawano-Dourado L, Molina-Molina M, Prasse A, Renzoni EA, van der Smagt J, Poletti V, **Antonίου K**, van Moorsel CHM. Genetic testing in interstitial lung disease: An international survey. *Respirology*. 2022 Sep;27(9):747-757.
217. Papaioannou AI, Fouka E, Tzanakis N, **Antonίου K**, Samitas K, Zervas E, Kostikas K, Bartziokas K, Porpodis K, Papakosta D, Tzouvelekis A, Gerogianni I, Kotsiou O, Makris M, Rovina N, Vlachou G, Markatos M, Vittorakis S, Katsoulis K, Papanikolaou I, Afthinos A, Katsaounou P, Steiropoulos P, Latsios D, Dimakou K, Koukidou S, Hillas G, Tryfon S, Kallieri M, Georgopoulou A, Avarlis P, Bakakos P, Markopoulou K, Gaki E, Paspala A, Kyriakaki Z, Gourgoulisanis KI, Papiris S, Loukides S. SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics. *J Allergy Clin Immunol Pract*. 2022 Oct;10(10):2588-2595.
218. Nikkho SM, Richter MJ, Shen E, Abman SH, **Antonίου K**, Chung J, Fernandes P, Hassoun P, Lazarus HM, Olschewski H, Piccari L, Psołka M, Saggat R, Shlobin OA, Stockbridge N, Vitulo P, Vizza CD, Wort SJ, Nathan SD. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension. *Pulm Circ*. 2022 Jul 1;12(3):e12127.
219. Nathan SD, Fernandes P, Psołka M, Vitulo P, Piccari L, **Antonίου K**, Nikkho SM, Stockbridge N. Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension. *Pulm Circ*. 2022 Oct 1;12(4):e12178.
220. Karampitsakos T, Spagnolo P, Mogulkoc N, Wuyts WA, Tomassetti S, Bendstrup E, Molina-Molina M, Manali ED, Unat ÖS, Bonella F, Kahn N, Kolilekas L, Rosi E, Gori L, Ravaglia C, Poletti V, Daniil Z, Prior TS, Papanikolaou IC, Aso S, Tryfon S, Papakosta D, Tzilas V, Balestro E, Papiris S, **Antonίου K**, Bouros D, Wells A, Kreuter M, Tzouvelekis A. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe. *Respirology*. 2023 Jan;28(1):56-65.

221. Karampitsakos T, Tzilas V, Papaioannou O, Chrysikos S, Vasarmidi E, Juge PA, Vizirianaki S, Bibaki E, Reppa A, Sidiropoulos P, Katsaras M, Sotiropoulou V, Tsiri P, Koulousousa E, Theochari E, Tsirikos G, Christopoulos I, Malakounidou E, Zarkadi E, Sampsonas F, Hillas G, Karageorgas T, Daoussis D, Kalogeropoulou C, Dimakou K, Tzanakis N, Borie R, Dieudé P, **Antoniou K**, Crestani B, Bouros D, Tzouvelekis A. Clinical features and outcomes of patients with myositis associated-interstitial lung disease. *Front Med (Lausanne)*. 2023 Jan 9;9:1096203.
222. Karampitsakos T, Sotiropoulou V, Katsaras M, Tsiri P, Georgakopoulou VE, Papanikolaou IC, Bibaki E, Tomos I, Lambiri I, Papaioannou O, Zarkadi E, Antonakis E, Pandi A, Malakounidou E, Sampsonas F, Makrodimitri S, Chrysikos S, Hillas G, Dimakou K, Tzanakis N, Sipsas NV, **Antoniou K**, Tzouvelekis A. Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model. *Front Med (Lausanne)*. 2023 Jan 17;9:1083264.
223. Nakshbandi G, Moor CC, **Antoniou K**, Cottin V, Hoffmann-Vold AM, Koemans EA, Kreuter M, Molyneaux PL, Wuyts WA, Wijsenbeek MS. Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE. *BMC Pulm Med*. 2023 Feb 2;23(1):51.
224. Spanakis M, Ioannou P, Tzalis S, Chouzouri F, Patelarou E, Kofteridis DP, **Antoniou KM**, Schiza SE, Patelarou A, Tzanakis N. Evaluation of Drug Interactions in Hospitalized Patients with Respiratory Disorders in Greece. *Adv Respir Med*. 2023 Feb 5;91(1):74-92.
225. Borie R, Kannengiesser C, **Antoniou K**, Bonella F, Crestani B, Fabre A, Froidure A, Galvin L, Griesse M, Grutters JC, Molina-Molina M, Poletti V, Prasse A, Renzoni E, van der Smagt J, van Moorsel CHM. European Respiratory Society statement on familial pulmonary fibrosis. *Eur Respir J*. 2023 Mar 16;61(3):2201383.
226. Piccari L, Allwood B, **Antoniou K**, Chung JH, Hassoun PM, Nikkho SM, Saggar R, Shlobin OA, Vitulo P, Nathan SD, Wort SJ. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension. *Pulm Circ*. 2023 Apr 1;13(2):e12213.
227. Karampitsakos T, Diep PP, Loth DW, Nadeem I, Khurtsidze E, Wijsenbeek MS, Wuyts WA, Bargagli E, Froidure A, Spagnolo P, Veltkamp M, Molina-Molina M, McCarthy C, **Antoniou KM**, Kreuter M, Moor CC. ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly. *ERJ Open Res*. 2023 Apr 17;9(2):00584-2022.
228. Karampitsakos T, Sotiropoulou V, Katsaras M, Tsiri P, Georgakopoulou VE, Papanikolaou IC, Bibaki E, Tomos I, Lambiri I, Papaioannou O, Zarkadi E, Antonakis E, Pandi A, Malakounidou E, Sampsonas F, Makrodimitri S, Chrysikos S, Hillas G, Dimakou K, Tzanakis N, Sipsas NV, **Antoniou K**, Tzouvelekis A.

Corrigendum: Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model. *Front Med (Lausanne)*. 2023 Apr 13;10:1194925.

229. Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS; ISABELA 1 and 2 Investigators. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials. *JAMA*. 2023 May 9;329(18):1567-1578.
230. Barbayianni I, Kanellopoulou P, Fanidis D, Nastos D, Ntouskou ED, Galaris A, Harokopos V, Hatzis P, Tsitoura E, Homer R, Kaminski N, **Antoniou KM**, Crestani B, Tzouvelekis A, Aidinis V. SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis. *Nat Commun*. 2023 Sep 21;14(1):5882.
231. Galaris A, Fanidis D, Tsitoura E, Kanellopoulou P, Barbayianni I, Ntatsoulis K, Touloumi K, Gramenoudi S, Karampitsakos T, Tzouvelekis A, **Antoniou K**, Aidinis V. Increased lipocalin-2 expression in pulmonary inflammation and fibrosis. *Front Med (Lausanne)*. 2023 Sep 7;10:1195501.
232. Molina-Molina M, Shull JG, Vicens-Zygmunt V, Rivera-Ortega P, **Antoniou K**, Bonella F, Renzoni E, Russell AM, Maher TM, Vancheri A, Bachs A, Avilés V, Palma J, Bermudo G, Suarez-Cuartin G, Tebé C, Rigo-Bonnin R, Montes-Worboys A, Wijsenbeek M, Vancheri C. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial. *Eur Respir J*. 2023 Oct 19;62(4):2300262.

7.8 ΚΕΦΑΛΑΙΑ ΣΕ ΔΙΕΘΝΕΙΣ ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΕΚΔΟΣΕΙΣ

1. Bouros D, **Antoniou K**. Immunotherapy for pulmonary fibrosis: a light in the dark? *Eur Respir Top*. 2000; 6: 23
2. Bouros D, **Antoniou K**. Do patients with cryptogenic fibrosing alveolitis have increased risk of Lung Cancer? *Eur Respir Top*. 2000; 6: 37
3. Bouros D, **Antoniou K**. Transforming growth factor (TGF-β) induces pleurodesis significantly faster than talc. *Eur Respir Top* 2001; 7: 61
4. Bouros D, **Antoniou K**. Influence of diuretics on transudative pleural effusions. *Eur Respir Top* 2002; 8: 4
5. Bouros D, **Antoniou KM**. Hot Topic. High-dose acetylcysteine in idiopathic pulmonary fibrosis. *Breath*, 2006; Volume 2: No 4
6. **Antoniou KM**, Wells AU. Diffuse parenchymal lung disease: a different perspective. *Breathe* 2008; 4: 240-1

7. Tzanakis N, **Antoniou K**. Pleural Effusions in pregnancy and gynecological diseases in “Pleural Diseases” editor Bouros D, Marcel Dekker, Inc publication, New York: Vol 186; 737-55
8. Bouros D, **Antoniou K**, Siafakas N. Pleural Effusions in pregnancy and gynecological diseases in “Pleural Diseases” editor Bouros D, New York: Marcel Dekker, Inc publication (2nd edition)
9. **Antoniou KM**, Wells AU, Bouros D. Immunological Diseases of the Pleura. Pleural Effusions in pregnancy and gynecological diseases. in “Pleural Diseases” editor Bouros D, New York: Marcel Dekker, Inc publication (2nd edition)
10. Wells AU, **Antoniou KM**. Interstitial lung disease in SSc in “Scleroderma-modern aspects of pathogenesis, diagnosis and therapy”, by Oliver Distler, pages 33-37
11. Margaritopoulos GA, Economidou FN, Siafakas NM, **Antoniou KM**. Immunopathogenesis of Sarcoidosis in “Sarcoidosis Diagnosis and Management”. IPF Monograph. 2011; page 1-20. ISBN 978-953-307-414-6
12. Wells AU, Margaritopoulos GA, **Antoniou KM**, Nicholson AG. Chapter 25. Interstitial Lung Disease in Systemic Sclerosis in “Orphan Lung Disease”. Springer-Verlag, London. 2015; page 379-90. ISBN 978-1-4471-2400-9 ISBN (electronic) 978-1-4471-2401-6
13. Wells AU, Margaritopoulos GA, **Antoniou KM**, Nunes H, Costabel U. Chapter 14. CPFE: distinctive and non-distinctive features. in “Idiopathic Pulmonary Fibrosis”. ERS monograph. 2016; Page 175-85. ISBN (electronic): 978-1-84984-068-2.
14. **Antoniou KM**, Vasarmidi E, Trachalaki, A, Bibaki E, Crestani B. Chapter 7 Systemic lupus erythmatosus, sjogren syndrome and mixed connective tissue disease, in “Pulmonary manifestations of systemic diseases”, ERS Monograph. 2019; Page 106-23. ISBN (electronic): 978-1-84984-112-2
15. **Antoniou K**. Chapter 29 Fibrosing organizing pneumonia, in “Fibrotic Interstitial Lung Diseases” CRC Press Book Proposal, Wells AU, Tomassetti S and Walsh SLF. *In preparation*
16. Margaritopoulos G, **Antoniou K**. Chapter in Pathobiology of Rare Lung Diseases. *In preparation*

7.9 ΕΡΓΑΣΙΕΣ ΣΕ ΔΙΕΘΝΗ ΕΠΙΣΤΗΜΟΝΙΚΑ ΣΥΝΕΔΡΙΑ

1. **Antoniou K**, Bouros D, Sourvinos G, Demadi M, Papa I, Labiri E, Polychronopoulos V. A multicenter randomised comparative trial of long-term treatment with interferon γ-1b versus colchicine in patients with idiopathic pulmonary fibrosis. 3rd Mediterranean congress on Thoracic Diseases – Lung Inflammation Disorders. Hersonissos Crete, Hellas, November, 2000; Abstact Book 138 (Oral presentation)
2. **Antoniou KM**, Drositis J, Chalkiadakis G, Schiza S, Siafakas NM. The role of video-assisted thoracoscopic surgery (VATS) in the treatment of pleural infection after fibrinolytics failure. 10th ERS Annual Congress, Florence, Italy, August 30-September 3; Eur Respir J 2000 p164s

3. Ferdoutsis M, Vakouti E, Meletis G, Christodoulou M, Pitsidianakis G, **Antoniou K**, Patsourakis G, Bachlitzanakis N. Sputum bacteriology in acute COPD exacerbations. Correlation with FEV1 deterioration. 11th ERS Annual Congress, Berlin, Sept. 22-26; Eur Respir J 2001; 18: Suppl. 33,1351
4. Ferdoutsis M, Christodoulou M, Meletis G, Vakouti E, **Antoniou K**, Pitsidianakis G, Gavrilidis G, Patsourakis G, Bachlitzanakis N. High prevalence of current smokers among COPD patients with anxiety and depression symptoms. 11th ERS Annual Congress, Berlin, Sept. 22-26; Eur Respir J 2001; 18: Suppl. 33,1370
5. Ferdoutsis M, Christodoulou M, Meletis G, Pitsidianakis G, **Antoniou K**, Gavrilidis G, Patsourakis G, Bibakis G, Bachlitzanakis N. Family history related to allergic asthma and rhinitis in children. 11th ERS Annual Congress, Berlin, Sept. 22-26; Eur Respir J 2001; 18: Suppl. 33,2543
6. Meletis G, Vakouti E, Ferdoutsis M, Hahlioutis K, Gavrilidis G, **Antoniou K**, Patsourakis G, Bachlitzanakis N. Analysis of the cases with hemoptysis in hospitalized patients (3 years retrospective study). 11th ERS Annual Congress, Berlin, Sept. 22-26; Eur Respir J 2001; 18: Suppl. 33,2597
7. Meletis G, Ferdoutsis M, Pitsidianakis G, Vakouti E, Christodoulou M, **Antoniou K**, Gavrilidis G, Bachlitzanakis N. Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasis. 11th ERS Annual Congress, Berlin, Sept. 22-26; Eur Respir J 2001; 18: Suppl. 33,3617
8. **Antoniou KM**, Tzanakis N, Kyriakou D, Koutala E, Siafakas NM, Bouros D. Induced sputum versus bronchoalveolar lavage fluid (BALF) in the evaluation of patients with idiopathic pulmonary fibrosis (IPF). ACCP Annual meeting, Philadelphia, Pennsylvania, November 4-8, 2001; Chest; 272S
9. **Antoniou KM**, Tzanakis N, Kyriakou D, Koutala E, Siafakas NM, Bouros D. Induced sputum versus bronchoalveolar lavage fluid (BALF) in the evaluation of patients with idiopathic pulmonary fibrosis (IPF). ATS Annual Congress, San Francisco, California, USA; Am J Respir Crit Care Med; s A711
10. **Antoniou K**, Dermitzakis A, Meletis G, Ferdoutsis M, Patsourakis G, Tzanakis N, Bachlitzanakis N, Bouros D. The influence of pulmonary disease on ventricular diastolic dysfunction in COPD and IPF. 12th ERS Annual Congress, Stockholm, Sept.14-18; Eur Respir J 2002; 20: Suppl. 38,689
11. **Antoniou KM**, Dimadi M, Mermigis Ch, Trigidou R, Labrakis C, Rapti A, Latsi P, Drositis J, Bachlitzanakis N, Nicholson A, Polychronopoulos V, Bouros D. Comparison of interferon gamma-1b and colchicine in the treatment of idiopathic pulmonary fibrosis: preliminary results of a prospective, multicenter randomised study. 12th ERS Annual Congress, Stockholm, Sept.14-18; Eur Respir J 2002; 20: Suppl. 38,3754 (Assembly symposium)
12. Dimadi MA, Trigidou R, Malagari K, **Antoniou K**, Rapti A, Koutsopoulos A, Mermigis C, Labrakis C, Nicholson A, Polychronopoulos V, Bouros D. Histological compared to high resolution computed tomography (HRCT) findings in Idiopathic Interstitial Pneumonias (IIP). 12th ERS Annual Congress, Stockholm, Sept.14-18; Eur Respir J 2002; 20: Suppl. 38,2887

13. **Antoniou KM**, Malagari K, Perisinakis K, Labiri E, Kostaki A, Karkavitsas N, Siafakas NM, Bouros D. Relationship between HRCT findings and clearance of technetium –99m-DTPA in the evaluation of patients with Idiopathic Pulmonary Fibrosis (IPF). 12th ERS Annual Congress, Stockholm, Sept.14-18; Eur Respir J 2002; 20: Suppl. 38,2892
14. **Antoniou KM**, Malagari K, Trigidou R, Koutsopoulos A, Polychronopoulos V, Rapti A, Dimadi M, Mermigkis C, Bachlitzanakis N, Bouros D. Correlation of high resolution computer tomography (HRCT) and histological findings in idiopathic interstitial pneumonias. ATS Annual Congress, Atlanta, USA; Am J Respir Crit Care Med 2002s; A46
15. Dimadi MA, Trigidou R, Malagari K, **Antoniou K**, Rapti A, Koutsopoulos A, Mermigis C, Labrakis C, Nicholson A, Polychronopoulos V, Bouros D. Histological compared to high resolution computed tomography (HRCT) findings in Idiopathic Interstitial Pneumonias. 6th State of Art, Athens, April 12-14, 2002; Interdisciplinary Review Course; Abstract Book n.37
16. Dermitzakis A, Kimioni E, Panagiotakis S, **Antoniou K**, Lamprogiannakis E, Avramakis G, Apostolaki A, Bouros D. Pulmonary hypertension and functionality of ascending aorta. 14th Annual Meeting of Mediterranean Association of Cardiology and Cardiac Surgery, Rhodes, Greece, October 9-12, 2002
17. Dermitzakis A, Kimioni E, **Antoniou K**, Panagiotakis S, Avramakis G, Lambrogiannakis E, Zaharaki A, Bouros D. Diastolic function of left ventricle in patients with chronic obstructive pulmonary disease. 14th Annual Meeting of Mediterranean Association of Cardiology and Cardiac Surgery, Rhodes, Greece, October 9-12, 2002
18. **Antoniou KM**, Zervou MI, Tzortzaki EG, Tzanakis N, Polychronopoulos V, Latsi P, Dimadi M, Siafakas NM, Nicholson AG, Bouros D Old-fashioned colchicine or interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis? The molecular perspective. 7th State of the Art, Athens, April 17-20, 2003; Abstract Book n.22
19. **Antoniou KM**, Malagari K, Perisinakis K, Tzanakis N, Meletis G, Karkavitsas N, Bachlitzanakis N, Siafakas NM, Bouros D. Relationship between findings and clearance of technetium-99m-DTPA in the evaluation of patients with Idiopathic Pulmonary Fibrosis (IPF). ATS Annual Congress, Seattle, Washington, USA; Am J Respir Crit Care Med 2003s; A989
20. **Antoniou KM**, Malagari K, Perisinakis K, Plataki M, Psathakis K, Maltezakis G, Karkavitsas N, Bachlitzanakis N, Siafakas NM, Bouros D. Relationship between HRCT findings and clearance of technetium-99m-DTPA in the evaluation of Sarcoidosis patients. ATS Annual Congress, Seattle, Washington, USA; Am J Respir Crit Care Med 2003s; A172
21. **Antoniou KM**, Polychronopoulos V, Dimadi M, Rapti A, Lambrakis C, Latsi P, Nicholson A, Bachlitzanakis N, Siafakas NM, Bouros D. Comparison of Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of

- idiopathic pulmonary fibrosis: Preliminary results of a prospective, multicenter randomized study. ATS Annual Congress, Seattle, Washington, USA; Am J Respir Crit Care Med 2003s; A168
22. **Antoniou KM**, Zervou M, Tzortzaki E, Dimadi M, Latsi P, Polychronopoulos V, Siafakas NM, Bouros D. Promoters and inhibitors mRNAs expression before and after treatment with interferon gamma-1b or colchicine in idiopathic pulmonary fibrosis: Preliminary results. ERS Annual Congress, Vienna; Eur Respir J 2003; 22: Suppl. 45,613
 23. **Antoniou KM**, Tzanakis N, Tzortzaki EG, Tsiligianni I, Zervou M, Siafakas NM, Bouros D. Induced sputum versus bronchoalveolar lavage fluid (BALF) in the evaluation of patients with Idiopathic Pulmonary Fibrosis (IPF). ERS Annual Congress, Vienna; Eur Respir J 2003; 22: Suppl. 45,1517
 24. Meletis G, Astrinaki E, Ferdoutsis M, Vakouti E, Hahlioutis K, **Antoniou K**, Zografistos N, Vrouhos G, Bachlitzanakis N. Acinetobacter baumani and Pseudomonas aeruginosa drug susceptibility after bacteriological analysis of sputum in patients mechanically ventilated in ICU. ERS Annual Congress, Vienna; Eur Respir J 2003; 22: Suppl. 45,2859
 25. **Antoniou K**, Dermitzakis A, Ferdoutsis M, Meletis G, Patsourakis G, Bachlitzanakis N. The influence of pulmonary disease on ventricular diastolic dysfunction in COPD patients. ERS Annual Congress, Vienna; Eur Respir J 2003; 22: Suppl. 45,3375
 26. Malagari K, Wells A, **Antoniou KM**, Dimadi M, Rapti A, Latsi P, Lambrakis C, Polychronopoulos V, Bouros D. High resolution computed tomography (HRCT) findings before and after treatment with interferon gamma-1b (IFN-γ) or colchicine in idiopathic pulmonary fibrosis (IPF) patients. ERS Annual Congress, Vienna; Eur Respir J 2003; 22: Suppl. 45,3706
 27. Dimadi M, Rapti A, Latsi P, **Antoniou KM**, Birba G, Trigidou R, Nicholson A, Bachlitzanakis N, Polychronopoulos V, Bouros D. Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF). ERS Annual Congress, Vienna; Eur Respir J 2003; 22: Suppl. 45, 1328
 28. **Antoniou KM**, Zervou MI, Tzortzaki EG, Tzanakis N, Polychronopoulos V, Latsi P, Dimadi M, Siafakas NM, Nicholson AG, Bouros D. Old-fashioned colchicine or interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis? The molecular perspective. ACCP Annual Meeting, Orlando, Florida, 25-30 October, 2003 (Oral presentation)
 29. **Antoniou KM**, Alexandrakis MG, Sfridaki K, Tzortzaki EG, Tzouvelekis A, Pataka A, Siafakas NM, Bouros D. Th1 Cytokine pattern (IL-12 and IL-18) in Bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b in patients with idiopathic pulmonary fibrosis (IPF/UIP). 8th State of the Art, Interdisciplinary Review Course on Thoracic, Critical Care & Emergency Medicine, Athens, Greece, May 7-9, 2004, Abstract Book, page 49, P35B

30. Zervou MI, Tzortzaki EG, Tsoumakidou M, Plataki M, Samara K, **Antoniou K**, Schiza SE, Siafakas NM. Cross-checking the incidence of microsatellite DNA instability in severe persistent asthma and COPD. ATS Annual Congress, Orlando-Florida, USA; Am J Respir Crit Med 2004s; A585
31. **Antoniou KM**, Alexandrakis M, Sfiridaki K, Tzortzaki EG, Tzanakis N, Dimadi M, Siafakas NM, Bouros D. Randomized, colchicine-controlled study of interferon gamma-1b (IFN gamma-1b) treatment on cytokine profile (IL-12 and IL-18) in patients with Idiopathic Pulmonary Fibrosis (IPF). ATS Annual Congress, Orlando-Florida, USA; Am J Respir Crit Med 2004s; A108
32. Tringidou R, Dimadi M, **Antoniou KM**, Koutsopoulos A, Karkaidos P, Vassiliou L, Gorgoulis VG, Bouros D. Expression and distribution of heat-shock protein-47 (HSP-47) and type I Procollagen synthesis in IPF and COP: Is it the key for the progression of fibrosis? A comparative study. ATS Annual Congress, Orlando-Florida, USA; Am J Respir Crit Med 2004s; A112
33. **Antoniou KM**, Alexandrakis M, Sfiridaki K, Tzanakis N, Symvoulakis EK, Tsiligianni I, Bouros D, Siafakas NM. Comparison of sputum induction with Bronchoalveolar Lavage Fluid Cytokine IL-12 and IL-18 levels in patients with idiopathic pulmonary fibrosis (IPF/UIP). ATS Annual Congress, Orlando-Florida, USA; Am J Respir Crit Med 2004s; A298
34. **Antoniou KM**, Tsiligianni I, Alexandrakis M, Sfiridaki K, Tzortzaki EG, Tzanakis N, Bouros D, Siafakas NM. Th1 cytokine profile pattern in peripheral blood, induced sputum and Bronchoalveolar lavage fluid in pulmonary sarcoidosis. ATS Annual Congress, Orlando-Florida, USA; Am J Respir Crit Med 2004s; A549
35. **Antoniou KM**, Tzortzaki EG, Malagari K, Zervou M, Tzanakis N, Dimadi M, Nicholson A, Siafakas NM, Bouros D. Randomized, colchicine-control study of interferon gamma-1b treatment on biomarkers of fibrosis in patients with idiopathic pulmonary fibrosis (IPF). ATS Annual Congress, Orlando-Florida, USA; Am J Respir Crit Med 2004s; A778
36. **Antoniou KM**, Mamoulaki M, Malagari K, Tzortzaki EG, Bouros D, Boumpas D, Siafakas NM. Infliximab therapy in Interstitial Lung Disease associated with rheumatoid arthritis. ERS Annual Congress, Glasgow; Eur Respir J 2004; 24: Suppl. 48: 1674 (Oral presentation)
37. R. Trigidou, M. A. Dimadi, A. Koutsopoulos, K. M. Antoniou, M. Fotinou, L. Vassiliou, P. Karkaidos, V. G. Gorgoulis, D. Bouros (Athens, Heraklion, Alexandroupolis, Greece). Matrix remodeling in IPF: the important role of MMPs-1, -2, -9 and TIMP-1, TIM-2. Eur Respir J 2004; 24: Suppl. 48, 2799
38. Zervou M, Tzortzaki EG, Makris D, Tsoumakidou M, Chrysafakis G, **Antoniou KM**, Tzanakis N, Siafakas NM. Differential diagnosis of COPD and asthma at the microsatellite DNA level. ERS Annual Congress, Glasgow; Eur Respir J 2004; 24: Suppl. 48: 4245
39. **Antoniou KM**, Trigidou R, Koutsopoulos A, Dimadi M, Fotinou M, Alexandrakis M, Sfiridaki K, Tzortzaki E, Siafakas NM, Bouros D. Matrix remodeling in Idiopathic Pulmonary Fibrosis: Increased levels of gelatinase B (mmp-9) in the bronchoalveolar lavage fluid in IPF patients. Am J Respir Crit Med 2005s; A636

40. **Antoniou KM**, Tzortzaki EG, Alexandrakis M, Tzanakis N, Sfiridaki K, Zervou M, Tsiligianni I, Bouros D, Siafakas NM. Investigation of the angiogenic chemokine interleukin-8 (IL-8/CXCL8) after interferon gamma-1b treatment in IPF patients. *Am J Respir Crit Med* 2005s; A123
41. **Antoniou KM**, Tsiligianni I, Kyriakou D, Alexandrakis M, Chrysophakis G, Pougounias M, Siafakas NM, Bouros D. Th1/Th2 profile in bronchoalveolar lavage and sputum induction in pulmonary sarcoidosis. *Am J Respir Crit Med* 2005s; A123
42. Plataki M, **Antoniou KM**, Alexandrakis M, Tzanakis N, Sfiridaki K, Tzortzaki EG, Lambiri I, Siafakas NM, Bouros D. Soluble form of fas-ligand in bronchoalveolar lavage fluid from patients with Idiopathic Pulmonary Fibrosis before and after interferon-γ-1b treatment. *Am J Respir Crit Med* 2005s; A638
43. Plataki M, **Antoniou KM**, Tzanakis N, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Tzortzaki EG, Bouros D, Siafakas NM. Soluble form of fas-ligand in bronchoalveolar lavage fluid from patients with sarcoidosis. *Am J Respir Crit Med* 2005s; A344
44. Economidou F, **Antoniou KM**, Alexandrakis M, Sfiridaki K, Tzanakis N, Tzortzaki EG, Bachlitzanakis N, Siafakas NM, Schiza SE. Role of tumor necrosis factor-alpha (TNF-α) in the diagnostic assessment of pleural effusion: preliminary results. *Am J Respir Crit Med* 2005s; A662
45. **Antoniou KM**, Tzortzaki EG, Tzanakis N, Sfiridaki K, Kandidaki E, Alexandrakis MG, Moraitaki D, Maltezakis G, Bouros D, Siafakas NM. Decreased levels of CXC Angiogenic Chemokines (IL-8, ENA-78 and GRO-α) in BALF after interferon gamma-1b treatment in IPF patients. *Eur Respir J* 2005; 26: Suppl.49,1803
46. Plataki M, **Antoniou KM**, Alexandrakis MG, Sfiridaki K, Tzanakis N, Tzortzaki EG, Siafakas NM, Bouros D. Soluble Fas-ligand levels in bronchoalveolar lavage fluid before and after interferon-gamma-1b treatment in idiopathic pulmonary fibrosis. *Eur Respir J* 2005; 26: Suppl.49,2190
47. **Antoniou KM**, Tzortzaki EG, Tzanakis N, Sfiridaki K, Alexandrakis MG, Bouros D, Siafakas NM. Angiogenic and angiostatic CXC chemokines in BALF and serum of IPF patients. *Eur Respir J* 2005; 26: Suppl.49,2191
48. **Antoniou KM**, Tzanakis N, Tsiligianni I, Kyriakou D, Alexandrakis MG, Tzortzaki E, Symvoulakis E, Siafakas NM, Bouros D. Perforin expression and lymphocytes adhesion molecules in patients pulmonary sarcoidosis. *Eur Respir J* 2005; 26: Suppl.49,3065 (Oral presentation)
49. **Antoniou KM**, Tzanakis N, Tzortzaki EG, Tsiligianni I, Sfiridaki K, Kandidaki E, Symvoulakis E, Bouros D, Siafakas NM. Investigation of angiogenetic markers (ENA-78 and GRO-α) in patients with pulmonary sarcoidosis. *Eur Respir J* 2005; 26: Suppl.49,598
50. Karakatsani A, Papakosta D, Rapti A, Dimadi M, Markopoulou A, Latsi P, Polychronopoulos V, Birba G, Serasli E, **Antoniou A**, Papagiannis A, Labrakis Ch, Pappa I, Katsiboula S, Bouros D. Incidence and prevalence of interstitial lung diseases in Greece. *Eur Respir J* 2005; 26: Suppl.49,1797

51. **Antoniou KM**, Tzouvelekis A, Alexandrakis MG, et al. Differential angiogenic activity in patients with pulmonary sarcoidosis and idiopathic pulmonary fibrosis. *Am J Respir Crit Med* 2006s; A801
52. **Antoniou KM**, Alexandrakis MG, Tzanakis N, Maltezas G, Lambiri I, Moraitaki D, Bouros D, Siafakas NM. Investigation of CXC angiogenic chemokines (IL-8, ENA-78, GRO- alpha) and angiostatic chemokines (IP-10, ITAC, MIG) in BALF after interferon gamma-1b treatment in IPF patients. *Am J Respir Crit Med* 2006s; A107
53. **Antoniou KM**, Hansell DM, Rubens MB, Marten K, Siafakas NM, Desai SR, du Bois RM, Wells AU. Idiopathic pulmonary fibrosis: does smoking status influence outcome? *Eur Respir J* 2006; 28: Suppl. 50, 4801
54. **Antoniou KM**, Hansell DM, Rubens MR, Marten K, Tennant R, Hansel T, Siafakas NM, Bois R du, Wells AU. Association between emphysema and pulmonary fibrosis are suggestive of a smoking pathogenesis common to both disorders. American Thoracic Society Annual Meeting, San Francisco, California, May 18-23, 2007; AJRCCM. Abstract book A144.
55. **Antoniou KM**, Lambiri I, Tzortzaki EG, Plataki M, Economidou F, Stamataki E, Tzanakis N, Maltezas G, Siafakas NM. Differential role of tyrosine kinase receptor Tie2 in pulmonary sarcoidosis. American Thoracic Society Annual Meeting, San Francisco, California, May 18-23, 2007; AJRCCM. Abstract book A363.
56. Economidou F, **Antoniou KM**, Sfiridaki K, Siafakas NM, Schiza SE. The role of angiogenesis in the differential diagnosis of pleural effusions. American Thoracic Society Annual Meeting, San Francisco, California, May 18-23, 2007; AJRCCM. Abstract book A914.
57. Economidou F, Margaritopoulos G, Protopapadakis C, Voloudaki A, Lambiri I, Malagari K, **Antoniou KM**, Siafakas NM. Long term clinical and radiological effects of interferon gamma-1b in idiopathic pulmonary fibrosis. Conference of European Society Thoracic Imaging. Athens, Greece June 8-10, 2007. Abstract book p.13
58. Protopapadakis C, Economidou F, Margaritopoulos G, **Antoniou K**, Lambiri I, Voloudaki A, Nicholson A, Karantans A. Erdheim-Chester disease: an atypical and severe case with multisystemic involvement. 2007 Conference of European Society Thoracic Imaging. Athens, Greece June 8-10, 2007. Abstract book p.22
59. Economidou F, Tzortzaki E, Neofytou E, **Antoniou K**, Tzanakis N, Siafakas N, Schiza S. Could microsatellite analysis of pleural fluid increase sensitivity of pleural fluid cytology? European Respiratory Society Annual Meeting Stockholm, Sweden, September 15-19; *Eur Respir J* 2007; 30: Suppl. 51, 3207
60. Papakosta D, Dimadi M, Stagaki E, Latsi P, Rapti A, **Antoniou K**, Tzouvelekis A, Daniil Z, Pitsiou G, Rallidis L, Tryfon S, Hainis K, Polychronopoulos V, Bouros D. Prevalence of pulmonary arterial hypertension in idiopathic pulmonary fibrosis: a multicenter study. *Eur Respir J* 2007; 30: Suppl. 51, 818
61. **Antoniou K**, Economidou F, Soufla G, Tzortzaki E, Lambiri I, Tzanakis N, Spandidos D, Siafakas N. VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis.

European Respiratory Society Annual Meeting Stockholm, Sweden, September 15-19; Eur Respir J 2007; 30: Suppl. 51, 3409

62. **Antoniou K**, Soufla G, Tzortzaki E, Manousakis M, Margaritopoulos G, Economidou F, Lambiri I, Spandidos D, Siafakas N. Down regulation of stromal cell-derived factor 1 (SDF-1/CXL12) in lung tissue of patients with idiopathic pulmonary fibrosis. European Respiratory Society Annual Meeting Stockholm, Sweden, September 15-19; Eur Respir J 2007; 30: Suppl. 51, 3411
63. **Antoniou K**, Soufla G, Tzortzaki E, Sourvinos G, Politis I, Drositi I, Spandidos D, Siafakas N. Down regulation of human insulin-like growth factor in lung tissue of patients with idiopathic pulmonary fibrosis. European Respiratory Society Annual Meeting Stockholm, Sweden, September 15-19; Eur Respir J 2007; 30: Suppl. 51, 3413
64. **Antoniou K**, Papadaki H, Soufla G, Darivianaki A, Koutal H, Kastrinaki MC, Economidou F, Spandidos D, Siafakas N. Expression analysis of the biological axis CXCL12/CXCR4 in bone marrow mesenchymal stem cells in patients with idiopathic pulmonary fibrosis (IPF). Sixth ERS lung Science Conference. Estoril Portugal, March 14-16, 2008, Final Programme p.119-120.
65. **Antoniou KM**, Papadaki H, Soufla G, Darivianaki D, Koutala H, Catrinaki C, Economidou F, Spandidos D, Siafakas NM. Functional and Molecular Characterization of bone marrow mesenchymal stem cells in idiopathic pulmonary fibrosis (IPF). American Thoracic Society Annual Meeting, Toronto, May 16-21, 2008; A739.
66. **Antoniou KM**, Soufla G, Economidou F, Lymbouridou R, Margaritopoulos G, Spandidos D, Siafakas NM. Investigation of the biological axis-stromal cell-derived factor 1 and receptor (SDF-1/CXL12) in patients with idiopathic pulmonary fibrosis (IPF). American Thoracic Society Annual Meeting, Toronto, May 16-21, 2008; A739.
67. **Antoniou KM**, Choulaki C, Soufla G, Economidou F, Drositis I, Manousakis M, Siafakas NM, Spandidos D. Transcriptional inactivation of p53 gene in the apoptotic pathway of Idiopathic pulmonary fibrosis: preliminary results. American Thoracic Society Annual Meeting, Toronto, May 16-21, 2008; A741.
68. Margaritopoulos G, **Antoniou KM**, Lymbouridou R, Soufla G, Economidou F, Proklou A, Lambiri I, Tzanakis N, Siafakas NM. VEGF expression in bronchoalveolar lavage fluid (BALF) in patients with fibrotic interstitial pneumonias: Idiopathic versus collagen vascular diseases related subtypes: preliminary results. American Thoracic Society Annual Meeting, Toronto, May 16-21, 2008; A742.
69. Economidou F, **Antoniou KM**, Soufla G, Tzortzaki EG, Lymbouridou R, Margaritopoulos G, Politis I, Tzanakis N, Siafakas NM. Angiogenetic profiles (VEGF and VEGF receptor-1, Flt-1) in bronchoalveolar lavage fluid in patients with interstitial lung diseases. American Thoracic Society Annual Meeting, Toronto, May 16-21, 2008; A742.

70. Economidou F, **Antoniou K**, Soufla G, Proklou A, Samara K, Choulaki C, Lymbouridou R, Siafakas NM. Impaired VEGF receptor-1 FLT-1 expression in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. 9th WASOG Meeting & 11th BAL international conference. Athens, June 19-22, 2008; PP01.
71. **Antoniou KM**, Papadaki H, Doufla G, Darivianaki A, Koutal H, Kastrinaki C, Economidou F, Spandidos D, Siafakas NM. Increased expression of the biological axis CXCL12/CXCR4 in bone marrow mesenchymal stem cells (BM MSCS) in patients with idiopathic pulmonary fibrosis (IPF). 9th WASOG Meeting & 11th BAL international conference. Athens, June 19-22, 2008; PP65
72. **Antoniou KM**, Soufla G, Kastrinaki MC, Economidou F, Damianaki A, Proklou A, Spandidos D, Papadaki HA, Siafakas NM. Investigation of telomerase expression in bone marrow mesenchymal stem cells (BM-MSCS) and lung tissue from patients with idiopathic pulmonary fibrosis. 9th WASOG Meeting & 11th BAL international conference. Athens, June 19-22, 2008; PP66
73. Margaritopoulos G, **Antoniou KM**, Soufla G, Economidou F, Choulaki C, Proklou A, Lymbouridou R, Lambiri I, Tzanakis N, Siafakas NM. Increased expression of stromal cell derived factor-1/CXC chemokine receptor 4 (SDF-1/CXCL12-CXCR4) biological axis in interstitial pneumonias associated with collagen vascular disease: A bronchoalveolar lavage fluid study. 9th WASOG Meeting & 11th BAL international conference. Athens, June 19-22, 2008; PP82
74. Proklou A, **Antoniou K**, Soufla G, Economidou F, Samara K, Manousakis M, Drositis I, Spandidos D, Siafakas NM. Expression of angiogenic growth factors and stromal cell derived factor SDF-1/CXC chemokine receptor 4 (SDF-1/CXCL12-CXCR4) biological axis in idiopathic pulmonary fibrosis: a lung tissue study. 18th European Respiratory Society Annual Meeting, Berlin, Germany, October 4-8; Eur Respir J 2008; 32: Suppl. 52, 196
75. **Antoniou K**, Papadaki H, Soufla G, Darivianaki A, Koutala H, Kastrinaki MC, Spandidos D, Siafakas N. Expression of the biological axis VEGF-CXCL12/CXCR4 in bone marrow mesenchymal stem cells (BM MSCs) in patients with idiopathic pulmonary fibrosis (IPF). 18th European Respiratory Society Annual Meeting, Berlin, October 4-8; Eur Respir J 2008; 32: Suppl. 52, 197
76. Economidou F, **Antoniou K**, Samara K, Soufla K, Choulaki C, Proklou A, Politis I, Moraitaki D, Tzanakis N, Siafakas N. Angiogenetic profiles (VEGF and VEGF receptor-1, Flt-1) in bronchoalveolar lavage fluid in patients with interstitial lung diseases. 18th European Respiratory Society Annual Meeting, Berlin, Germany, October 4-8; Eur Respir J 2008; 32: Suppl. 52, 1879
77. Margaritopoulos G, **Antoniou K**, Soufla G, Economidou F, Choulaki C, Proklou A, Lymbouridou R, Lambiri I, Tzanakis N, Siafakas N. Differential expression of stromal cell derived factor-1/CXC chemokine receptor 4 (SDF-1/CXCL12 – CXCR4) biological axis between idiopathic pulmonary fibrosis and interstitial pneumonia associated with collagen vascular disease: a bronchoalveolar la. Eur Respir J 2008; 32: Suppl. 52, 1896

78. Economidou F, **Antoniou K**, Soufla G, Proklou A, Lymbouridou R, Maltezas G, Tzanakis N, Siafakas N. Increased expression of angiogenic growth factor stromal cell derived factor-1 (SDF-1/CXCL12) in pleural fluid of patients with lung cancer: preliminary results. 18th European Respiratory Society Annual Meeting, Berlin, Germany, October 4-8; Eur Respir J 2008; 32: Suppl. 52, 2600
79. **Antoniou K**, Hansell D, Rubens M, Marten K, Tennant R, Hansel T, Desai S, Siafakas N. Associations between emphysema and pulmonary fibrosis are suggestive of a smoking pathogenesis common to both disorders. 18th European Respiratory Society Annual Meeting, Berlin, Germany, October 4-8; Eur Respir J 2008; 32: Suppl. 52, 4223
80. **Antoniou KM**, Soufla G, Proklou A, Samara K, Lymbouridou R, Economidou F, Choulaki C, Spandidos DA, Siafakas NM. Differential activity of the biological axis VEGF –Flt-1 between granulomatous and fibrotic disorders: A bronchoalveolar lavage fluid. 13th World Congress on Advances in Oncology and 11th International Symposium on Molecular Medicine. October 9-11, 2008; International Journal of Molecular Medicine; S86.
81. **Antoniou KM**, Soufla G, Papadaki H, Darivianaki A, Koutala H, Kastrinaki C, Economidou F, Spandidos DA, Siafakas NM. Functional molecular and proteomic characterization of bone marrow mesenchymal stem cells in idiopathic pulmonary fibrosis. 13th World Congress on Advances in Oncology and 11th International Symposium on Molecular Medicine. October 9-11, 2008; International Journal of Molecular Medicine; S88.
82. Economidou F, Antoniou KM, Soufla G, Proklou A, Samara K, Choulaki C, Lymbouridou R, Siafakas NM. Impaired VEGF receptor-1, FLT-1 expression in bronchoalveolar lavage fluid in patients with pulmonary Sarcoidosis. 9th WASOG Meeting and 11th BAL International Conference, June 19-22 2008, Athens, Greece.
83. **Antoniou K**, Lasithiotaki I, Derdas SP, Sarchianaki E, Psaraki A, Spandidos DA, Stathopoulos EN, Siafakas NM, Sourvinos G. The role of Polyoma virus in Lung Cancer: a possible etiopathogenetic link? 17th World Congress on Advances in Oncology and 15th International Symposium on Molecular Medicine. Oct. 9-11, 2008. Int J Mol Med. Vol.30, S58.
84. Proklou A, **Antoniou K**, Lymbouridou R, Soufla G, Karagiannis K, Kasithiotaki I, Siafakas NM. Angiopoietins' (Ang-1 and Ang-2) mRNA expression levels in lung tissue of IPF patients. International conference of American Thoracic Society. San Diego, May 15-20; Am J Respir Crit Care Med 2009;179: A2868.
85. Margaritopoulos G, **Antoniou K**, Proklou A, Soufla G, Lymbouridou R, Economidou F, Siafakas NM. Angiogenetic balance in Fibrotic Interstitial Pneumonia versus collagen vascular diseases-associated pneumonias. International conference of American Thoracic Society. San Diego, May 15-20; Am J Respir Crit Care Med 2009;179: A2869.
86. Economidou F, **Antoniou K**, Proklou A, Lasithiotaki I, Kragiannis K, Lymbouridou R, Soufla G, Siafakas NM. Investigation of Angiogenetic mechanisms in pleural fluid of patients with lung cancer: preliminary results.

International conference of American Thoracic Society. San Diego, May 15-20; Am J Respir Crit Care Med 2009;179: A2876.

87. **Antoniou K**, Soufla G, Economidou F, Proklou A, Lymbouridou R, Papadaki H, Siafakas N. Increased CXCR4 expression and short telomeres in bone marrow mesenchymal stem cells of patients with idiopathic pulmonary fibrosis. ERS Annual Congress, Viena, September 12-16; Eur Respir J 2009; 34: Suppl. 53, 223
88. Lasithiotaki I, **Antoniou K**, Lymbouridou R, Karagiannis K, Spandidos D, Siafakas N, Sourvinos G. Detection of herpes simplex virus type-1 (HSV-1) in lung tissue and bronchoalveolar lavage fluid (BALF) of patients with fibrotic idiopathic interstitial pneumonias (f-IIPs). ERS Annual Congress, Viena, September 12-16; Eur Respir J 2009; 34: Suppl. 53, 234
89. Proklou A, **Antoniou K**, Gvazava G, Soufla G, K. Christina, Lymbouridou R, Karagiannis K, Lasithiotaki I, Siafakas N. Phenotypical and molecular characteristics of bone marrow mesenchymal stem cells in rheumatoid lung. ERS Annual Congress, Viena, September 12-16; Eur Respir J 2009; 34: Suppl. 53, 235
90. Karagiannis K, **Antoniou K**, Margaritopoulos G, Proklou A, Lasithiotaki I, Lymbouridou R, Koutala H, Moraitaki D, Siafakas N. Toll-like receptor 4 is overexpressed in bronchoalveolar lavage fluid of patients with fibrotic idiopathic interstitial pneumonias (F-IIPs): preliminary results; ERS Annual Congress, Viena, September 12-16; Eur Respir J 2009; 34: Suppl. 53, 238
91. **Antoniou K**, Margaritopoulos G, Desai SR, Hansell D, Rubens M, Tennant RC, Hansel TT, Siafakas N, DuBois R, Wells A. Pulmonary fibrosis is associated with emphysema in systemic sclerosis: indirect support for a smoking pathogenesis hypothesis. ERS Annual Congress, Viena, September 12-16; Eur Respir J 2009; 34: Suppl. 53, 2821
92. **Antoniou K**, Proklou A, Lymbouridou R, Soufla G, Lasithiotaki I, Karagiannis K, Spandidos DA, Siafakas NM. Differential expression of SDF-CXCR4 biological axis in bone marrow mesenchymal stem cells in Rheumatoid Arthritis associated lung fibrosis. 14th World Congress on Advances in Oncology and 12th International Symposium on Molecular Medicine; Int J Mol Med. 2009; Vol.24,S74.
93. Lasithiotaki I, **Antoniou K**, Lymbouridou R, Symvoulakis EK, Lagoudaki E, Spandidos DA, Siafakas NM, Sourvinos G. Investigation of Herpes Simplex Virus type 1 (HSV-1), Human Herpesvirus 6 HHV-6) and Cytomegalovirus in lung tissue biopsy and bronchoalveolar lavage fluid (BALF) of patients with Fibrotic Idiopathic Interstitial Pneumonias (f- IIPs). 14th World Congress on Advances in Oncology and 12th International Symposium on Molecular Medicine; Int J Mol Med. 2009; Vol.24,S74.
94. Karagiannis K, **Antoniou K**, Lymbouridou R, Kalpadaki C, Vassalou E, Lasithiotaki I, Proklou A, Siafakas N, Tzanakis N. Does cigarette smoking influence boe marrow microenvironment? Down-regulation of CXCR4 expression in bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with chronic obstructive pulmonary disease (COPD): preliminary results. 8th ERS Lung Science Conference. Estoril, Portugal, March 26-28, 2010; Final Programme p153.

95. Karagiannis K, **Antoniou KM**, Lymbouridou R, Proklou A, Kalpadaki C, Vassalou E, Lasithiotaki I, Siafakas N, Tzanakis N. Down-regulation of CXCR4 expression in Bone marrow-derived Mesenchymal stem cells (BM-MSCs) in patients with Chronic Obstructive Pulmonary Disease (COPD): preliminary results. American Thoracic Society Congress, New Orleans, May 14-19, 2010; Publication Page: A3821
96. Margaritopoulos G, Karagiannis K, Lymbouridou R, Vassalou E, Sifaki L, Tzanakis N, Siafakas N, **Antoniou KM**. Up-regulation of telomerase activity in Collagen Vascular Diseases associated with Pulmonary Fibrosis: a bronchoalveolar lavage study. American Thoracic Society Congress, New Orleans, May 14-19, 2010; Publication Page: A2357
97. Daniil Z, Malli F, Dimadi M, **Antoniou K**, Tzouvelekis A, Drakopanagiotakis F, Kokkinis F, Maragritopoulos G, Manika K, Bouros D, Papakosta D. Combined pulmonary fibrosis and emphysema: A report from the Hellenic Interstitial Lung Diseases group. 20th European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22; Eur Respir J 2010; 36: Suppl. 54, 785
98. Margaritopoulos G, Vassalou E, Karagiannis K, Lymbouridou R, Lasithiotaki I, Lambiri I, Siafakas N, **Antoniou K**. Differential expression of telomerase activity in patients with autoimmune pulmonary fibrosis in BALF. 20th European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22; Eur Respir J 2010; 36: Suppl. 54, 819
99. Samara KD, Vassalou E, Karagiannis K, Siafakas NM, **Antoniou K**. Impaired expression of telomerase activity in bronchoalveolar lavage fluid cells in patients with lung cancer: Preliminary results. 20th European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22; Eur Respir J 2010; 36: Suppl. 54, 3243
100. Margaritopoulos G, **Antoniou K**, Karagiannis K, Vassalou E, Lasithiotaki I, Lymbouridou R, Siafakas N. Investigation of angiogenetic axis angiopoietins 1 and 2/Tie-2 in fibrotic lung diseases. Eur Respir J 2010; 36: Suppl. 54, 4169
101. **Antoniou K**, Proklou A, Kastrinaki M, Samara KD, Papadaki H, Siafakas NM. Increased TERT mRNA expression of Bone Marrow Mesenchymal Stem Cells (BM-MSCs) in Idiopathic Pulmonary Fibrosis (IPF). 20th European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22; Eur Respir J 2010; 36: Suppl. 54, 4177
102. Karagiannis K, **Antoniou KM**, Kalpadaki C, Vassalou E, Samara KD, Siafakas NM, Tzanakis N. Increased expression of TERT mRNA expression in Bone marrow-derived Mesenchymal stem cells (BM-MSCs) in patients with Chronic Obstructive Pulmonary Disease (COPD): preliminary results. 20th European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22; Eur Respir J 2010; 36: Suppl. 54, 4333
103. Karagiannis K, **Antoniou K**, Lymbouridou R, Kalpadaki C, Vassalou E, Lasithiotaki I, Proklou A, Siafakas N, Tzanakis N. LSC 2010 Abstract: Does cigarette smoking influence bone marrow microenvironment?

Down-regulation of CXCR4 expression in bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with chronic obstructive pulmonary disease (COPD): preliminary results. Eur Respir J 2010; 36: Suppl. 54, 4334

104. Samara KD, **Antoniou K**, Vassalou E, Karagiannis K, Lymbouridou R, Siafakas NM. Endosomal Toll-like receptors (TLR3 and 9) are overexpressed in bronchoalveolar lavage fluid of patients with lung cancer: Preliminary results. 20th European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22; Eur Respir J 2010; 36: Suppl. 54, 5676
105. Samara K, **Antoniou K**, Margaritopoulos G, Soufla G, Giannarakis I, Augousti M, Siafakas N. Telomerase activity profiles in Lung Cancer and Idiopathic Pulmonary Fibrosis. 9th ERS Lung Science Conference on "Immune System Dysregulation in Chronic Lung Disease". European Respiratory Society, Estoril, Portugal, April 1-3, 2011.
106. **Antoniou KM**, Samara KD, Lasithiotaki I, Pantelidis P, Siafakas N, Wells AU. Investigation of the citrullination pathway in the pathogenesis of Fibrotic Lung Disorders: preliminary results. ATS International Conference, Denver, Colorado, USA, May 13-18; Am J Respir Crit Care Med, 2011; Abstracts Issue, Vol.183,
107. Margaritopoulos G, **Antoniou KM**, Goh N, Desai S, Hansell DM, Maher T, Renzoni E, Siafakas N, Wells A. Is smoking implicated in the pathogenesis of lung involvement in systemic sclerosis? Am J Respir Crit Care Med, 2011;183:A3032
108. Proklou A, Karagiannis K, Giannarakis I, Kalpadaki C, Lymbouridou R, Siafakas N, **Antoniou KM**. Toll-like receptors expression in human bone marrow mesenchymal stem cells (bm-Mscs) of patients with pulmonary fibrosis. Am J Respir Crit Care Med, 2011;183:A513.
109. Karagiannis K, **Antoniou KM**, Proklou A, Giannarakis I, Vassalou E, Tzanakis N, Siafakas N. Down-regulation of toll-like receptors expression in human bone marrow mesenchymal stem cells (bm-Mscs) of COPD patients. Am J Respir Crit Care Med, 2011;183:A3512.
110. Lasithiotaki I, **Antoniou KM**, Karagiannis K, Lymbouridou R, Spandidos D, Siafakas N, Sourvinos G. Detection of herpes simplex virus type-1 (hsv-1) in lung tissue biopsy and bronchoalveolar lavage fluid (balf) of patients with fibrotic idiopathic interstitial pneumonias (f-Lips). Am J Respir Crit Care Med, 2011;183:A3554
111. Samara KD, Vassalou E, Giannarakis I, Lasithiotaki I, Tzanakis N, Siafakas NM, **Antoniou KM**. Effect of Bosentan on MMP-7 levels as add-on therapy in Idiopathic Pulmonary Fibrosis. A prospective study. 21th European Respiratory Society Annual Congress, Amsterdam, Netherlands, September 24-28; Eur Respir J 2011; 38: Suppl. 55, 663
112. Samara KD, Giannarakis I, Lasithiotaki I, Lambiri I, Siafakas N, **Antoniou K**. Overexpression of Matrix Metalloproteinase-7 (MMP-7) in bronchoalveolar lavage fluid (BALF) of IPF and Lung Cancer patients. 21th

- European Respiratory Society Annual Congress, Amsterdam, Netherlands, September 24-28; Eur Respir J 2011; 38: Suppl. 55, 4761
113. Samara KD, Giannarakis I, Lasithiotaki I, Margaritopoulos G, Choulaki C, Sidiropoulos P, Siafakas NM, **Antoniou KM**. NLRP3- Inflammasome Pathway Activation in Fibrotic Lung Diseases in Human Bronchoalveolar Lavage Fluid (BALF). 10th ERS Lung Science Conference, Estoril, Portugal March 30 – April 01, 2012.
 114. Samara KD, Karagiannis K, Lasithiotaki I, Lambiri I, Siafakas NM, **Antoniou KM**. Overexpression Of Matrix Metalloproteinases In Bronchoalveolar Lavage Fluid (BALF) And Lung Tissue Of Non-Small Cell Lung Cancer (NSCLC) Patients: Comparison With Idiopathic Pulmonary Fibrosis (IPF). ATS International Conference, San Fransisco California, USA, May 18-23 Am J Respir Crit Med 2012; Vol. 185, Abstracts Issue
 115. Giannarakis I, Lasithiotaki I, Samara KD, Margaritopoulos G, Choulaki C, Sidiropoulos P, Siafakas NM, **Antoniou KM**. Inflammasome Pathway Activation in Fibrotic Lung Diseases In Human Bronchoalveolar Lavage Fluid (BALF). ATS International Conference, San Fransisco California, USA, May 18-23 Am J Respir Crit Med 2012; Vol. 185, Abstracts Issue
 116. Karatzanis A, Samara K, Kaprana A, **Antoniou K**, Chatzakis N, Velegarakis G, Siafakas N. Investigating the role of angiogenetic factors in nasal polyposis. 24th Congress of the European Rhinologic Society; 31st International Symposium of Infection and Allergy of the Nose, Toulouse, France, June 17-21, 2012.
 117. Bardaka F, Daniil Z, **Antoniou KM**, Mamara A, Malli F, Gourgoulialis KI, Germeis AE, Speletas M. Association study of ANXA11-R230C with sarcoidosis. Eur Respir J 2012; 40: Suppl. 56, 170
 118. Samara KD, Lasithiotaki I, Soufla G, Giannarakis I, Velivassaki M, Psaraki A, Siafakas NM, **Antoniou KM**. Telomerase expression in Idiopathic Pulmonary Fibrosis (IPF) and Non Small Cell Lung Cancer (NSCLC). 22th European Respiratory Society Annual Congress, Vienna, Austria, September 1-5; Eur Respir J 2012; 40: Suppl. 56, 702
 119. Mermigkis C, Bouloukaki I, **Antoniou K**, Giannarakis G, Mermigkis D, Siafakas N, Schiza S. CPAP therapy in idiopathic pulmonary fibrosis (IPF) patients with obstructive sleep apnea (OSA). 22th European Respiratory Society Annual Congress, Vienna, Austria, September 1-5; Eur Respir J 2012; 40: Suppl. 56, 884.
 120. Mermigkis C, Bouloukaki I, **Antoniou K**, Giannarakis G, Mauroudi H, Moniaki V, Siafakas N, Schiza S. Correlation of pulmonary function and sleep disordered breathing parameters in patients with idiopathic pulmonary fibrosis. 22th European Respiratory Society Annual Congress, Vienna, Austria, September 1-5; Eur Respir J 2012; 40: Suppl. 56, 894.
 121. **Antoniou KM**, Lasithiotaki I., Derdas SP, Sarchianaki E, Psaraki A, Spandidos DA, Stathopoulos EN, Siafakas NM, Sourvinos G. Increased incidence of Merkel cell polyoma virus in non-small-cell lung cancer.

- European Respiratory Society Annual Congress, Vienna, Austria, September 1-5; Eur Respir J 2012; 40: Suppl. 56, 1227
122. **Antoniou K**, Samara KD, Lasithiotaki I, Pantelidis P, Siafakas NM, Wells AU. Investigation of the Citrullination pathway in the pathogenesis of Fibrotic Lung Disorders. 22th European Respiratory Society Annual Congress, Vienna, Austria, September 1-5; Eur Respir J 2012; 40: Suppl. 56, 1764
 123. Samara K, Lasithiotaki I, Pantelidis P, Siafakas N, Wells A, **Antoniou K**. Investigation of the Citrullination Pathway in the Pathogenesis of Fibrotic Lung Disorders. 17th International Colloquium on Lung and Airways Fibrosis, Modena, Italy, September 29 - October 3, 2012.
 124. **Antoniou KM**, Lasithiotaki I, Derdas SP, Sarchianaki E, Psaraki A, Spandidos DA, Stathopoulos EN, Siafakas NM, Sourvinos G. The role of polyoma virus in lung cancer: A possible etiopathogenetic link? 17th World Congress on Advances in Oncology and 15th International Symposium on Molecular Medicine, Hersonissos, Crete, Greece, October 11-13, 2012.
 125. Giannarakis I, Margaritopoulos GA, Lasithiotaki I, Psaraki A, Samara KD, Papadogiannis G, Sidiropoulos P, Siafakas NM, **Antoniou KM**. Inflammasome Pathway Activation In Fibrotic Lung Diseases In Human Bronchoalveolar Lavage Fluid. ATS Annual International Congress; Am J Respir Crit Med 2013, Suppl.187.
 126. Margaritopoulos GA, Lasithiotaki I, Proklou A, Papadogiannis G, Chatziantoniou I, Siafakas NM, **Antoniou KM**. The stomal derived-1/CXCR4 axis regulates the migration of bone marrow mesenchymal stem cells in the rheumatoid lung. ATS Annual International Congress; Am J Respir Crit Med 2013, Suppl.187.
 127. Karagiannis K, **Antoniou K**, Moraitaki D, Psaraki A, Soufla G, Kalpadaki C, Siafakas N, Tzanakis N. Impaired migration of bone marrow mesenchymal stem cells in COPD. ERS Annual Congress; Eur Respir J 2013; 42: Suppl. 57, 245.
 128. Tsitoura E, **Antoniou K**, Psaraki A, Lasithiotaki I, Spandidos D, Siafakas N, Sourvinos G. Regulation of microRNAs in response to herpes simplex virus type-1 (HSV-1) infection in idiopathic pulmonary fibrosis (IPF): Preliminary results. ERS Annual Congress; Eur Respir J 2013; 42: Suppl. 57, 3225.
 129. Samara K, **Antoniou K**, Giannarakis I, Lasithiotaki I, Psaraki A, Soufla G, Sidiropoulos P, Siafakas N. Inflammasome pathway activation in patients with non-small cell lung cancer (NSCLC): A bronchoalveolar lavage fluid study. ERS Annual Congress; Eur Respir J 2013; 42: Suppl. 57, 4516.
 130. **Antoniou K**, Margaritopoulos G, Hansell D, Desai S, Maher T, Renzoni E, Siafakas N, Wells A. Scleroderma lung disease: Detection of pulmonary hypertension using pulmonary function tests is problematic in patients with emphysema. ERS Annual Congress; Eur Respir J 2013; 42: Suppl. 57, 5115.
 131. **Antoniou K**, Hansell D, Goh N, Samara K, Renzoni E, Toby M, Siafakas N, Wells A. Scleroderma lung disease: A scleroderma physiologic index (SPI) derived from lung physiology and oxygen saturation. ERS Annual Congress; Eur Respir J 2013; 42: Suppl. 57, 5119.

132. Tsitoura E, **Antoniou KM**, Psaraki A, Lasithiotaki I, Spandidos DA, Siafakas NM, Sourvinos G: Expression of microRNAs involved in fibrosis in response to Herpes Simplex Virus type-1 (HSV-1) infection in Idiopathic Pulmonary Fibrosis; *Int J Mol Med*. 2013, 32:S70-S70.
133. Tsitoura E, Kokkinaki C, Spandidos DA, **Antoniou KM**, Sourvinos G: HSV-1 controls cellular microRNAs involved in innate immune responses; *Int J Mol Med*. 2013, 32:S70-S70.
134. **Antoniou KM**; Tsitoura E, Sarantoulaki S, Giannarakis I, Psaraki A, Karagiannis K, Sato H, Wells AU, Sourvinos G, Siafakas NM. Regulation of micrnas involved in Idiopathic Pulmonary Fibrosis (IPF) and the role of herpes simplex virus Type-1 (HSV-1) infection in micrna expression in Bronchoalveolar Lavage Fluid (BALF) cells. ATS Annual International Congress; *Am J Respir Crit Care Med*, 2014; Suppl.189.
135. Cottin V, Hansell D, **Antoniou KM**, Nair A, Atwood M, Bradford WZ, Oster G, Kirchgaessler K, Weber F, Weycker D, Collard HR, Wells AU. The Influence of concurrent emphysema on pulmonary function decline in Idiopathic Pulmonary Fibrosis. ATS Annual International Congress; *Am J Respir Crit Care Med*, 2014; Suppl.189.
136. Karagiannis K, Sato H, Stock C, Handa T, **Antoniou KM**, Maher T M, Wells A U, Lindahl G, Renzoni E. Activin A and Follistatin Like-3 levels in Bronchoalveolar Lavage Fluid of patients with systemic sclerosis related Interstitial Lung Disease. ATS Annual International Congress; *Am J Respir Crit Care Med*, 2014; Suppl.189.
137. Cottin V, Hansen D, **Antoniou K**, Nair A, Atwood M, Sverzellati N, Oster G, Weycker D, Collard HR., Wells A. The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPP)/ combined pulmonary fibrosis and emphysema (CPFE). ERS Annual Congress; *Eur Respir J* 2014; 44: Suppl. 58, 747.
138. Sarantoulaki S, Margaritopoulos G, Tsitoura E, Karagiannis K, Bibaki E, Wells A, Siafakas N, Sourvinos G, **Antoniou K**. Autophagy is not impaired in BALF alveolar macrophages in IPF: Preliminary results. ERS Annual Congress; *Eur Respir J* 2014; 44: Suppl. 58, 779
139. Chatziantoniou A, Apostolou E, Soultzis N, Neofytou E, Synolaki E, **Antoniou KM**, Tzanakis N, Sideras P, Siafakas NM. Activin-A expression in COPD exacerbations: Local index of airway inflammation? Preliminary results; ERS Annual Congress; *Eur Respir J* 2014; 44: Suppl. 58, 3957.
140. Bibaki E, Koutsopoulos A, Tsitoura E, Lagoudaki E, Sarantoulaki S, Lasithiotaki I, Siafakas N, Sourvinos G, **Antoniou K**. Retinoic acid-related orphan receptor-a (Rora) expression in patients with fibrotic interstitial pneumonias: A lung tissue study; ERS Annual Congress; *Eur Respir J* 2014; 44: Suppl. 58, 4631
141. Lasithiotaki I, **Antoniou KM**, Tsitoura E, Koutsopoulos A, Lagoudaki E, Spandidos DA, Siafakas NM, Sourvinos G: MicroRNA-21 is significantly overexpressed in Merkel cell polyomavirus-positive non-small cell lung cancer. *Int J Mol Med*. 2014; 34:S92-S92.

142. Tsitoura E, Wells AU, Karagiannis K, Lasithiotaki I, Sarantoulaki S, Sato H, Spandidos DA, Siafakas NM, Sourvinos G, **Antoniou KM**: Decreased MicroRNA29a expression in Idiopathic Pulmonary Fibrosis (IPF) is associated with Collagen type, 1a1 expression and eosinophilia in Bronchoalveolar Lavage Fluid (BALF). *Int J Mol Med*. 2014; 34:S105-S105.
143. Tsitoura E, Koutsopoulos A, Lagoudaki E, Charalambous E, Sourvinos G, Siafakas N, **Antoniou KM**. Retinoic Acid-Related Orphan Receptor-alpha (ror alpha) Expression And Subcellular Localization In Lung Fibroblasts And Pneumocytes Is Associated With Fibroblast Activation And Fibrosis In Fibrotic Lung Tissue Specimens. *ATS Annual International Congress; Am J Respir Crit Med*. 2015; Suppl.191.
144. Samara KD, Lasithiotaki I, Tsitoura E, Giannarakis I, Psaraki A, Bibaki E, Lambiri I, Siafakas N, **Antoniou KM**. Lung cancer immune cells exhibit inhibited inflammasome response *ERS Annual Congress; Eur Respir J* 2015; 46: Suppl. 59, 530.
145. Lasithiotaki I, Tsitoura E, Koutsopoulos A, Lagoudaki E, Spandidos D, Siafakas N, Sourvinos G, **Antoniou K**. Overexpression of miR-21 in non-small cell lung cancer, positive for Merkel cell polyoma virus (MCPyV) *ERS Annual Congress; Eur Respir J* 2015; 46: Suppl. 59, 2929
146. Bibaki E, Tsitoura E, Koutoulaki C, Vasarmidi E, Stamataki E, Moraitaki D, Tzanakis N, **Antoniou K**. Expression of miR-185 targets DNA methyltransferase 1 and Cyclin D2 in IPF and lung cancer in BALF cells: Preliminary results. *ERS Annual Congress; Eur Respir J* 2015; 46: Suppl. 59, 3039
147. Vasarmidi E, Tsitoura E, Sarantoulaki S, Koutoulaki C, Charalambous I, Margaritopoulos G, Siafakas N, **Antoniou K**. Investigation of mitochondria homeostasis and mitophagy in bronchoalveolar lavage fluid (BALF) cells in pulmonary fibrosis. *ERS Annual Congress; Eur Respir J* 2015; 46: Suppl. 59, 3513.
148. Cottin V, Hansell DM, Sverzellati N, Weycker D, **Antoniou KM**, Atwood M, Oster G, Weber F, Kirchgaessler KU, Collard H-R, Wells AU. Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome. *ERS Annual Congress; Eur Respir J* 2015; 46: Suppl. 59, 4488.
149. Lasithiotaki I, **Antoniou KM**, Tsitoura E, Spandidos DA, Siafakas NM, Sourvinos G: Possible pathogenetic effect of microRNA expression profiles in Merkel cell polyomavirus-positive non-small cell lung cancer; *Int J Mol Med*. 2015; 36:S93-S93.
150. Tsitoura E, Binbaki E, Koutsopoulos A, Koutoulaki H, Lagoudaki E, Charalambous E, Siafakas N, Sourvinos G, **Antoniou KM**: Retinoic acid-related orphan receptor alpha (ROR alpha) expression in pulmonary fibrosis; *Int J Mol Med*. 2015; 36:S103-S103.
151. Vasarmidi E, Tsitoura E, Margaritopoulos G, Koutoulaki C, Michelakis S, Charalambous I, Tzanakis N, Georgopoulos D, **Antoniou K**. IPF Balf Cells Show Reduced Expression Of Pink1 Coupled To Elevated Oxidized Mitochondria Levels. *ATS Annual International Congress; Am J Respir Crit Med* 2016; Suppl.193

152. Proklu A, Pitsidianakis G, Tsitoura E, Koutoulaki C, Hatziantoniou A, Moraitaki D, Georgopoulos D, **Antoniou K**, Tzanakis N. Triggering receptor expressed on myeloid cells (TREM1): A novel biomarker in the investigation of non-CF bronchiectasis? Preliminary results. ERS Annual Congress; Eur Respir J 2016; 48: Suppl. 60, 910.
153. Tsitoura E, Wells AU, Koutoulaki C, Karagiannis K, Lasithiotaki I, Vasarmidi E, Sato H, Spandidos DA, Siafakas NM, Sourvinos G, **Antoniou K**. MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF alveolar macrophages. ERS Annual Congress; Eur Respir J 2016; 48: Suppl. 60, 2094
154. Michelakis S, Tsitoura E, Bouloukaki I, Moniaki V, Malliaraki N, Papadogiannis G, Varda S, Georgopoulos D, Tzanakis N, Schiza SE, **Antoniou K**. Investigation of KL-6 levels in patients with IPF- OSA overlap syndrome: Preliminary results. ERS Annual Congress; Eur Respir J 2016; 48: Suppl. 60, 3901
155. Cottin V, Hansell DM, Sverzellati N, Weycker D, **Antoniou KM**, Atwood M, Oster G, Kirchgaessler K-U, Wells AU. Analyses of the relationship between Δ FVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF). ERS Annual Congress; Eur Respir J 2016; 48: Suppl. 60, 4568
156. Karagiannis K, Trachalaki A, Bibaki E, Vasarmidi E, Papastratigakis G, Michelakis S, Stamataki E, Moraitaki D, Tzanakis N, **Antoniou K**. Late Breaking Abstract - Six years experience of Pirfenidone treatment in IPF patients in Crete: Real life data. ERS Annual Congress; 2017; OA3397 Session Idiopathic pulmonary fibrosis (IPF): treatment highlights.
157. Chatziantoniou A, Apostolou E, Tsitoura E, Synolaki E, Markaki L, Gialamas I, Ritvos O, Siafakas NM, **Antoniou KM**, Paschalis Sideras, Nikolaos Tzanakis, Athina Trachalaki. Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline.. ERS Annual Congress; 2017; PA997 Thematic Poster Infection and exacerbation science.
158. Bibaki E, Georgopoulou T, Koutoulaki C, Tsitoura E, Vasarmidi E, Tzanakis N, **Antoniou K**. The expression of miR185, miR29a and their targets in IPF and lung cancer (LC). A BALF study. ERS Annual Congress; 2017; OA480 Oral Presentation Interstitial lung diseases (ILDs): novel pathogenetic pathways.
159. Cottin V, Sverzellati N, Weycker D, **Antoniou KM**, Atwood M, Oster G, Kirchgaessler K-U, Wells AU. Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF). ERS Annual Congress; 2017; PA847 Thematic Poster ILDs: clinical aspects.
160. Tsitoura E, Bibaki E, MD, Koutsopoulos A, Lagoudaki E, Karagianni K, Vasarmidi E, Trachalaki A, Tzanakis N, Crestani B, **Antoniou K**. Upregulation of Retinoic Acid-Related Orphan Receptor-alpha (RORa) in IPF; a promising therapeutic target; WASOG, June 07-09, 2018; OP-06.
161. Trachalaki A, Tsitoura E, Vasarmidi E, Bibaki E, Papastratigakis G, Margaritopoulos G, Tzanakis N, **Antoniou K**. Development of assays for the evaluation of inflammasomes' activity in alveolar macrophages in fibrotic lung diseases; WASOG, June 07-09, 2018; OP-07.

162. Bibaki E, Tsitoura E, Vasarmidi E, Margaritopoulos G, Trachalaki A, Koutoulaki C, Georgopoulou T, Tzanakis N, **Antoniou K**. MiR-185/miR-29a similarly expressed in IPF and CA BALF-cells show disease specific DNMT1 and COL1A1 patterns; WASOG, June 07-09, 2018; OP-08.
163. Bolaki M, Fanaridis M, Ligerou D, Trachalaki A, Stylianou K, Lambiri E, Tzanakis N, **Antoniou K**. Cases of extrapulmonary sarcoidosis; WASOG, June 07-09, 2018; PP-23.
164. Trachalaki A, Margaritopoulos G, Michelakis S, Bibaki E, Vasarmidi E, Fanaridis M, Bouloukaki I, Schiza S, Tzanakis N, **Antoniou K**. Comorbidities in Idiopathic pulmonary fibrosis patients and their impact on survival: one-center (Heraklion, Crete) study; WASOG, June 07-09, 2018; PP-36.
165. Vasarmidi E, Tsitoura E, Koutoulaki C, Margaritopoulos G, Trachalaki A, Tzanakis N, **Antoniou K**. Alveolar macrophages show elevated oxidized mitochondria levels in IPF. Possible link with mitophagy and autophagy; WASOG, June 07-09, 2018; SOP-11.
166. Kokosi M, Kouranos V, Trachalaki A, Stock C, Donovan J, Tsitoura E, Renzoni E, Wells AU, **Antoniou K**. Serum KL-6 in Fibrosing Interstitial Lung Diseases ; WASOG, June 07-09, 2018; SOP-12.
167. Tzouvelekis A, Karampitsakos T, Gomatou G, Tzilas V, Bouros E, Chrysikos S, Markozannes E, Kolilekas L, Manali E, Tomos I, Korbila I, Tomos P, Loverdos K, Gaga A, **Antoniou K**, Trachalaki A, Daniil Z, Bardaka F, Markopoulou K, Papiris S, Tringidou R, Bouros D. Prevalence of cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study; ERS International Congress, Paris, France, September 15-19; European Respiratory Society, 2018; p PA2908.
168. Manali ED, Kannengiesser C, Kolilekas L, Korbila I, Papadaki G, Kallieri M, Giouleka P, Papaioannou AI, Tomos IP, Stagaki E, Papaportfyriou A, Karakatsani A, Loukides S, Kagouridis K, Tzilas V, Tzouvelekis A, Bouros E, **Antoniou K**, Trachalaki A, Markopoulou A, Daniil Z, Fouka E, Papakosta D, Xyfteri A, Gogali A, Konstantinidis A, Steiropoulos P, Papanikolaou IC, Bazaka C, Charitou A, Maniati M, Lyberopoulos P, Vlami K, Raptakis T, Revy P, Gaga M, Dieude P, Nathan N, Borie R, Boileau C, Bouros D, Crestani B, Papiris S. TERT/TERC Mutations in a Greek Cohort of Suspected Genetic Pulmonary Fibrosis Patients; In Idiopathic interstitial pneumonias, ERS International Congress, Paris, France, September 15-19; European Respiratory Society, 2018; p PA2939.
169. Kotsiou O, Daniil Z, Bouzetos E, Panagiotidou H, Fouka M, Malli F, Bardaka F, **Antoniou K**, Psara A-M, Mamuris Z, Gourgoulisanis K, Zifa E. Late Breaking Abstract - Reduced Activity of Energy-Transducing NADH-Quinone Oxidoreductase (Complex I) Indicates Mitochondrial Respiratory Chain Dysfunction in Patients with Sarcoidosis; In Sarcoidosis and other granulomatous ILD/DPLD, ERS International Congress, Paris, France, September 15-19; European Respiratory Society, 2018; p PA2997.
170. Tsitoura E, Bibaki E, Vasarmidi E, Koutoulaki C, Margaritopoulos G, Karagiannis K, Proklou A, Trachalaki A, Moraitaki D, Tzanakis N, Wells A, **Antoniou K**. LSC - 2018 - AKT1/AKT2 MRNA Balance Is Significantly

- Different In IPF BAL Cells Compared To Other Fibrotic ILDs; In Idiopathic interstitial pneumonias, ERS International Congress, Paris, France, September 15-19; European Respiratory Society, 2018; 3705.
171. Tsitoura E, Bibaki E, Koutsopoulos A, Lagoudaki E, Karagianni K, Tzanakis N, Crestani B, **Antoniou K**. Upregulation of Retinoic Acid-Related Orphan Receptor-alpha (RORa) in IPF; a promising therapeutic target; ERS International Congress, Paris, France, September 15-19; European Respiratory Society, 2018; p PA3713.
 172. Tsitoura E, Bibaki E, Vasarmidi E, Trachalaki A, Koutoulaki C, Margaritopoulos GA, Karagiannis K, Proklou A, Moraitaki D, Tzanakis N, Wells AU, **Antoniou KM**. Let7c and AKT1/AKT2 mRNA Balance Is Different In IPF BAL Cells Compared to Other Fibrotic ILDs, In Idiopathic interstitial pneumonias; ERS International Congress, Paris, France, September 15-19; European Respiratory Society, 2018; p PA3719.
 173. **Antoniou K**, Trachalaki A., Vasarmidi E., Margaritopoulos G., Papastratigakis G., Bibaki E., Stamataki E., Meletis G., Tzanakis N. Long-Term (4 Years) Experience of Nintedanib in IPF Patients in Crete: A Real Life Data Study. In Idiopathic interstitial pneumonias; ERS International Congress, Paris, France, September 15-19; European Respiratory Society, 2018; p PA4787.
 174. Trachalaki A, Tsitoura E, Vasarmidi E, Bibaki E, Papastratigakis G, Margaritopoulos G, Tzanakis N, **Antoniou K**. Development of assays to evaluate inflammasomes' activity in the peripheral blood and in alveolar macrophages in fibrotic lung diseases; ERS International Congress, Paris, France, September 15-19; European Respiratory Society, 2018; 4813.
 175. Kotsiou O, Daniil Z, Bouzetos E, Panagiotidou H, Fouka M, Malli F, Bardaka F, **Antoniou K**, Psara A-M, Mamuris Z, Gourgoulisanis K, Zifa E. Late Breaking Abstract - Reduced activity of energy-transducing NADH-quinone oxidoreductase (complex I) indicates mitochondrial respiratory chain dysfunction in patients with sarcoidosis; ERS International Congress, Paris, France, September 15-19; European Respiratory Society, 2018; 2997.
 176. Trachalaki A. Inflammasomes' activation in alveolar macrophages and peripheral blood mononuclear cells in fibrotic Interstitial Lung Diseases; 17th ERS Lung Science Conference, Estoril, Portugal, March 7-10, 2019; PP127.
 177. Tsitoura E. Let7c is reduced in IPF BAL cells relative to other f-ILDs and is associated with disease progression and survival in fibrotic lung diseases; 17th ERS Lung Science Conference, Estoril, Portugal, March 7-10, 2019; OP08.
 178. Behr J, Nathan SD, Harari S, Wuyts W, Mogulkoc Bishop N, Bouros DE, **Antoniou K**, Guiot J, Kramer M, Kirchgaessler K, Bengus M, Gilberg F, Wells AU. Baseline Characteristics of All Patients Randomized in a Phase IIb Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension; ATS International Conference, May 17-22, 2019; A4092 / 114

179. **Antoniou K**, Trachalaki A, Chrysovalantis S, Vasarmidi E, Bardaka F, Bibaki E, Fouka E, Meletis G, Trifon S, Daniil Z, Papakosta D. A Multicenter Study for the Evaluation of Effectiveness and Safety of Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis; ATS International Conference, May 17-22, 2019; A4773 / P1100
180. Tzouvelekis A, **Antoniou K**, Kreuter M, Evison M, Blum T, Poletti V, Spagnolo P, Bonella F, Girgoriu B, Vancheri C, Cadranet J, Bouros D. Late Breaking Abstract - The DIAMORFOSIS (DIagnosis and Management Of lung cancer and FibrOSIS) survey. ERS International Congress, Madrid, Spain, Sept 28 - Oct 02, 2019; 249
181. Vasarmidi E, Bibaki E, Koutoulaki C, Mastrodimitou S, Trachalaki A, Tzanakis N, Tsitoura E, **Antoniou K**. Evaluation of CD163 Expression on Alveolar Macrophages from BAL of Patients with Fibrotic Lung Diseases. ERS International Congress, Madrid, Spain, Sept 28 - Oct 02, 2019; p PA4694.
182. Bibaki E, Vasarmidi E, Koutoulaki C, Mastrodimitou S, Trachalaki A, Tzanakis N, Tsitoura E, **Antoniou K**. CD163 Positive Alveolar Macrophages from Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis and Lung Cancer. In Idiopathic interstitial pneumonias; European Respiratory Society, 2019; p PA1306
183. Karampitsakos T, Gomatou G, Tzilas V, Bouros E, Markozannes E, Manali E, Tomos I, **Antoniou K**, Trachalaki A, Kolilekas L, Korbila I, Tomos P, Chrysikos S, Dimakou K, Loverdos K, Gaga A, Daniil Z, Bardaka F, Papanikolaou I, Papakosta D, Markopoulou K, Tringidou R, Papiris S, Bouros D, Tzouvelekis A. Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis. A Retrospective Multicenter Study; ERS International Congress, Madrid, Spain, Sept 28 - Oct 02, 2019; p PA1311.
184. Kotsiou O, Malli F, Tsanakas P, Maglogiannis I, **Antoniou K**, Papakosta D, Vasarmidi E, Efthymiou CN, Gourgoulidis KI, Daniil Z. A Telemonitoring Homecare Platform for patients with Pulmonary Fibrosis; ERS International Congress, Madrid, Spain, Sept 28 - Oct 02, 2019; 1720.
185. Margaritopoulos G, Prokhou A, Badenes Bonet D, F. Chua F, George P, Kokosi M, Kouranos V, Renzoni E, **Antoniou K**, Wells A. Nocturnal desaturation predicts mortality in immune-mediated ILDs; ERS International Congress, Madrid, Spain, Sept 28 - Oct 02, 2019; 5196
186. Trachalaki A, E. Tsitoura E, Vasarmidi E, Bibaki E, Tzanakis N, **Antoniou K**. LSC - 2019 - Inflammasomes' activation in alveolar macrophages and peripheral blood mononuclear cells in fibrotic Interstitial Lung Diseases; ERS International Congress, Madrid, Spain, Sept 28 - Oct 02, 2019; 5369
187. Tsitoura E, Trachalaki A, Mastrodimitou S, Vasarmidi E, Bibaki E, Tzanakis N, **Antoniou K**. Increased NLRP3 and AIM2 Activation in IPF Alveolar Macrophages Is Associated with mtROS; ATS Virtual, August 05-10, 2020; P182.
188. **Antoniou K**, Tsitoura E, Trachalaki A, Vasarmidi E, Margaritopoulos G, Boboki A, Bibaki E, Stamataki E, Meletis G, Tzanakis N. Long-Term (7 Years) Experience of Nintedanib in IPF Patients in Crete: A Real Life Data Study; ATS Virtual, August 05-10, 2020; P626

189. Tzouvelekis AE, **Antoniou K**, Kreuter M, Evison M, Karampitsakos T, Blum T, Poletti V, Spagnolo P, Bonella F, Grigoriu BD, Vancheri C, Cadranel J, Bouros D. The DIAMORFOSIS (Diagnosis and Management of Lung Cancer and Fibrosis) Survey; ATS Virtual, August 05-10, 2020; 723
190. Behr J, Nathan SD, Wuyts WA, Bishop N, Bouros DE, **Antoniou K**, Guiot J, Kramer MR, Kirchgaessler K, Bengus M, Gilbert F, Perjesi A, Harari S, Wells AU. Efficacy and Safety of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH) ; ATS Virtual, August 05-10, 2020;
191. Mpolaki M, Bakiri K, Vasarmidi E, Trachalaki A, Lambiri E, Tzanakis N, **Antoniou K**. Pleural Effusion as a Sole Manifestation of Nocardiosis in an Immunocompetent Patient; ATS Virtual, August 05-10, 2020; P820.
192. Kokosi M, Trachalaki A, Stock C, Donovan J, Tsitoura E, Kouranos V, George PM, Molyneaux PL, Chua F, Maher TM, Renzoni EA, Tzanakis N, Wells AU, **Antoniou K**. Serum KL-6 Identifies ILD Patients with a Progressive Fibrosing Phenotype; ERS Virtual Congress, September 06 -09, 2020; p 445.
193. Manali ED, Kannengiesser C, Borie R, Ba I, Bouros D, Tzilas V, Tzouvelekis A, Bouros E, Markopoulou A, **Antoniou K**, Trachalaki A, Kolilekas L, Daniil Z, Fouka E, Papakosta D, Xyfteri A, Korbila I, Papaioannou AI, Tomos IP, Karakatsani A, Loukides S, Kagouridis K, Gogali A, Konstantinidis A, Steiropoulos P, Papanikolaou IC, Bazaka C, Haritou A, Maniati M, Vassilakopoulos T, Markozannes E, Lyberopoulos P, Malamadakis N, Spyropoulou S, Revy P, Lainey E, Dieudé P, Nathan N, Legendre M, Rebah K, Ménard C, Oudin C, Boileau C, Crestani B, Papiris S. Telomere-Related Gene Mutations in a Greek Cohort of Suspected Monogenic Pulmonary Fibrosis Patients; ERS Virtual Congress, September 06 -09, 2020; p 446.
194. Vasarmidi E, Tsitoura E, Mastrodemou S, Trachalaki A, Tzanakis N, **Antoniou K**. Levels of oxidised mitochondria in BAL macrophages in fibrotic ILDs; ERS Virtual Congress, September 06 -09, 2020; 603
195. Karampitsakos T, Torrisi S, **Antoniou K**, Bouros E, Korbila I, Manali E, Vasarmidi E, Papakosta D, Domvri K, Daniil Z, Dimeas I, Kirgou P, Papanikolaou I, Bibaki E, Markopoulou K, Kounti G, Tsapakidou E, Papadopoulou E, Papiris S, Bouros D, Kreuter M, Tzouvelekis A. Increased Monocyte Count and Red Cell Distribution Width Represent Negative Prognostic Markers in Patients with Idiopathic Pulmonary Fibrosis; ERS Virtual Congress, September 06 -09, 2020; p 720.
196. Trachalaki A, Tsitoura E, Invernizzi R, Mastrodimou S, Vasarmidi E, Byrne A, Maher TM, **Antoniou K**, Molyneaux PL. Inflammasome Activation in Airway Macrophages and the Lung Microbiome in IPF; ERS Virtual Congress, September 06 -09, 2020; p 725.
197. Tsitoura E, Trachalaki A, Vasarmidi E, Mastrodimou S, Kokosi M, Karagiannis K, Margaritopoulos G, Tzanakis N, Wells AU, **Antoniou KM**. Collagen1a1 mRNA Expression in BAL Cells Is Associated with Disease Progression and Poor Survival in ILDs; ERS Virtual Congress, September 06 -09, 2020; p 726.

198. Tzilas V, Tzouvelekis A, Bouros E, Karampitsakos T, Ntassiou M, Avdoula E, Trachalaki A, **Antoniou K**, Bouros D. Efficacy of Antifibrotics in Chronic Hypersensitivity Pneumonitis. A 3 Year Real-Life Observational Study.; ERS Virtual Congress, September 06 -09, 2020; p 737.
199. **Antoniou K**, Bolaki M, Karagiannis K, Ierodiakonou D, Stamatopoulou V, Trachalaki A, Chatzinikolaou C, Vakouti E, Vlachaki E, Solakis T, Markatos M, Vittorakis S, Kostaki A, Varoucha M, Stamataki E, Pitsidianakis G, Lambiri I, Mitrouska I, Tzanakis N. The Cretan Registry of the use of Biologics in Severe Asthma (CREBS) of the University Hospital of Heraklion, Greece; ERS Virtual Congress, September 06 -09, 2020; 2238
200. **Antoniou K**, Karagiannis K, Bolaki M, Ierodiakonou D, Trachalaki A, Stamatopoulou V, Chatzinikolaou C, Vakouti E, Vlachaki E, Kostaki A, Varoucha M, Solakis T, Markatos M, Vittorakis S, Stamataki E, Pitsidianakis G, Lambiri I, Mitrouska I, Tzanakis N. Cretan Severe Asthma Registry; ERS Virtual Congress, September 06 -09, 2020; 2239
201. Fontanilles E, Vancheri C, Wijsenbeek M, **Antoniou K**, Rivera P, Bonella F, Renzoni E, Anne-Marie A.-M, Vicens-Zygmunt V, Suarez-Cuartin G, Dorca J, Palma J, Bachs A, Avilés V, Tebé C, Shull J, Molina Molina M. Monounsaturated Fatty Acid Diet Associates Less Gastrointestinal Adverse Events of Pirfenidone: Phase IV Clinical Trial. In Idiopathic interstitial pneumonias; ERS Virtual Congress, September 06 -09, 2020; p 3712.
202. Karampitsakos T, Mogulkoc N, Kreuter M, Wuyts WA, Tomassetti S, Bendstrup E, Molina-Molina M, Spagnolo P, Manali ED, Unat OS, Kahn N, Kolilekas L, Rosi E, Gori L, Ravaglia C, Daniil Z, Prior TS, Papanikolaou IC, Aso S, Tryfon S, Papakosta D, Balestro E, Papiris S, **Antoniou K**, Bouros D, Tzouvelekis A. Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe; ERS International Congress, Zurich, Switzerland, 05-08 September 2021 (webinar)

7.10 ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΕΛΛΗΝΙΚΑ ΠΕΡΙΟΔΙΚΑ ΚΑΙ ΚΕΦΑΛΑΙΑ ΣΕ ΒΙΒΛΙΑ

1. Δημάδη ΜΑ, Νικολόπουλος Π, **Αντωνίου Κ**. Αναπνευστική βρογχιολίτις με διάμεση πνευμονική νόσο. Πνεύμων 69-70
2. Μπούρος Δ, Πλατάκη Μ, **Αντωνίου Κ**. Θεραπεία των παραπνευμονικών συλλογών. Οδηγίες βασισμένες σε ενδείξεις. Πνεύμων 263-275
3. **Αντωνίου Κ**, Μπαχλιτζανάκης Ν. Τι νεώτερο στη διάγνωση των ρευματικών διάχυτων νοσημάτων 1998-2000, Πνεύμων

4. **Αντωνίου Κ**, Δημάδη Μ. Κριτική Παρουσίαση: Αποδείξεις μαστοκυτταρικής ενεργοποίησης σε ασθενείς με ηωσινοφιλική χρόνια αποφρακτική πνευμονοπάθεια (ΧΑΠ). Ανάπτυπο από το Περιοδικό Πνεύμων Τόμος 16, Τεύχος 2β (Άρθρο Νο:1.45)
5. **Αντωνίου Κ**, Δημάδη Μ. Κριτική Παρουσίαση: Διήθηση μαστοκυττάρων στις λείες μυικές ίνες των αεραγωγών στο άσθμα. Ανάπτυπο από το Περιοδικό Πνεύμων Τόμος 16, Τεύχος 2β (Άρθρο Νο:1.43)
6. **Αντωνίου Κ**, Δημάδη Μ. Κριτική Παρουσίαση: Διαφορές σχετιζόμενες με την ηλικία στον έλεγχο του άσθματος: οδηγίες και πραγματικότητα. Ανάπτυπο από το Περιοδικό Πνεύμων Τόμος 16, Τεύχος 2β (Άρθρο Νο:1.44)
7. **Αντωνίου Κ**, Δελαβέρη Α, Λάτση Π. Τι νεώτερο στη διάγνωση των ιδιοπαθών διαμέσων πνευμονιών. Πνεύμων, Τόμος 17, Τεύχος 26, Μάρτιος 2004
8. Μπούρος Δ, **Αντωνίου ΚΜ**. Τρέχουσες και μελλοντικές θεραπευτικές προσεγγίσεις στην ιδιοπαθή πνευμονική ίνωση. European Respiratory Journal (Ελληνική Έκδοση) 2006; 1 (3):134-1
9. Πρόκλου Α, Οικονομίδου Φ, **Αντωνίου Κ**, Τζωρτζάκη Ε, Βολουδάκη Α, Μαλαγάρη Κ, Σιαφάκας Ν. Κλινικά, ακτινολογικά και μοριακά ευρήματα σε τρεις ασθενείς με ιδιοπαθή πνευμονική ίνωση, μετά από μακροχρόνια χορήγηση ιντερφερόνης γ-1b. Πνεύμων 2009;22(2):156-161
10. **Αντωνίου Κ**. Update in Idiopathic Pulmonary Fibrosis. Βοηθήστε τους να συνεχίσουν το ταξίδι (Roche) Τόμος 1, No 2, 2017
11. **Αντωνίου Κ**. COVID-19 Alert: Η διατροφή και ο ήλιος, τα όπλα της Κρήτης! Νέα Κρήτη, 06 Απριλίου 2020.
12. **Αντωνίου Κ**. Ενδοθελίτιδα προκαλεί η λοίμωξη από τον ιό SARS-CoV-2. Νέα Κρήτη, 24 Απριλίου 2020.
13. **Αντωνίου Κ**. Αναστέλλει τη φλεγμονή που προκαλεί ο κορωναιϊός. Νέα Κρήτη, 30 Απριλίου 2020.
14. **Αντωνίου Κ**. Επαναλειτουργεί το Ιατρείο Άσθματος. Νέα Κρήτη, 08 Μαΐου 2020.
15. **Αντωνίου Κ**. «Πιθανό» ένα δεύτερο κύμα της πανδημίας. Νέα Κρήτη, 13 Μαΐου 2020.
16. **Αντωνίου Κ**. Τι νεότερο για τη νόσο COVID-19. Νέα Κρήτη, 25 Μαΐου 2020.
17. **Αντωνίου Κ**. Χάπι για την υπέρταση και ηπαρίνη κατά COVID-19. Νέα Κρήτη , 29 Μαΐου 2020.
18. **Αντωνίου Κ**. Η Κρήτη στην πρώτη γραμμή. Επιστημονικά webinars-Σύγχρονη διαδικτυακή εκπαίδευση στη θέση ιατρικών συνεδρίων-Πρωτοστατούν Ιατρική Σχολή Κρήτης και Πνευμονολογία. Νέα Κρήτη , 18 Ιουνίου 2020.
19. **Αντωνίου Κ**. Τριπλή Θεραπεία στο Άσθμα: Τι δείχνουν οι νεότερες μελέτες για τους ασθενείς. The Docotor, ΙΟΥΛ-ΣΕΠ 2020.
20. **Αντωνίου Κ**, Κοκόση Μ. Ιδιοπαθείς διάχυτες πνευμονοπάθειες πλην της ιδιοπαθούς πνευμονικής ίνωσης. Στο Πολυζωγόπουλος Δ, Πολυχρονόπουλος Βλ. *Κλινική Πνευμονολογία*, εκδόσεις Πασχαλίδη. 3η έκδοση. 2021
21. Τζουβελέκης Α, Βιτωράκης Σ, Καραμπισάκος Θ, Σωτηροπούλου Β, Μπούτου Α, Δανιήλ Ζ, **Αντωνίου Αικ**, ΔΣ ΕΠΕ. Long-Post Covid Διαγνωστική και θεραπευτική προσέγγιση, Ελληνική Πνευμονολογική Εταιρεία

22. Λασιθιωτάκης Κ, Κονδύλη Ε, **Αντωνίου Αικ**, Κωνσταντίνου Ι. Κεφάλαιο 5. Η φυσική εξέταση του θώρακα. Στο Λασιθιωτάκης Κ. *Χειρουργική Σημειολογία*, εκδόσεις Broken Hill Publishers, 2021 *στάδιο της σελιδοποίησης*
23. **Αντωνίου Κ.** Διάμεσες πνευμονοπάθειες σε αυτοάνοσα νοσήματα, στο σύγγραμμα *Πνευμονολογία – Εντατική θεραπεία. Σε προετοιμασία*

7.11 ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΕΔΡΙΑ-ΣΥΜΠΟΣΙΑ ΜΕ ΕΙΣΗΓΗΣΕΙΣ-ΔΙΑΛΕΞΕΙΣ ΣΤΟ ΕΣΩΤΕΡΙΚΟ

1. Συμμετοχή στο 16^ο Μεταπτυχιακό σεμινάριο της Ελληνικής Βρογχολογικής Εταιρείας « Τι νεώτερο στην Πνευμονολογία 1998-2000 »ως εισηγήτρια στη Συνεδρία «Διάχυτες Πνευμονοπάθειες » με θέμα: Ρευματικά και επαγγελματικά διάχυτα νοσήματα: διάγνωση. Αθήνα, Μάιος 2000
2. Συμμετοχή στο 20^ο Μεταπτυχιακό σεμινάριο της Ελληνικής Βρογχολογικής Εταιρείας « Τι νεώτερο στην Πνευμονολογία 2002-2004 »ως εισηγήτρια στη Συνεδρία «Διάχυτες Πνευμονοπάθειες » με θέμα: Τι νεώτερο στη διάγνωση των ιδιοπαθών διαμέσων πνευμονιών. Αθήνα, Μάρτιος 2004
3. Συμμετοχή στο 20^ο Μεταπτυχιακό σεμινάριο της Ελληνικής Βρογχολογικής Εταιρείας « Τι νεώτερο στην Πνευμονολογία 2002-2004 »ως εισηγήτρια στη Συνεδρία «Διάχυτες Πνευμονοπάθειες » με θέμα: Τι νεώτερο στη θεραπεία της Ιδιοπαθούς Πνευμονικής Ίνωσης. Αθήνα, Μάρτιος 2004
4. Ομιλία με θέμα: Εμπυήματα: συντηρητική θεραπεία, 14^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Θεσσαλονίκη 1-4 Δεκεμβρίου 2005
5. Ομιλία με θέμα: Ανοσοπαθογένεια Σαρκοείδωσης, 15^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, ως εισηγήτρια στη Στρογγυλή Τράπεζα με θέμα “ Τρέχουσες εξελίξεις στη Σαρκοείδωση” , Ηράκλειο Κρήτης, 2-5 Νοεμβρίου 2006
6. Ομιλία με θέμα: Μείωση των αγγειογενετικών CXC χυμοκινών στο βρογχοκυψελιδικό έκπλυμα ασθενών με ιδιοπαθή πνευμονική ίνωση μετά από θεραπεία με ιντερφερόνη γ-1b, στην τελετή λήξης του 13^{ου} Παγκρήτιου Συνεδρίου, Ηράκλειο Κρήτης, Νοέμβριος 2006
7. Ομιλία με τίτλο: Ιστιοκυττάρωση Πνεύμονος στη Στρογγυλή Τράπεζα της Επιστημονικής Ομάδας Διαμέσων Νοσημάτων, 16^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Αθήνα, Δεκέμβριος 2007
8. Ομιλία με τίτλο: Τι νεότερο στην Πνευμονική Ίνωση , στη Στρογγυλή Τράπεζα “Επίκαιρα Θέματα Πνευμονολογίας”, 14^ο Παγκρήτιο Ιατρικό Συνέδριο, 29 Οκτωβρίου-1 Νοεμβρίου 2008
9. Ομιλία με τίτλο: Διάχυτα παρεγχυματικά νοσήματα και κάπνισμα, Ημέρες Πνευμονολογίας 2009, Πνευμονολογική Κλινική Πανεπιστημίου Θεσσαλίας, Λάρισα, 18-19 Σεπτεμβρίου 2009
10. Ομιλία με τίτλο: Ετήσια Κλινική Ανασκόπηση και Θέμα Διάχυτες Διάμεσες Πνευμονοπάθειες, στη Στρογγυλή Τράπεζα της Επιστημονικής Ομάδας Διαμέσων Νοσημάτων, 19^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Ρόδος , 21-24 Οκτωβρίου 2010

11. Διάλεξη με θέμα : Οι νέες διεθνείς οδηγίες για τη διάγνωση και αντιμετώπιση της Ιδιοπαθούς Πνευμονικής Ίνωσης, 20^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Αθήνα 2011
12. Ομιλία με θέμα: Ιδιοπαθής Πνευμονική Ίνωση, 1^ο Πνευμονολογικό Συμπόσιο Δημοκρίτειου Πανεπιστημίου Θράκης, Μάρτιος 2012
13. Ομιλία με θέμα: Πνευμονία Κοινότητας: Αξιολόγηση και θεραπεία, 1^ο Συνέδριο Ιδιωτών Πνευμονολόγων Κρήτης, 8-9 Μαΐου 2010, Χανιά
14. Ομιλία με θέμα: Καρκίνος και Πνευμονική Ίνωση, 11^ο Μετεκπαιδευτικό Σεμινάριο Πνευμονολογικής Κλινικής Πανεπιστημίου Ιωαννίνων , Ιωάννινα, 26-29 Μαΐου, 2011
15. Διάλεξη με θέμα: Νεώτερες απόψεις γύρω από την παθογένεια Ιδιοπαθούς Πνευμονικής Ίνωσης, στη Στρογγυλή Τράπεζα 'Ιδιοπαθής Πνευμονική Ίνωση', 21^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Αθήνα 18-21 Οκτωβρίου 2012
16. Ομιλία με θέμα: Υπάρχει απόφραξη στα Διάμεσα Νοσήματα του Πνεύμονα, Επιστημονική Εκδήλωση ELPEN "Τι γνωρίζουν οι ασθενείς για τα αποφρακτικά νοσήματα του πνεύμονα: ΧΑΠ και άλλα, Ηράκλειο Κρήτης, 14 Νοεμβρίου 2012
17. Κλινικό φροντιστήριο, Παθήσεις διαμέσου πνευμονικού ιστού, Ιστιοκυττάρωση κυτάρων Langerhans, 12^ο Συνέδριο Πνευμονολογικής Κλινικής Πανεπιστημίου Ιωαννίνων, 26-29 Απριλίου 2013
18. Κλινικό Φροντιστήριο, Διαχείριση αναπνευστικών νοσημάτων στην πρωτοβάθμια φροντίδα υγείας: Διαχείριση διάχυτων διάμεσων πνευμονοπαθειών στο ιατρείο- Παρουσίαση & συζήτηση κλινικών περιστατικών, Σάββατο 11 Οκτωβρίου 2014, Αθηνά
19. Ιδιοπαθής Πνευμονική Ίνωση: Θεραπευτική προσέγγιση, Ημέρες Πνευμονολογίας 2014, 26-28 Σεπτεμβρίου 2014
20. Στρογγυλή Τράπεζα Πνευμονολογίας, Πνευμονική Ίνωση, 17^ο Παγκρήτιο Ιατρικό Συνέδριο, Hotel Atlantis –Ηρακλειο, 30 Οκτωβριου- 2 Νοεμβριου 2014
21. Στρογγυλή Τράπεζα 'Τι νεώτερο στα διάμεσα νοσήματα': Κολλαγονικά Νοσήματα και Πνεύμονας, 23^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, 5-8 Νοεμβρίου 2014
22. Νεότερα δεδομένα στις κατευθυντήριες οδηγίες οδηγίες για τις αναπνευστικές παθήσεις, 1^η Εκπαιδευτική συνάντηση, Εκπαιδευτικές Ημέρες Πρωτοβάθμιας Φροντίδας Υγείας, Ηράκλειο, Ιανουαριος 2015
23. Πνευμονία Κοινότητας, Εκπαιδευτική Ημερίδα, Η πνευμονολογία στην κλινική πράξη, Ηράκλειο, 7 Φεβρουαρίου 2015
24. Διάμεση πνευμονοπάθεια με χαρακτηριστικά αυτοάνοσου νοσήματος με χαρακτηριστικά αυτοάνοσου νοσήματος (IPAF) ERS/ATS TASK Force για τις διαχυτες πνευμονοπάθειες: Τι νεοτερο στα Ιδιοπαθή και άλλα σπάνια Διάμεσα Νοσήματα του Πνευμονα, 4 Απριλιου 2015
25. Νεώτερα δεδομένα στη θεραπευτική αντιμετώπιση της ΧΑΠ, Κλινικό Φροντιστήριο, 27^ο Πανελλήνιο Συνέδριο Γενικής Ιατρικής, Χερσόνησος Ηρακλείου Κρήτης, 15-18 Απριλίου 2015

26. Εισπνεόμενες θεραπείες –Χορήγηση μία ή δύο φορές την ημέρα: Κλινικά δεδομένα για τις αποφρακτικές Πνευμονοπάθειες, Ηράκλειο, 29 Απριλίου 2015
27. Γενετικοί και επιγενετικοί μηχανισμοί στην παθογένεια της ΙΠΙ, 13^ο Συνέδριο Πνευμονολογικής κλινικής Ιωαννίνων, Ιωάννινα, 8-10 Μαΐου 2015
28. Η Ρευματολογία σήμερα; Πρακτικά προβλήματα της καθημερινής κλινικής πράξης, 7^ο Κρητο-Κυπριακό Συμπόσιο Ρευματολογίας: 23-25 Οκτωβρίου 2015
29. Κλινικό φροντιστήριο: Εξελίξεις στα νοσήματα του Πνεύμονα: Nintedanib: Στοχευμένη θεραπεία στην Ιδιοπαθή Πνευμονική Ίνωση, Ομάδες εργασίας ελληνικού κολλεγίου Γενικών ιατρών, 18-20 Σεπτεμβρίου 2015
30. Μεταμορφώνοντας το τοπίο στην Ιδιοπαθή Πνευμονική Ίνωση: Βελτιώνοντας την επιβίωση των ασθενών με Ιδιοπαθή Πνευμονική Ίνωση, Δορυφορικό Συμπόσιο, Roche, 24^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Νοέμβριος 2015
31. Μεταμορφώνοντας το τοπίο στην Ιδιοπαθή Πνευμονική Ίνωση: Πιρφενιδόνη: 5 χρόνια κλινικής εμπειρίας στην Δορυφορικό Συμπόσιο, Roche, 24^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Νοέμβριος 2015
32. Επιστημονική εκδήλωση: Ιδιοπαθής Πνευμονική ίνωση: Νεότερες εξελίξεις στη θεραπεία της: Κατευθυντήριες οδηγίες ATS/ERS/JRS/ALAT για τη θεραπεία της Ιδιοπαθούς Πνευμονικής Ίνωσης, Αίγλη Ζαππείου, 20 Φεβρουαρίου 2016
33. Παθογένεση Πνευμονικής Σαρκοειδωσης, 4^ο Ετησιο Σεμινάριο Διαμεσων Πνευμονοπαθειων, Απρίλιος 2016
34. Πνευμονική Εμβολή στην Κύηση, 8^ο Παγκρήτιο Συνέδριο Μαιευτικής –Γυναικολογίας, 16-17 Απριλίου 2016, Ηράκλειο Κρήτης
35. Βελτιώνοντας την επιβίωση των ασθενών με Ιδιοπαθή Πνευμονική Ίνωση, 42^ο Ετήσιο Πανελλήνιο Ιατρικό Συνέδριο, Αθήνα, 11-14 Μαΐου 2016
36. Στρογγυλή τράπέζα: Διάχυτες Διάμεσες Πνευμονοπάθειες: Αντιπαράθεση : Να χρησιμοποιούνται οι διαβρογχικές βιοψίες στη διάγνωση της IPF ?, 25^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα, 23-26 Ιουνίου 2016
37. Πιρφενιδόνη: Βελτιώνοντας την επιβίωση των ασθενών με Ιδιοπαθή Πνευμονική Ίνωση, Δορυφορικό Συμπόσιο, Roche, Δο25^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα, 23-26 Ιουνίου 2016
38. Συμπτώματα και ποιότητα ζωής στη ΧΑΠ: Νέα θεραπευτική προσέγγιση στη Χρόνια Αποφρακτική Πνευμονοπάθεια (Menarini Hellas): Υπό την αιγίδα της Πνευμονολογικής Κλινικής Πανεπιστημιακού Νοσοκομείου Ηρακλείου, Ηράκλειο, 21 Οκτωβρίου 2016
39. Ανασκόπηση των ομιλιών από το Ευρωπαϊκό Πνευμονολογικό Συνέδριο 2016, Νεότερα δεδομένα γύρω από τη θεραπεία του ασθματος, Περιφερειακό Σεμινάριο Κρήτης, Νεότερες Εξελίξεις στην ΠΦΥ, Ηρακλειο Κρήτης, 30 Σεπτεμβρίου-2 Οκτωβρίου 2016

40. Επιδημιολογικά στοιχεία και Παθοφυσιολογία της ΧΑΠ, Χρόνια Αποφρακτική Πνευμονοπάθεια, Επιστημονική Εκδήλωση, Ηρακλειο Κρήτης, 22 Οκτωβρίου 2016
41. Παθογένεση Πνευμονικής Σαρκοείδωσης, 4^ο Ετήσιο Σεμινάριο Διάμεσων Πνευμονοπαθειών, Απρίλιος 2016
42. IPAF, 5^ο Ετήσιο Σεμινάριο Διάμεσων Πνευμονοπαθειών, Απρίλιος 2016
43. Η Πνευμονολογία κοντά στον Πνευμονολόγο, Χανιά, 11 Ιουλίου 2018
44. IPAF, Διάχυτες Πνευμονοπάθειες 6^ο Ετήσιο Σεμινάριο, Θεσσαλονίκη, 10-11 Νοεμβρίου 2018
45. Πνευμονολογικά νοσήματα και καρκίνος πνεύμονα, Θεματικό Συνέδριο Καρκίνος του Πνεύμονα, Ηράκλειο Κρήτης, 17-18 Νοεμβρίου 2018
46. PRECISION Εξατομικευμένη Ιατρική στο Σοβαρό Άσθμα, Αθήνα, 24 Νοεμβρίου 2018
47. IPF novel therapeutic approaches, 27^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα, 13-16 Δεκεμβρίου 2018
48. Προσεγγίζοντας την Ιδιοπαθή Πνευμονική Ίνωση Ξανά: Νεότερα Δεδομένα στη Διάγνωση & Θεραπεία, Δορυφορικό Συμπόσιο (Roche), 27^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα, 13-16 Δεκεμβρίου 2018
49. Σχολιαστής σε στρογγυλή τράπεζα με θέμα: Πρόληψη και Έγκαιρη Διάγνωση στον Καρκίνο: υπόθεση όλων μας II, Ογκολογία: Από την πρόληψη στη θεραπεία- ένας συνεχής δρόμος, Ηράκλειο Κρήτης, 1-2 Φεβρουαρίου 2019
50. Ολιστική διαχείριση του ασθενούς με IPF, Βάζοντας τη «σφραγίδα» στη θεραπεία της ΧΑΠ και της IPF: Η Καινοτομία στην εποχή των Νέων Οδηγιών (Boehringer Ingelheim) , Αθήνα, 20 Φεβρουαρίου 2019
51. Διαχείριση και θεραπεία με βιολογικούς παράγοντες στο βρογχικό άσθμα, Energy (gsk) , Ηράκλειο Κρήτης, 30 Μαρτίου 2019
52. Αναγνωρίζοντας τους ασθενείς με σοβαρό άσθμα: Ώρα για θεραπεία σταδίο 5 κατά GINA; PRECISION Εξατομικευμένη Ιατρική στο Σοβαρό άσθμα, Ηράκλειο Κρήτης, 6 Απριλίου 2019
53. Ο ρόλος των μακροφάγων στην ίνωση: νεότερα δεδομένα, Διάχυτες Πνευμονοπάθειες 7^ο Ετήσιο Σεμινάριο «Παλαιάς Βουλής» , Αθήνα, 20-21 Απριλίου 2019
54. Διαχείριση του ασθενή με IPF στην καθημερινή κλινική πρακτική-η μακροχρόνια εμπειρία με το nintedanib (Boehringer Ingelheim), Διάχυτες Πνευμονοπάθειες 7^ο Ετήσιο Σεμινάριο «Παλαιάς Βουλής» , Αθήνα, 20-21 Απριλίου 2019
55. Η αποτελεσματικότητα της Πιρφενιδόνης στην θεραπεία της Ιδιοπαθούς Πνευμονικής Ίνωσης: real life experience (Roche), Διάχυτες Πνευμονοπάθειες 7^ο Ετήσιο Σεμινάριο «Παλαιάς Βουλής» , Αθήνα, 20-21 Απριλίου 2019
56. Με επίκεντρο τον Ασθενή με Σοβαρό Αλλεργικό Άσθμα, Διάλογος για τα Αναπνευστικά Αποφρακτικά Νοσήματα (Novartis) , Ρέθυμνο, 08 Ιουνίου 2019

57. Ιδιοπαθής Πνευμονική Ίνωση, Παθογένεια, Διάχυτες Πνευμονοπάθειες 7^ο Ετήσιο Σεμινάριο, Θεσσαλονίκη, 9-10 Νοεμβρίου 2019
58. Έγκαιρη θεραπευτική παρέμβαση στη ΧΑΠ, Διαχείριση ασθενών με ΧΑΠ και καρδιαγγειακά νοσήματα, Ηράκλειο, 20 Νοεμβρίου 2019
59. Η πιρφενιδόνη στη θεραπεία της Ιδιοπαθούς Πνευμονικής (Roche), 28^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα, 11-15 Δεκεμβρίου 2019
60. Ομιλήτρια στο e-conference 5 Διακεκριμένοι Επιστήμονες, 5 Νοσοκομεία πρώτης γραμμής, 1 Στόχος: Covid-19, 23 Μαΐου 2020. (webinar)
61. Νεότερα δεδομένα για τη μακροχρόνια χορήγηση βιολογικών παραγόντων αλλά και τη διακοπή της θεραπείας, Προσκλήσεις στη διαχείριση των ασθενών με Σοβαρό Άσθμα, 8 Ιουλίου 2020. (webinar)
62. What is New in Respiratory Medicine, Ιωάννινα, 18-20 Σεπτεμβρίου 2020 (webinar)
63. Αναγνώριση της πνευμονικής ίνωσης στην πρωτοβάθμια φροντίδα. Ο Γενικός Ιατρός προς τον Πνευμονολόγο, Πόρτο Χέλι, 25-29 Σεπτεμβρίου 2020 (webinar)
64. Τι νεότερο σε επίπεδο καθεθυντήριων οδηγιών στα διάμεσα νοσήματα, ΦΑΡΟΣ ΠΝΕΥΜΟΝΟΛΟΓΙΑΣ, 2^ο Διεπιστημονικό Συμπόσιο «Διαταραχές ύπνου: Από την έρευνα στην καθημερινή κλινική πράξη και τη δημόσια υγεία», 9-11 Οκτωβρίου 2020. (webinar)
65. Πνευμονική Ίνωση και Εμφύσημα, Σειρά Μεταπτυχιακών Σεμιναρίων σε Ειδικά Θέματα Πνευμονολογίας-Χρόνια Αποφρακτική Πνευμονοπάθεια, 27-29 Νοεμβρίου 2020. (webinar)
66. Πνευμονική ίνωση και φλεγμονόσωμα, 29^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα, 17-20 Δεκεμβρίου 2020 (webinar).
67. Ινωτικές Διάμεσες Πνευμονοπάθειες: από τις κλινικές μελέτες στην κλινική πράξη, 29^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα, 17-20 Δεκεμβρίου 2020 (webinar).
68. Αποτελεσματικότητα στον έλεγχο του άσθματος και της ΧΑΠ σε περιβάλλον καθημερινής κλινικής πρακτικής, Βελτιώνοντας τη Συμμόρφωση και τα Οφέλη των Ασθενών στη Διαχείριση του Άσθματος και της ΧΑΠ (Menarini) , Αθήνα, 26 Μαΐου 2021 (webinar)
69. Novel insights in progressive fibrotic diseases, 4^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Θεσσαλονίκη, 27-30 Μαΐου 2021 (webinar)
70. Νεότερα δεδομένα στην θεραπευτική των ινωτικών διάμεσων πνευμονοπαθειών, 4^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Θεσσαλονίκη, 27-30 Μαΐου 2021 (webinar)
71. What's new in the evaluation and management of progressive fibrotic disease, Διάχυτες Πνευμονοπάθειες 8^ο ετήσιο σεμινάριο ΥΒΡΙΔΙΚΟ, Θεσσαλονίκη, 26-27 Ιουνίου 2021 (webinar)
72. Η κλινική εμπειρία στην Κρήτη. Επιδημιολογικά δεδομένα ασθενών με Σοβαρό Άσθμα, Η κλινική εμπειρία ως αρωγός της έρευνας για τις θεραπευτικές εξελίξεις στο Σοβαρό άσθμα: Διεθνή & Ελληνικά δεδομένα (GSK), 07 Ιουλίου 2021 (webinar)

73. Αυτοάνοσα ρευματικά νοσήματα και πνεύμονες: ERS-EULAR Guidelines, 2^ο Πανελλήνιο Συνέδριο Σπανίων Παθήσεων και Ορφανών Φαρμάκων, Αθήνα, 10-12 Σεπτεμβρίου 2021 (webinar)
74. Idiopathic Pulmonary Fibrosis, What is New in Respiratory Medicine, Ιωάννινα, 16-19 Σεπτεμβρίου 2021 (webinar)
75. Πνευμονική Ίνωση, Ιπποκράτειες Ημέρες Π.Φ.Υ. Περιφερειακό Συμπόσιο Κρήτης, Αγ. Νικόλαος Κρήτης, 01-03 Οκτωβρίου 2021 (webinar)
76. Unmet needs: continuing our advancement in IPF management, Διάχυτες Πνευμονοπάθειες 9^ο ετήσιο σεμινάριο «Παλιάς Βουλής», Αθήνα, 02-03 Οκτωβρίου 2021 (webinar)
77. Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from there? , Διάχυτες Πνευμονοπάθειες 9^ο ετήσιο σεμινάριο «Παλιάς Βουλής», Αθήνα, 02-03 Οκτωβρίου 2021 (webinar)
78. European Respiratory Society και διάμεσες πνευμονοπάθειες στην εποχή της πανδημίας COVID-19, Φάρος Πνευμονολογίας 2021, Αλεξανδρούπολη, 08-10 Οκτωβρίου 2021 (webinar)
79. Φαρμακοθεραπεία για την πρόληψη της αναπνευστικής ανεπάρκειας στα διάμεσα νοσήματα του πνεύμονα, Η Αναπνευστική Ανεπάρκεια από την ΠΦΥ έως τη ΜΕΘ, Πορταριά Μαγνησίας, 19-21 Νοεμβρίου 2021
80. ERS projects, Διάχυτες Πνευμονοπάθειες 9^ο ετήσιο σεμινάριο Θεσσαλονίκης Σαρκοείδωση, Ίνωση, Σπάνια και Σπάνια των Σπανίων, Θεσσαλονίκη, 11-12 Δεκεμβρίου 2021
81. Σαρκοείδωση: Οι θέσεις της ERS, 30^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα, 15-19 Δεκεμβρίου 2021
82. Σαρκοείδωση - Τι νεότερο από τις κατευθυντήριες οδηγίες, 2ος ΚΥΚΛΟΣ ΕΚΠΑΙΔΕΥΤΙΚΩΝ ΕΚΔΗΛΩΣΕΩΝ ΕΠΕ, 9 Φεβρουαρίου 2022 (Webinar)
83. Ομιλία στη Στρογγυλή Τράπεζα: Tips και προκλήσεις για την έγκαιρη διάγνωση και ολιστική φροντίδα ασθενών με Ιδιοπαθή Πνευμονική ίνωση στην κοινότητα, 4ο Ιπποκράτειο Πανελλήνιο Συνέδριο Γενικής Ιατρικής και Π.Φ.Υ.* Θεσσαλονίκη, 7-10 Απριλίου 2022.
84. Νεότερα δεδομένα στη διαχείριση των ασθενών με IPF στην post-covid εποχή, IPF status in Covid-19 era: Where are we?, 13 Απριλίου 2022 (Webinar)
85. Ο ρόλος των μακροφάγων στην παθογένεια και την θεραπεία της ΙΠΙ: τι νεότερο, 10ο Ετήσιο Σεμινάριο Παλαιάς Βουλής «Διάχυτες Πνευμονοπάθειες», Αθήνα, 16-17 Απριλίου 2022.
86. Ιδιοπαθής Πνευμονική Ίνωση: με στόχο την Πρώιμη Διάγνωση, 5^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Θεσσαλονίκη, 12-14 Μαΐου 2022.
87. Εξελίσσοντας τη διάγνωση και τη διαχείριση των ασθενών με IPF, 5^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Θεσσαλονίκη, 12-14 Μαΐου 2022.
88. Διεθνείς κατευθυντήριες οδηγίες στην σαρκοείδωση, Γέφυρα Πνευμονολογίας, Πάτρα, 03-05 Ιουνίου 2022.

89. Therapeutic advances in Pulmonary Fibrosis: from bench to bedside, 22^ο Ερευνητικό Σεμινάριο της Ιατρικής Σχολής για το έτος 2022, 22 Ιουνίου 2022 (Webinar)
90. Θεραπείες πρόληψης της αναπνευστικής ανεπάρκειας στις διάμεσες πνευμονοπάθειες, Η Αναπνευστική Ανεπάρκεια από την ΠΦΥ έως τη ΜΕΘ, Σύρος, 23-26 Ιουνίου 2022.
91. Combined Pulmonary Fibrosis and Emphysema, What is New in Respiratory Medicine, Ιωάννινα, 22-25 Σεπτεμβρίου 2022.
92. ERS initiatives in ILDs, Ημέρες Πνευμονολογίας, Βόλος, 13-16 Οκτωβρίου 2022.
93. Ανθρωποκεντρική φροντίδα στην ιδιοπαθή πνευμονική ίνωση; Τι νεότερο, Ημερίδα με θέμα: Πνευμονική Ίνωση, άκουσε το σώμα σου πριν να είναι αργά, Αθήνα, 22 Οκτωβρίου 2022.
94. Ο ρόλος των μακροφάγων στην πνευμονική ίνωση. Τι νεότερο; , Διάχυτες Πνευμονοπάθειες 10^ο ετήσιο σεμινάριο Θεσσαλονίκης, 19-20 Νοεμβρίου 2022.
95. Debates: Διάγνωση και διαχείριση ασθενών με διάμεσες πνευμονοπάθειες, έναρξη αντι-ινωτικής αγωγής σε ασθενείς με ινωτική πνευμονίτιδα εξ' υπερευσθησίας (fibrotic HP) και ινωτική διάμεση πνευμονοπάθεια σε έδαφος αυτοάνοσου νοσήματος (fibrotic CTD-ILD) ΜΟΝΟ σε περίπτωση εξελισσόμενης νόσου; Υπέρ: Αικ. Αντωνίου, 31^ο Πανελλήνιο Πνευμονολογικό Συνέδριο Πνευμονολογίας, Αθήνα, 08-11 Δεκεμβρίου 2022.
96. Πνευμονική ίνωση και συννοσηρότητες, 31^ο Πανελλήνιο Πνευμονολογικό Συνέδριο Πνευμονολογίας, Αθήνα, 08-11 Δεκεμβρίου 2022.
97. "Theragnostics", οι προκλήσεις στην πνευμονική ίνωση: Το αύριο, σήμερα!, 31^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα, 8-11 Δεκεμβρίου 2022.
98. CPFE, 11^ο Ετήσιο Σεμινάριο Παλαιάς Βουλής «Διάχυτες Πνευμονοπάθειες», Αθήνα, 12-14 Μαΐου 2023
99. ERS Projects and Initiatives, 11^ο Ετήσιο Σεμινάριο Παλαιάς Βουλής «Διάχυτες Πνευμονοπάθειες», Αθήνα, 12-14 Μαΐου 2023
100. Challenges and Advances in Interstitial Lung Diseases, Bridges of Pulmonology, Πάτρα, 9-11 Ιουνίου 2023
101. Διαχείριση ασθενών με πνευμονική ίνωση στην καθ' ημέρα κλινική πράξη, 15^ο Πανελλήνιο Συνέδριο Μυοσκελετικής Υγείας, Ηράκλειο, 28 Σεπτεμβρίου-01 Οκτωβρίου 2023
102. Θέσεις ομοφωνίας ERS και EULAR για CTD-ILDs, Ετήσιο Πανελλήνιο Συνέδριο Ημέρες Πνευμονολογίας, Βόλος, 12-15 Οκτωβρίου 2023
103. Διάμεσες Πνευμονοπάθειες, 1^ο Πολυθεματικό Συνέδριο Ιατρικού Συλλόγου Ηρακλείου, Ηράκλειο, 03-05 Νοεμβρίου 2023

7.12 ΠΡΟΕΔΡΕΙΑ ΣΤΟ ΕΣΩΤΕΡΙΚΟ

1. Πρόεδρος στη Συνεδρίαση των Προφορικών Ανακοινώσεων με θέμα “Διάχυτα –Διάμεσα”, 16^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Αθήνα, 6-7 Δεκεμβρίου 2007
2. Πρόεδρος στη Συνεδρίαση των Αναρτημένων Ανακοινώσεων με θέμα “Διάχυτες- Διάμεσες Πνευμονοπάθειες”, 18^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Θεσσαλονίκη 26-29 Νοεμβρίου 2009
3. Πρόεδρος στη διάλεξη με ομιλητή τον Prof Athol Wells, 19^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Ρόδος , 21-24 Οκτωβρίου 2010
4. Πρόεδρος στη διάλεξη με ομιλητή τον Prof Bruno Crestani στη διάλεξη με τίτλο “ The new classification of IIPs”, 21^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Αθήνα, 18-21 Οκτωβρίου 2012
5. Πρόεδρος στη διάλεξη με ομιλητή τον Prof Athol Wells στη διάλεξη με τίτλο : ATS/ERS TASK Force: Acute exacerbation of IPF, 25^ο Πανελλήνιο Πνευμονολογικό Συνέδριο, Αθήνα 23-26 Ιουνίου 2016
6. Πρόεδρος στη Στρογγυλή Τράπεζα: Νοσηματα Πνευμονικής Κυκλοφορίας, 2ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος & Παθήσεων από το περιβάλλον, Θεσσαλονίκη, 10-13 Νοεμβρίου 2016
7. Νέα φάρμακα για την πνευμονική ίνωση, Ετήσιο Συνέδριο, Κατευθυντήριες Οδηγίες στην Πρωτοβάθμια Φροντίδα Υγείας των Πνευμονολογικών Ασθενών, 10-12 Φεβρουαρίου 2017
8. Φαινότυποι και Θεραπεία II, Σειρά Μεταπτυχιακών Σεμιναρίων σε Ειδικά Θέματα Πνευμονολογίας-Χρόνια Αποφρακτική Πνευμονοπάθεια, 27-29 Νοεμβρίου 2020. (webinar)
9. Υπεύθυνη Στρογγυλής Τραπέζης: Διάμεσα Πνευμονικά Νοσήματα και Πνευμονική Κυκλοφορία, 1^ο Πανελλήνιο Πνευμονολογικό Forum Φοιτητών Ιατρικής, 22-23 Μαΐου 2021 (webinar)
10. Άσθμα και αναπνευστική ανεπάρκεια, Η Αναπνευστική Ανεπάρκεια από την ΠΦΥ έως τη ΜΕΘ, Πορταριά Μαγνησίας, 19-21 Νοεμβρίου 2021
11. Μηχανισμοί αναπνευστικής ανεπάρκειας, Η Αναπνευστική Ανεπάρκεια από την ΠΦΥ έως τη ΜΕΘ, Πορταριά Μαγνησίας, 19-21 Νοεμβρίου 2021
12. Fibrosing ILDs: Patient journey from early diagnosis to pulmonary rehabilitation, 5^ο Πανελλήνιο Συνέδριο Νοσημάτων Θώρακος, Θεσσαλονίκη, 12-14 Μαΐου 2022
13. Προσεγγίζοντας τις παθήσεις των αεραγωγών, Γέγυρα Πνευμονολογίας, Πάτρα, 03-05 Ιουνίου 2022
14. Αναπνευστική ανεπάρκεια σε διάφορες καταστάσεις, Η Αναπνευστική Ανεπάρκεια από την ΠΦΥ έως τη ΜΕΘ, Σύρος, 23-26 Ιουνίου 2022.
15. Μικροσωματιδιακή σταθερή τριπλή θεραπεία-κλινικά αποτελέσματα, Η Αναπνευστική Ανεπάρκεια από την ΠΦΥ έως τη ΜΕΘ, Σύρος, 23-26 Ιουνίου 2022.
16. Έρευνα στα αποφρακτικά νοσήματα και στις διάμεσες πνευμονοπάθειες, Ημέρες Πνευμονολογίας, Βόλος, 13-16 Οκτωβρίου 2022
17. Co-morbidities in ILDs: Does the size matter?, 31^ο Πανελλήνιο Πνευμονολογικό Συνέδριο Πνευμονολογίας, Αθήνα, 08-11 Δεκεμβρίου 2022

18. Research Seminar; from bench to bedside, 3rd SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Ηράκλειο, 29 Ιουνίου-02 Ιουλίου 2023
19. Emerging Methodologies in Respiratory medicine, 3rd SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Ηράκλειο, 29 Ιουνίου-02 Ιουλίου 2023
20. Grand Debate: Antifibrotics in all stages in SSC-ILD, 3rd SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Ηράκλειο, 29 Ιουνίου-02 Ιουλίου 2023
21. IPAF? Is ti clinical Diagnosis?, 3rd SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Ηράκλειο, 29 Ιουνίου-02 Ιουλίου 2023
22. What is New in Interstitial Lung Disease, What is New in Respiratory Medicine, Κέρκυρα, 28 Σεπτεμβρίου-01 Οκτωβρίου 2023

8. ΕΚΠΑΙΔΕΥΤΙΚΟ – ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ

8.1 ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΕΠΙΠΕΔΟ ΠΡΟΠΤΥΧΙΑΚΗΣ ΕΚΠΑΙΔΕΥΣΗΣ

1. Διδασκαλία στο του μάθημα «Παθολογία Β» σε προπτυχιακούς φοιτητές της Ιατρικής Σχολής του Πανεπιστημίου Κρήτης το ακαδημαϊκό έτος 2006-2007 έως σήμερα
2. Διδασκαλία προπτυχιακών φοιτητών της Ιατρικής Σχολής του Πανεπιστημίου Κρήτης στα πλαίσια του μαθήματος “Παθοφυσιολογία”. Ιατρική Σχολή Πανεπιστημίου Κρήτης, από το ακαδημαϊκό έτος 2007-2008 έως σήμερα
3. Υπεύθυνη διδασκαλίας Προπαιδευτικής Άσκησης, στα πλαίσια του μαθήματος Παθολογία Α, Ακαδημαϊκό έτος 2008-2009, και διδασκουσα από το ακαδημαϊκό έτος 2006-2007 έως σήμερα
4. Υπεύθυνη διδασκαλίας Κλινικής Άσκησης, Ακαδημαϊκό έτος 2009-2017, 2021-2022
5. Διδασκαλία προπτυχιακών φοιτητών της Ιατρικής Σχολής του Πανεπιστημίου Κρήτης στα πλαίσια του μαθήματος “Μικροβιολογία Β”. Ιατρική Σχολή Πανεπιστημίου Κρήτης, από το ακαδημαϊκό έτος 2014 -2018

8.2 ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΕΠΙΠΕΔΟ ΜΕΤΑΠΤΥΧΙΑΚΗΣ ΕΚΠΑΙΔΕΥΣΗΣ

1. Συμμετοχή στο εκπαιδευτικό πρόγραμμα της Πνευμονολογικής Κλινικής Πανεπιστημιακού Γενικού Νοσοκομείου Ηρακλείου (ΠαΓΝΗ) (2003-σήμερα)
2. Συμμετοχή στο εκπαιδευτικό πρόγραμμα της Παθολογικής Κλινικής Πανεπιστημιακού Γενικού Νοσοκομείου Ηρακλείου (ΠαΓΝΗ) (2003-2004)
3. Συμμετοχή στο εκπαιδευτικό πρόγραμμα της ΜΕΘ (Μονάδα Εντατικής Θεραπείας) Πανεπιστημιακού Γενικού Νοσοκομείου Ηρακλείου (ΠαΓΝΗ) (2004-2005)
4. Συμμετοχή στο εκπαιδευτικό πρόγραμμα της Ρευματολογικής Κλινικής Πανεπιστημιακού Γενικού Νοσοκομείου Ηρακλείου (ΠαΓΝΗ) (2006)
5. Συμμετοχή στο εκπαιδευτικό πρόγραμμα των Πνευμονολογικών Κλινικών και Τμήματος Πνευμονολογίας και Αναπνευστικής Ανεπάρκειας της Κλινικής Εντατικής Θεραπείας της Ιατρικής Σχολής του Πανεπιστημίου Αθηνών , Συνεχιζόμενη ιατρική εκπαίδευση στην Πνευμονολογία, Αθήνα 2006, Ομιλία με Θέμα “ Τα ινωδολυτικά είναι χρήσιμα στη θεραπεία της παραπνευμονικής συλλογής και του εμπυήματος θώρακα”, Αθήνα 15/11/2006
6. Συμμετοχή στο Ετήσιο Εκπαιδευτικό Πρόγραμμα για τη χορήγηση τίτλου Παθολογικής Νοσηλευτικής Ειδικότητας (2008-2009)
7. Υπεύθυνη Εκπαιδευτικού Προγράμματος της Πνευμονολογικής Κλινικής Πανεπιστημιακού Γενικού Νοσοκομείου Ηρακλείου (ΠαΓΝΗ) (2016-2021)

8. Συμμετοχή στο πρόγραμμα μετεκπαιδευτικών διαλέξεων Κλινικής Χειρουργικής Ογκολογίας, ΠΑΓΝΗ (2015-2016)
9. Συμμετοχή στο πρόγραμμα μετεκπαιδευτικών διαλέξεων Πυρηνικής Ιατρικής, ΠΑΓΝΗ (2015-2016)
10. Συμμετοχή στα μετεκπαιδευτικά μαθήματα Παθολογίας, της Παθολογικής Κλινικής Πανεπιστημιακού Γενικού Νοσοκομείου Ηρακλείου (ΠΑΓΝΗ). «Διάμεσα Νοσήματα: Ταξινόμηση και Διαγνωστική Προσπέλαση.» (2021-2022)
11. Συμμετοχή ως ομιλήτρια στα εκπαιδευτικά μαθήματα της ΕΠΕ στο 3ο μάθημα της ενότητας Διάμεσα Νοσήματα, «Σαρκοείδωση- Τι νεότερο από τις κατευθυντήριες οδηγίες». 09/02/2022
12. Συμμετοχή στο εκπαιδευτικό πρόγραμμα των μαθημάτων των ειδικευόμενων και ειδικευμένων του Πνευμονολογικού τμήματος του Πανεπιστημίου Πατρών «Σαρκοείδωση – Διαγνωστική και θεραπευτική προσέγγιση-Τι νεότερο από τις κατευθυντήριες οδηγίες». 16/02/2022

8.3 ΟΜΙΛΙΕΣ ΣΕ ΜΕΤΕΚΠΑΙΔΕΥΤΙΚΑ ΣΕΜΙΝΑΡΙΑ

1. Ομιλία με θέμα: Ανοσολογικός μηχανισμός επίδρασης φαρμάκων, 16ο Ετήσιο Μετεκπαιδευτικό Σεμινάριο, Παρενέργειες φαρμάκων στον Πνεύμονα, Ιατρικά Λάθη κατά την άσκηση της Κλινικής Πνευμονολογίας, 31 Ιανουαρίου 2008
2. Ομιλία με θέμα: Ιδιοπαθής Πνευμονική Ίνωση, 5ο Εκπαιδευτικό Φροντιστήριο, Εκπαίδευση στην Πνευμονολογία: Συνδυάζοντας την τεκμηριωμένη θεωρία με την Κλινική Πράξη (Pulmonary Board Review Refreshing Course), 25-28 Φεβρουαρίου 2010
3. Ομιλία στη Στρογγυλή Τράπεζα 'Προσέγγιση Διαχύτων Πνευμονοπαθειών', με τίτλο: Ερωτήσεις πολλαπλών επιλογών στη διάγνωση και θεραπεία της Σαρκοείδωσης, 18ο Ετήσιο Μετεκπαιδευτικό Σεμινάριο, Συχνές Ερωτήσεις στην Πνευμονολογία, 18 Ιανουαρίου – 22 Μαρτίου 2010
4. Ομιλία με θέμα: Σαρκοείδωση. Διάγνωση και θεραπεία-κλινικά περιστατικά, 7ο Εκπαιδευτικό Φροντιστήριο, Εκπαίδευση στην Πνευμονολογία, Ελληνική Πνευμονολογική Εταιρεία: Συνδυάζοντας την τεκμηριωμένη θεωρία με την Κλινική Πράξη, Ναύπλιο, 5-8 Μαΐου 2011
5. Ομιλία με θέμα: Ιδιοπαθής Πνευμονική Ίνωση. Διάγνωση και θεραπεία-κλινικά περιστατικά, 7ο Εκπαιδευτικό Φροντιστήριο, Εκπαίδευση στην Πνευμονολογία, Ελληνική Πνευμονολογική Εταιρεία: Συνδυάζοντας την τεκμηριωμένη θεωρία με την Κλινική Πράξη, Ναύπλιο, 5-8 Μαΐου 2011
6. Ομιλία με θέμα: NSIP και COP. Διαγνωστικοί και θεραπευτικοί αλγόριθμοι- Κλινικά Περιστατικά, 7ο Εκπαιδευτικό Φροντιστήριο, Εκπαίδευση στην Πνευμονολογία, Ελληνική Πνευμονολογική Εταιρεία: Συνδυάζοντας την τεκμηριωμένη θεωρία με την Κλινική Πράξη, Ναύπλιο, 5-8 Μαΐου 2011
7. Παρουσίαση Ενδιαφέροντος Περιστατικού: Ασθενής με εμπύρετο και δύσπνοια κοπώσεως, 19ο Ετήσιο Μετεκπαιδευτικό Σεμινάριο, Ελληνική Πνευμονολογική Εταιρεία, 14/02/2011-18/04/2011

8. Ομιλία με θέμα: Το αναπνευστικό Σύστημα, Ανασκόπηση Παθολογίας, Παθολογική Κλινική Πανεπιστημιακού Νοσοκομείου Ηρακλείου, Συνεχιζόμενη Ιατρική Εκπαίδευση για Παθολόγους, Γενικούς Ιατρούς και Ιατρούς Παθολογικών Υποειδικοτήτων, Ιανουάριος- Φεβρουάριος 2011,.
9. Ομιλία με τίτλο: Σαρκοείδωση- Διάγνωση, 10^ο Εκπαιδευτικό Φροντιστήριο, Ελληνική Πνευμονολογική Εταιρεία, Ερέτρια 14-16/6/2012,
10. Εκπαιδευτικές ημερίδες Διαχείρισης ασθενών με ΧΑΠ στην Π.Φ.Υ, Ιπποκράτης Εταιρεία Γενικής/Οικογενειακής Ιατρικής Ελλάδος, Χανιά Κρήτη, Φεβρουάριος 2017
11. Πρότυπα Διάχυτων Διάμεσων Πνευμονοπαθειών, 6^ο Μετεκπαιδευτικό Σεμινάριο στην Ακτινολογία Θώρακος, Ελληνική Πνευμονολογική Εταιρεία, Αθήνα, Απρίλιος 2017
12. Combined Pulmonary Fibrosis Emphysema, 6^ο Σεμινάριο Συνεχιζόμενης Ιατρικής Εκπαίδευσης, Ημέρες ΧΑΠ 2017, Πόρτο Χέλι, Αργολίδα, 23-25 Ιουνίου 2017

8.4 ΕΠΙΒΛΕΨΗ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΦΟΙΤΗΤΩΝ

Ως επιβλέπουσα

- | | |
|--------------------------|---|
| Βαρσαμίδη Ειρήνη: | Διπλωματική εργασία στα πλαίσια του μεταπτυχιακού προγράμματος "Molecular Basis Of Human Disease" της ιατρικής σχολής Παν. Κρήτης με θέμα : "Macrophage homeostasis in Idiopathic Pulmonary Fibrosis (IPF): a Bronchoalveolar Lavage Fluid Study". (2014-2015). |
| Δήμητρα Ζέβλα | Διπλωματική εργασία στα πλαίσια του μεταπτυχιακού προγράμματος "Molecular Basis Of Human Disease" της ιατρικής σχολής Παν. Κρήτης με θέμα : "Role of RORα in fibroblast activation in Idiopathic Pulmonary Fibrosis". (τρέχουσα, έναρξη 2021). |

8.5 ΕΠΙΒΛΕΨΗ ΔΙΔΑΚΤΟΡΙΚΩΝ ΔΙΑΤΡΙΒΩΝ

Ως επιβλέπουσα

- | | |
|------------------------------|--|
| Σαραντουλάκη Στυλιανή | Μελέτη της αυτοφαγίας σε συνδυασμό με την ενεργοποίηση του φλεγμονοσώματος, στα κύτταρα του βρογχοκυψελιδικού εκπλύματος, στην ιδιοπαθή πνευμονική ίνωση (IPF) και στην αυτοάνοση πνευμονική ίνωση που σχετίζεται με την ρευματοειδή αρθρίτιδα (RA-UIP). |
|------------------------------|--|

Μπιμπάκη Ελένη	Μελέτη της έκφρασης γονιδίων που ρυθμίζονται από miRNAs και επιγενετικούς μηχανισμούς σε μακροφάγα από βρογχικό έκπλυμα ασθενών με Ιδιοπαθή Πνευμονική Ίνωση.
Βαρσαμίδα Ειρήνη	Μελέτη για την ομοιόσταση των μιτοχονδρίων σε ασθενείς με Ιδιοπαθή Πνευμονική ίνωση (A study of mitochondrial homeostasis in Idiopathic Pulmonary Fibrosis).
Τραχαλάκη Αθηνά	Μελέτη της ενεργοποίησης των Φλεγμονοσωμάτων σε κυψελιδικά μακροφάγα και ινοβλάστες και της συμμετοχής τους στην παθογένεια και στην πρόοδο της νόσου στην Ιδιοπαθή πνευμονική ίνωση και στην Συνήθη διάμεση πνευμονία επί Ρευματοειδούς αρθρίτιδας.
Κοκόση Μαρία	Η μελέτη της KL-6 στο πλάσμα, ως δυνητικού προγνωστικού και θεραπευτικού βιοδείκτη στην Ιδιοπαθή Πνευμονική Ίνωση.

Ως μέλος τριμελούς

Αναγνώστης Αριστοτέλης	Η έκφραση των υποδοχέων EGF σε καπνιστές με ή χωρίς Χρόνια Αποφρακτική Πνευμονοπάθεια.
Βασσάλου Ευαγγελία	Διαθωρακική υπερηχοτομογραφία πνευμόνων σε ασθενείς με ιδιοπαθή πνευμονική ίνωση: συσχέτιση με τα ευρήματα της υψηλής ευκρίνειας αξονικής τομογραφίας θώρακος και συγκριτική αξιολόγηση νέων απεικονιστικών πρωτοκόλλων.
Γιανναράκης Ιωάννης	Διερεύνηση του ρόλου των φλεγμονοσωμάτων στην παθογένεια της πνευμονικής ίνωσης.
Λασηθιωτάκη Ισμήνη	Πολυόμα ιοί και καρκίνος του πνεύμονα: παθογένεση και κλινική σημασία.
Κουνδουράκης Ελευθέριος	Μοριακοί δείκτες λεμφογενούς διασποράς του ακανθοκυτταρικού καρκινώματος κεφαλής και τραχήλου.
Χατζηαντωνίου Αργυρώ	Διερεύνηση του ρόλου της Ακτιβίνης στα αποφρακτικά νοσήματα των αεραγωγών.
Μιχελάκης Στυλιανός	Ανίχνευση πιθανής δυσλειτουργίας των μικρών αεραγωγών στο σύνδρομο IPF-OSAHS (Idiopathic Pulmonary Fibrosis-Obstructive Sleep Apnoea Hypopnoea Syndrome) : ο ρόλος τους στην ανάδειξη βιοδεικτών στο αίμα και στα προκλητά πτύελα (biomarkers in induced sputum & serum).
Σπερελάκης Ιωάννης	Η διερεύνηση του ρόλου και των λειτουργικών και μοριακών χαρακτηριστικών των μεσεγχυματικών κυττάρων (MSCs) στην ενδομυελική ήλωση.

Πιτσιδιανάκης Γεώργιος	Η χρήση της διαθωρακικής υπερηχοτομογραφίας των πνευμόνων στη βραχυπρόθεσμη και μακροπρόθεσμη διαχείριση ασθενών με παρεγχυματικές νόσους και στη μακροπρόθεσμη παρακολούθηση ασθενών με διάμεσες πνευμονοπάθειες.
Καραγιάννης Κων/νος	Ο ρόλος των προδρόμων μεσεγχυματικών κυττάρων μυελού των οστών στην Χρόνια Αποφρακτική Πνευμονοπάθεια.
Παπαδογιάννης Γεώργιος	Ινωτικές διάμεσες πνευμονοπάθειες και διαταραχές της αναπνοής κατά τον ύπνο.
Μάλλιου Αγγελική	Καρδιακές αρρυθμίες σε ασθενείς που νοσηλεύονται στην εντατική μονάδα για οξεία καρδιακά επεισόδια.
Λιβιά Γεωργία	Ο ρόλος των πρωτεϊνών προσκόλλησης του επιθηλιακού φραγμού στο φαινότυπο και την παθοφυσιολογία της χρόνιας ρινοκολπίτιδας με ρινικούς πολύποδες και η πιθανή χρήση τους ως δείκτες ανταπόκρισης στη θεραπεία με βιολογικούς παράγοντες.
Ελένη Λαδοπούλου	Ο ρόλος του μεταγραφικού παράγοντα RORα στο νυχθημερή ρυθμό: Μια προσέγγιση βιολογικής χημείας.
Ως μέλος επταμελούς	
Κακολύρης Νικόλαος	Διαχείριση της χρόνιας αποφρακτικής πνευμονοπάθειας στην Πρωτοβάθμια Φροντίδα Υγείας και στη Γενική Ιατρική.
Σαρχιανάκη Εμμανουέλα	Ανίχνευση του ιού Human Papillomavirus (HPV) στον καρκίνο του πνεύμονα.
Πρόκλου Αθανασία	Οξειδωτική βλάβη του DNA στο άσθμα.
Αρκολάκη Ευαγγελία	Η επίδραση της ασύγχρονης κοιλιακής διέγερσης μετά από μόνιμη καρδιακή βηματοδότηση από την κορυφή της δεξιάς κοιλίας στην εμφάνιση δυσλειτουργίας της αριστεράς κοιλίας. Προβλεπτικοί δείκτες εμφάνισης κοιλιακής δυσλειτουργίας.
Τσελεμπής Αθανάσιος	Ψυχολογικά χαρακτηριστικά ασθενών με χρόνια αποφρακτική πνευμονοπάθεια και η μεταβολή τους σε πρόγραμμα πνευμονικής αποκατάστασης.
Δετοράκης Ευστάθιος	Μελέτη του πνευμονικού παρεγχύματος σε ασθενείς με ρευματοειδή αρθρίτιδα με υπολογιστική τομογραφία υψηλής ευκρίνειας πριν και μετά τη θεραπεία με anti-TNF παράγοντες.
Αντωνογιαννάκη Ελβίρα-Μαρκέλα	Η φυσικοχημική προσέγγιση των οξεοβασικών διαταραχών.

Αδαμίδα Τώνια

Η έκφραση των πρωτεϊνών ΥΚL-40 και MIP-1α στις υπεζωκοτικές συλλογές.

8.6 ΥΠΟΤΡΟΦΙΕΣ-ΒΡΑΒΕΙΑ ΜΕΛΩΝ ΤΗΣ ΕΡΕΥΝΗΤΙΚΗΣ ΟΜΑΔΑΣ ΔΙΑΜΕΣΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΠΝΕΥΜΟΝΑ

1. Short term research fellowship, European Respiratory Society (2008) to George Margaritopoulos, Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK under the supervision of Prof Athol U. Wells. Project title: Scleroderma Lung Disease: is smoking-related damage increased in prevalence, and does smoking status influence outcome?
2. Short term research fellowship, European Respiratory Society to Katerina Samara (Reference number: STRTF27-2010, Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK under the supervision of Prof Athol U. Wells. Project title: "Investigation of the citrullination pathway in the pathogenesis of IPF". ILD Unit, Royal Brompton & Harefield Hospital, Imperial College London, National Heart and Lung Institute (NHLI), London, UK. April-May, November 2010.
3. Long term research fellowship (12 months), European Respiratory Society (2010) to George Margaritopoulos, Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK under the supervision of Prof Athol U. Wells. Project title: The identification of a pro-malignant fibrogenetic gene expression profile as a possible risk biomarker for lung cancer
4. ERS Lung Science Congress Bursary 2010 to Konstantinos Karagiannis: Does cigarette smoking influence bone marrow microenvironment? Downregulation of CXCR4 expression in bone marrow-derived mesenchymal stem cells (BMMSCs) in patients with chronic obstructive pulmonary disease (COPD): preliminary results, K. Karagiannis, K. Antoniou, R. Lymbouridou, C. Kalpadaki, E. Vassalou, I. Lasithiotaki, A. Proklou, N. Siafakas, N. Tzanakis
5. ERS Travel Award, 2009 to Ismini Lasithiotaki, I. Lasithiotaki, K. Antoniou, R. Lymbouridou, K. Karagiannis, D. Spandidos, N. Siafakas, G. Sourvinos. Detection of herpes simplex virus type-1 (HSV-1) in lung tissue and bronchoalveolar lavage fluid (BALF) of patients with fibrotic idiopathic interstitial pneumonias (f-IIPs). ERS Annual Congress, Viena, September 12-16, 2009. ERJ 2009;34(sup 53):18s
6. ERS Travel Award to A. Proklou, A. Proklou, K. Antoniou, G. Gvazava, G. Soufla, K. Christina, R. Lymbouridou, K. Karagiannis, I. Lasithiotaki, N. Siafakas. Phenotypical and molecular characteristics of bone marrow mesenchymal stem cells in rheumatoid lung. ERS Annual Congress, Viena, September 12-16, 2009. ERJ 2009;34(sup 53): 18s
7. ERS Lung Science Congress Bursary 2009 to F. Economidou, Oral presentation: Increased CXCR4 expression and short telomeres in bone marrow mesenchymal stem cells of patients with idiopathic

pulmonary fibrosis , F. Economidou, K. Antoniou, G. Soufla, A. Proklou, R. Lymbouridou, H. Papadaki, N. Siafakas(Heraklion, Greece)

8. Long term research fellowship (12 months), European Respiratory Society (2012) to Konstantinos Karagiannis, Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK under the supervision of Prof Athol U. Wells. Project title: Long term research fellowship (12 months), European Respiratory Society (2011), Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK under the supervision of Prof Athol U. Wells. Project title: "The role of Bronchoalveolar Lavage pepsin levels in patients with Idiopathic Pulmonary Fibrosis"
9. Short term research fellowship, European Respiratory Society to Athanasia Proklou (2015), Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK under the supervision of Prof Athol U. Wells. Project title: Idiopathic Pulmonary Fibrosis (IPF) and Obstructive Sleep Apnea (OSAHS): Investigation of common pathogenetic pathways and emerging biomarkers.

9. ΣΥΣΤΑΤΙΚΕΣ ΕΠΙΣΤΟΛΕΣ

1. Καθηγητής Πνευμονολογίας Imperial College, Faculty of Medicine, Royal Brompton Hospital, UK, **Athol Wells**
2. Καθηγητής Πνευμονολογίας, University of Seattle, **Ganesh Raghu**
3. Καθηγητής Πνευμονολογίας, University of Paris-Saclay, **Marc Humbert**
4. Καθηγητής Πνευμονολογίας, University of Bologna , **Venerino Poletti**
5. Καθηγητής Πνευμονολογίας, Institut de Cancerologie, Lyon, **Vincent Cottin**
6. Καθηγητής Πνευμονολογίας, University of Paris, **Bruno Crestani**